The role of integrin a4B7 binding in HIV-1 subtype C pathogenesis in phenotypically variant CD4+ T cell subsets by Richardson, Simone Irene
 
 
 
 
 
 
THE   ROLE   OF    INTEGRIN   α4β7   BINDING   IN   
HIV-1   SUBTYPE   C   PATHOGENESIS   IN   
PHENOTYPICALLY   VARIANT   CD4+   T    CELL   
SUBSETS 
 
Simone Irene Richardson 
 
 
 
 
 
 
 
 
 
 
 
A dissertation submitted to the Faculty of Health Sciences, University of the 
Witwatersrand, in fulfilment of the requirements for the degree  
of 
Master of Science in Medicine 
 
Johannesburg, 17 February 2014 
i 
 
Declaration 
I, Simone Irene Richardson declare that this dissertation is my own work. It is being submitted for the 
degree of Master of Science in Medicine in the University of the Witwatersrand, Johannesburg. It has 
not been submitted before for any degree or examination at this or any other University.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii 
 
Dedication 
This work is dedicated to my parents Caryll and Derrick Richardson who have poured their heart and 
soul into my well-being and education, never faltering in their faith in me.  
 
Acknowledgements 
Firstly it has been a privilege to be part of the HIV virology lab. Being surrounded by incredibly 
talented and hardworking individuals has motivated me to expand my horizons.  
 
My supervisor and HOD Prof Lynn Morris has not only offered academic guidance but also provided 
a fantastic example of how to be a successful and internationally-renowned scientist.  By always 
expecting more than most, Lynn has taught me to aim high. My co-supervisor, Dr Nono Mkhize has 
been the source of a wealth of flow cytometry knowledge and a fresh perspective on a challenging 
subject. As this project is an extension of my Honours project, I would be amiss not to thank Dr Elin 
Gray, an extraordinary science brain and my ‘original’ supervisor for all her input and advice even 
following her move ‘down under’. Besides that I thank her for most of my training, without which this 
project wouldn’t have been possible.  
 
Thank you to Dr Penny Moore for advice, Bronwen Lambson for technical input and Mary Phoswa 
for the monitoring of my viruses and routine PBMC isolation. I would also like to thank the women of 
the CAPRISA 002 cohort and its administrators for data and samples. 
 
To my friends and family, who have always been excited about my results, even if they had no idea 
what I was talking about, thank you for your unwavering love and support. And finally to Tim, for 
cooking endless dinners and listening to my constant gripes, I appreciate it more than you know.  
 
This project was supported financially by the National Research Foundation, Poliomyelitis Research 
Foundation and a postgraduate merit award from the University of the Witwatersrand, Faculty 
Research Committee.  
iii 
 
Presentations from this study 
Simone Richardson, Bronwen Lambson, Salim S. Abdool Karim, Elin Gray, Lynn Morris. The role of 
α4β7 in HIV-1 subtype C infection. Poster presentation on 26-31 March, 2012 at the HIV Pathogenesis 
meeting at the Keystone Symposia in Whistler, Canada. 
 
Simone Richardson, Nonhlanhla Mkhize, Elin Gray, Lynn Morris. Expression of integrin α4β7 on Treg 
and Th17 subsets indicates a novel route of HIV-1 dissemination. Oral presentation on 2-5 September 
2012 at EMBO Global Exchange Lecture Course on Innate Immunity – evolution and advances in 
clinical medicine, Johannesburg, South Africa.   
 
Simone Richardson, Bronwen Lambson, Salim S. Abdool Karim, Elin Gray, Lynn Morris. The role of 
α4β7 in HIV-1 subtype C infection. Poster presentation on 19th September 2012 at the University of 
the Witwatersrand Postgraduate Research Day, Johannesburg, South Africa.  
 
Simone Richardson, Nonhlanhla Mkhize, Elin Gray, Lynn Morris. Expression of integrin α4β7 on Treg 
and Th17 subsets indicates a novel route of HIV-1 dissemination. Poster presentation on 2-5 
December 2012 at the 8th conference of the Federation of African Immunological Societies (FAIS) in 
Durban, South Africa. 
 
Simone Richardson, Bronwen Lambson, Salim S. Abdool Karim, Elin Gray, Lynn Morris. The role of 
α4β7 in HIV-1 subtype C infection. Oral presentation on 18-21 June 2013 at the SA AIDS Conference 
in Durban, South Africa.  
 
Simone Richardson, Nonhlanhla Mkhize, Elin Gray, Lynn Morris. Expression of integrin α4β7 on 
Treg and Th17 subsets indicates a novel route of HIV-1 dissemination. Oral presentation on 30 
August 2013 at the 4th Symposium of Infectious Diseases in Africa: “Immune escape from HIV-1, 
Malaria and TB: implications” in Cape Town, South Africa.  
 
Simone Richardson, Bronwen Lambson, Salim S. Abdool Karim, Elin Gray, Lynn Morris. The role of 
α4β7 in HIV-1 subtype C infection. Oral presentation on 5-10 October, 2013 at the AIDS Vaccine 
conference, Barcelona, Spain.  
 
 
 
iv 
 
Abstract 
The integrin α4β7, which mediates the trafficking of T lymphocytes to the gut associated lymphoid 
tissue (GALT), a site of rapid HIV replication, has been described as an attachment factor for the HIV 
envelope protein gp120. While differences in binding affinity of early transmitting and chronic 
gp120s for α4β7 have previously been noted by others, this has not translated to differences in 
replication. We aimed to investigate what role this binding interaction has in HIV pathogenesis over 
time and determine the factors that influence α4β7 reactivity. Understanding the subsets on which 
α4β7 is expressed may indicate the phenotype of the first host cells infected by HIV. The level of 
expression of α4β7 on Th17 and Treg CD4+ T cells was of interest as both subsets are important in 
HIV immunity in the GALT and represented in both the GALT and genital mucosa.   
 
All-trans retinoic acid-activated CD4
+
 T cells isolated from whole blood of healthy donors were 
incubated with or without HP2/1 (anti-α4 monoclonal antibody) or Act-1 (anti-α4β7 monoclonal 
antibody) prior to adding virus. Sixty infectious envelope clones were prepared using matched 
envelope genes from 11 individuals in the CAPRISA 002 Acute Infection cohort representing the T/F 
virus and variants from 1-39 months post infection (p.i.). Replication was monitored by p24 ELISA 
over 10 days. ATRA-stimulated CD4
+
 T cells were subjected to intracellular and surface staining for 
flow cytometric analysis using a FACSAria to distinguish Th17 and Treg CD4
+
 T cells and to 
determine the expression of CD45RA, CCR5, p24, α4β7.  
 
The dependence on α4β7 for HIV subtype C replication changes over time and varies across 
individuals. In three individuals, dependence on α4β7 was higher using T/F viruses and decreased 
sharply during acute infection (1-3 months post-infection). α4β7 dependence showed an increasing 
trend in chronic infection over time which was slight in the first year. Factors that influence α4β7 
reactivity include glycan distance from α4β7-binding motif, glycan density and length of the V1/V2 
region of gp120. Several glycans positioned in conserved regions of gp120 including N234, N332 and 
N334 were present more or less frequently in viruses with high α4β7 reactivity. There was an 
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association between high dependence on α4β7 for replication at transmission and those T/F viruses 
that have a S/PDI/V α4β7 binding motif as well T/F viruses found in individuals diagnosed with 
bacterial vaginosis during acute infection. Several cytokines in the cervicovaginal lavage (CVL) of 
these individuals during early infection (IL-8, IL-7 and IL-1α) positively correlated with α4β7 
dependence for replication. Treg CD4
+
 T cells expressed slightly higher levels of α4β7 as compared to 
Th17 CD4
+
 cells. In addition, Th17 cells in this and other studies were shown to rapidly deplete in 
vitro following HIV infection while Treg CD4
+
 T cell were shown to expand. Despite this, Treg CD4
+
 
T cells were significantly more permissive to infection as compared to Th17 CD4
+
 T cells.  
 
Collectively, these data suggest that there is a role for α4β7 in HIV pathogenesis and that the 
interaction is selected for during transmission by a number of bottlenecks, one of which is the 
presence of bacterial vaginosis and elevated expression of IL-7, IL-8 and IL-1α. Due to high levels of 
α4β7 expression and the ability to bind gp120, presence in both the genital tract and the GALT, 
regulation by ATRA similar to α4β7 upregulation, expansion following HIV infection and elevated 
permissiveness to acute infection, Treg CD4
+
 T cells may be a robust vector from the genital mucosa 
to the GALT shortly after transmission. This population of T cells may be more suited for this 
function than Th17 CD4
+
 T cells which are more susceptible to depletion either by HIV or bystander 
effects. As a result of the α4β7 binding motif being in a highly immunogenic region of gp120 and 
antibodies directed against this region associated with protection in the only effective vaccine trial to 
date, further understanding of the interaction between the virus and the integrin provides an 
opportunity for the development of future vaccine and therapeutic strategies.  
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INTRODUCTION 
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1.1 The shape of the HIV/AIDS epidemic in South Africa and efforts to fight it 
 
HIV/AIDS is the defining pandemic of the 21
st
 century. An estimated 34 million people were infected 
with HIV at the turn of 2012 globally and Sub-Saharan Africa bears approximately 69% of the burden 
(UNAIDS, 2012). Although a declining trend in new HIV infections both globally and in Southern 
Africa was reported by UNAIDS in 2012, an astounding 71% of new infections are accounted for by 
this population, despite the implementation of prevention and awareness strategies. In South Africa, it 
is estimated that 5.38 million people are living with HIV, and with new infections estimated to total 
316,900 people in 2011 (STATSSA, 2011), innovative strategies for the development of prevention 
methods are essential.  
 
Current HIV behavioural and awareness teachings on abstinence, faithfulness and frequent condom 
use have had a limited impact on HIV incidence in South Africa. Several other prevention strategies 
have yielded measurable success with the most notable including a microbicide efficacy trial using a 
1% formulation of the antiretroviral (ARV) drug, tenofovir (Abdool Karim et al., 2010), medical male 
circumcision (Auvert et al., 2005; Bailey et al., 2007; Gray et al., 2007b) and treatment of sexually 
transmitted diseases (Grosskurth et al., 1995). These successes yielded efficacies of 39%, 57% and 
42% respectively in clinical trials with only circumcision and treatment of sexually transmitted 
diseases currently used in practice. Recent data from the HIV Prevention Trials Network Study 052 
show ARVs can prevent transmission in HIV discordant couples with 96% efficacy (Anglemyer et al., 
2011) and as a direct result of this, the United States Food and Drug Administration (FDA) approved 
Truvada, an ARV, for pre-exposure prophylaxis (PrEP) for use in healthy but high-risk populations. 
Due to the high cost of this intervention and the fact that stable, cohabiting couples are often not the 
case, it has been extensively debated whether this strategy could be efficiently implemented in an 
under-resourced setting such as Southern Africa. Despite this, HIV acquisition risk declined 
significantly with increasing ART coverage in a high risk community in Kwa-Zulu Natal, South 
Africa (Tanser et al., 2013). While the introduction of antiretroviral therapy (ART) has had a dramatic 
impact on HIV morbidity and mortality (Bor et al., 2013), a vaccine is largely considered to be the 
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only practical solution to curb the spread of the pandemic. Despite this view, many vaccine trials have 
been carried out in recent times with little translatable success. The first evidence that vaccination can 
prevent HIV-1 infection in humans was provided by the RV144 phase 3 clinical trial in Thailand 
(Rerks-Ngarm et al., 2009), a discovery that rejuvenated the field. The level of efficacy was modest at 
31.2% and efforts to understand how to improve the vaccine regimen are on-going. From progress 
made across all echelons of HIV prevention, it is clear that understanding the mechanisms underlying 
HIV-1 pathogenesis, with renewed focus on mucosal transmission and the immune system’s response 
to the virus, will allow for improved rational design.  
 
1.2 HIV structure  
The overall structure of HIV is illustrated in Figure 1.1A. HIV is classified in the family Retroviridae 
and genus Lentivirus and contains two identical copies of single stranded RNA enclosed in a virus 
capsid, made of multiple copies of the viral protein p24, an antigen commonly used to detect HIV 
infection. There are three structural genes namely pol, gag and env which encode the replication 
enzymes (reverse transcriptase, integrase and protease), the structural proteins of the core and matrix 
and the viral envelope glycoproteins (gp120 and gp41) respectively. The heterodimeric envelope 
glycoprotein that allows for attachment and budding to and from the host cell comprises of three 
gp120 subunits and three gp41 subunits that are non-covalently associated (Figure 1.1B). The 
sequence of a gp120 monomer is conventionally divided into five conserved constant regions (C1-C5) 
with five variable regions (V1-V5) shown in Figure 1.1C (Modrow et al., 1987). The crystal structure 
of gp120 has been elucidated in complex with a number of soluble CD4 receptor and co-receptor 
binding site directed monoclonal antibodies (mAb) and ligands which has allowed for greater 
understanding of the interface between the host immune response and the virus itself (Chen et al., 
2009; Zhou et al., 2010; Zhou et al., 2007). In the past, to facilitate crystal formation these structures 
lacked the hyper-variable V1/V2 domain, and in many instances portions of the N-terminal and C-
terminal ends and V3 loop. However, the structure of V1/V2 in complex with mAb PG9 has been 
elucidated (McLellan et al., 2011). 
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Figure 1.1: Structure of HIV 
(A) Schematic representation of the HIV virion with two copies of viral RNA and viral enzymes 
enclosed in a capsid made of numerous copies of p24. The entire virion core is enclosed in a matrix 
(p17) and lipid membrane with 3 anchored gp41 subunits and 3 covalently linked gp120 subunits. (B) 
A schematic representation of the glycoprotein envelope spike is shown with V1/V2 loops represented 
in red, the CD4 binding site is shown in yellow, gp41 shown in green and gp120 subunits in purple 
(Adapted from (Haynes et al., 2012b). (C) A linear schematic of the HIV-1 envelope sequence where 
the conserved regions C1-C5 are indicated in maroon, and variable sequences V1/V2, V3, V4, and V5 
are shown in pink, red, purple, and blue respectively. The secondary structure of the conserved 
regions (in the first row) and variable loops (second row) are indicated by ribbon diagrams (Adapted 
from (Wibmer, 2011). The Greek key motif of V1/V2 is shown in green. Strands are shown as arrows 
and disulphide bonds as yellow boxes (McLellan et al., 2011). 
 
A 
C 
B 
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In addition, the uncleaved gp120 trimer at 6Å resolution was recently published (Mao et al., 2013). 
The envelope structure has great plasticity, a feature accommodated by the variable loops.  Among 
these variable regions, the V1/V2 loop is the most relevant to this study.  
 
V1/V2 structure and function: closer to a successful vaccine 
The structure of the V1/V2 region as elucidated by McLellan et al, is shown in Figure 1.1.C and 
furthermore cryo-electron microscopy illustrated that the V2 loop appears at the tip of the env trimer 
and is exposed on the envelope (Julien et al., 2013; White et al., 2010). The correlate of protection in 
the RV144 phase 3 trial in Thailand HIV infection was found to be IgG antibody binding to 
scaffolded V1/V2 Env proteins (Haynes et al., 2012a), leading to the notion that the design of 
vaccines to induce high levels of V1/V2 antibodies may enhance vaccine efficacy. The V1/V2 loop is 
one of the first targets of the early immune response; anti-V1/V2 mAbs have strong neutralising 
activity against the autologous virus (Gray et al., 2007a; Moore et al., 2008). Indeed, V1/V2 has been 
described as integral in conformation masking, by partially occluding V3 (Chen et al., 2005). Two 
potent broadly neutralising mAbs, PG9 and PG16 have been isolated that target the V1/V2 loop 
(Walker et al., 2009). There is increasing evidence that sequence variation in the V1/V2 loop mediates 
neutralisation resistance (Moore et al., 2009), viral tropism and cell entry regulation (Cheng-Mayer et 
al., 1999; Wyatt et al., 1995). The V1/V2 loop is shortened and has fewer N-linked glycosylations in 
the case of transmitted/founder (T/F) viruses compared to chronic viruses (Derdeyn et al., 2004). 
Combined, this evidence suggests that not only is this region of gp120 important in the establishment 
of the transmission bottleneck, but is a common target of the immune system, one that could be 
exploited in vaccine design. Finally, and most applicable for this study, the putative binding site for 
the gut homing receptor α4β7 on gp120 is located in the V1/V2 loop (as discussed in Section 1.7).   
 
Potential N-linked glycans (PNGs) 
An unusual feature of HIV is the dense glycan shield that encompasses exposed envelope antigens 
which accounts for more than half of the molecular mass of gp120 (Lasky et al., 1986). The folding of 
viral glycoproteins, viral transmission, viral escape and host immune response are all significantly 
6 
 
influenced by the presence of these carbohydrates, which are the targets of several potent broadly 
neutralising antibodies (Scanlan et al., 2007; Walker et al., 2011; Wang et al., 2012). Two major types 
of protein glycosylation are N-linked and O-linked glycosylation. N-linked glycans are attached to the 
amide nitrogens of asparagine side chains in the concensus sequences N-X-S/T, where X represents 
any amino acid residue except proline (Spiro, 2002). O-linked glycans are attached to the hydroxyl 
group of serine or threonine (Hang and Bertozzi, 2005), however there is no current algorithm to 
predict these sites. There are approximately 30 sites encoded in the extracellular domain of envelope 
with two thirds encoded in conserved regions and the remaining third in variable regions 
(Ochsenbauer et al., 2012; Salazar-Gonzalez et al., 2009). Interestingly, the HIV genome does not 
include any capability to synthesise carbohydrates; the glycan shield is formed by host enzymes 
(Scanlan et al., 2007).  
 
Since an ideal vaccine would aim to block the interaction between susceptible host cells and the virus 
defining the receptors, co-receptors and attachment factors on the host cells and the gp120 trimer is of 
particular interest. 
 
1.3 Mechanism of HIV binding to receptors and co-receptors 
HIV-1 must invade human immune cells to ensure viral spread. Essential to this is attachment to the 
host cell membrane involving gp41 and gp120 imperative for the recognition of the virus, binding and 
entry into the target cell. The primary binding action between the host cell and the HIV virion 
involves CD4 and gp120. In its physiological role, CD4 functions as a receptor for major 
histocompatibility complex class II molecules during foreign antigen recognition by T cell 
lymphocytes (Miceli and Parnes, 1993).  
 
During binding, the glycoprotein envelope complex undergoes a structural conformational change 
rearranging both the gp120 core and the variable loops resulting in exposure of the V3 loop that 
facilitates binding to chemokine receptors in addition to CD4 (Berger et al., 1999). Chemokine 
receptors are involved in the homing and recruitment of immune cells to the site of inflammation 
(Coakley et al., 2005). The most common of these co-receptors for HIV-1 are CCR5 and CXCR4, 
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however a variety of others have been implicated in the binding of some HIV-1 isolates (Alkhatib and 
Berger, 2007). The necessity of these chemokine receptors for infection is reflected by the finding that 
individuals that have a homozygous mutation for CCR5 are resistant to HIV infection (Samson et al., 
1996).  
 
Following binding of gp120 to the chemokine co-receptor, gp41 is released from its high energy state 
and the previously buried fusion peptide springs out towards the host cell membrane (Kilby and Eron, 
2003). At this point, gp120 is thought to disassociate from the host cell membrane and gp41 
transiently becomes an integral component of the cellular membrane of the host (Doms and Moore, 
2000). Gp41 refolds allowing for the release of energy and formation of a fusion pore which 
ultimately allows the capsid to enter the cytoplasm of the host cell (Doms and Moore, 2000). It is 
conceivable that there are additional receptors and attachment factors on the host cell that may bind 
the virus and offer a selective advantage to pathogenesis; one of which will be explored further in this 
dissertation. 
  
1.4 Clinical immunopathology of HIV 
 
 
 
 
 
 
 
 
 
Figure 1.2: Events during acute HIV infection 
The period between the time of initial infection and the point of possible viral detection is the eclipse 
phase. Between 7 and 21 days, the virus disseminates to secondary tissues and reaches peak viremia 
between 21 and 28 days. Viral concentrations decrease slightly over time and the individual 
progresses to chronic pathogenesis following 100 days of infection (McMichael et al., 2010).  
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The pathogenesis of HIV can be simplified as consisting of two parts: an acute phase which lasts 
approximately 100 days, is designated into Fiebig stages and is characterised by unchecked viral 
replication and the chronic phase which lasts several years and is characterised by destructive immune 
activation and weak immune responses (Picker and Watkins, 2005). Events that occur during the 
acute phase of infection often dictate the kinetics of HIV replication and the rate of disease 
progression. The eclipse phase is the initial period between the moment when the first cell is infected 
and virus is first detectable and is thought to be between 7 and 21 days (Lindback et al., 2000). During 
this clinically silent phase, virus is produced in CD4
+
 T cells in the mucosa, submucosa, draining 
lymphatics and, to a modest extent, the gut associated lymphoid tissues (GALT) and systemic tissues 
(Haase, 2010). Following detectable viremia in the blood plasma (designated T0), levels exponentially 
increase as a result of the sudden rapid viral expansion in the GALT and peripheral lymphoid tissues 
reaching a peak at 21-28 days (Brenchley et al., 2004; Ribeiro et al., 2010). By this time, significant 
and irreversible depletion of mucosal CD4
+
 T cells has already occurred and some individuals may 
become symptomatic (McMichael et al., 2010). As the plasma viral load begins to plateau, individuals 
progress from acute infection to early chronic infection at the end of Fiebig stage V, approximately 
100 days following infection. Acute infection is the stage of infection in which a vaccine and other 
prevention strategies must be most effective.  
 
1.5 HIV transmission 
HIV-1 transmission results from viral exposure at mucosal surfaces or from percutaneous inoculation. 
HIV has been classified phylogenetically into groups M, N and O and P (a new putative designation); 
each of which represent a separate introduction of SIV from infected great apes into humans (Sharp 
and Hahn, 2011). Of these groups, M has manifested into the current pandemic, with viral population 
bottlenecks causing diversification into distinct subtypes (Taylor et al., 2008). HIV-1 clade C is the 
most common subtype in circulation accounting for 48% of all infections (Stephens, 2012), the most 
prevalent subtype in the South African pandemic. Despite this level of diversity which could provide 
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an opportunity for the evolution of altered transmissibility, group M viruses have been remarkably 
consistent in transmission over time, geography, behaviour and populations (Taylor et al., 2008). 
 
Routes of transmission and the transmission bottleneck 
There are multiple routes of HIV transmission including vaginal, rectal, oral, percutaneous, 
intravenous and in utero. Heterosexual transmission is responsible for approximately 70% of HIV-1 
infections worldwide. This is despite the fact that heterosexual transmission is an inefficient process, 
with an average of only 0.01 transmissions per coital act (Wawer et al., 2005). This risk factor is 
exponentially increased dependent on the presence of sexually transmitted diseases, male 
circumcision, socio-economic status, pregnancy, HIV disease stage and route of exposure (El-Sadr et 
al., 2010; Galvin and Cohen, 2004; Powers et al., 2008) . During early or acute infection, an HIV 
infected individual in a discordant couple is far more likely to infect their partner than during chronic 
infection (Brenner et al., 2007; Miller et al., 2010; Powers et al., 2008; Wawer et al., 2005). This may 
be as a result of the high viral load, a lack of neutralising antibodies that may inactivate circulating 
virus or clonal expansion of very fit viruses that are particularly suited for the establishment of 
productive infection (Keele et al., 2008; Richman et al., 2003; Wawer et al., 2005; Wei et al., 2003).  
 
Current observations of HIV transmission suggests that two thresholds need to be overcome for 
infection to occur: firstly, there may be a threshold of infectious virus needed in genital secretions of 
the infected partner and secondly there may be a threshold density of susceptible cell targets in the 
mucosa of the uninfected partner (Iqbal and Kaul, 2008). HIV transmission involves a genetic 
bottleneck in which a limited number of variants from a diverse quasispecies in the transmitting 
partner establish productive infection in the newly infected partner (Wolfs et al., 1992; Wolinsky et 
al., 1992). This definition implies that there are selective pressures acting on these variants, 
corroborated by the fact that in most cases only 1 virus is able to withstand the genetic bottleneck and 
productively infect its’ host. This virus, known as the transmitted/founder (T/F) virus, can be inferred 
by using a novel experimental sequencing strategy developed by Keele and colleagues in 2008 based 
on single genome amplification. It is likely that a number of abortive infections do arise during 
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transmission but that only one in the case of sexual transmission establishes productive infection 
(Figure 1.3). It has been determined that approximately 80% of heterosexual subjects are productively 
infected by a single viral genome irrespective of genetic subtype (Abrahams et al., 2009; Haaland et 
al., 2009; Keele et al., 2008). Approximately 60% and 40% of men who have sex with men and 
intravenous drug users respectively, are also productively infected by a single virus. In one case of an 
injection-drug user, up to 16 T/F viruses were found to cause infection (Bar et al., 2010). Rectal 
transmission also seems to mitigate the genetic bottleneck that is evident in cervicovaginal 
transmission (Li et al., 2010). The fact that multiple viruses initiating infection are more prevalent in 
non-heterosexual transmissions is an indicator of the strength of the mucosa as a barrier to infection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Model of HIV infection 
While a selection of phenotypically variant viruses are present in the infected fluid and a number of 
abortive infection events may occur, in most cases only one virus results in productive infection. This 
may be because other viruses are less fit or fail to come into contact with target cells. During the 
eclipse phase of infection, viral diversity is thought to be limited (Cohen et al., 2011).  
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Transmission signatures 
Various studies have focused on the determination of a defining phenotype of T/F viruses in order to 
explain why these viruses are preferentially selected by the transmission bottleneck. Phenotypic 
identification of transmission signatures has been difficult to correlate with genotypic changes. 
Transmission of HIV-1 in humans selects for CCR5-tropic viruses, and viruses could be distinguished 
from CXCR4-tropic viruses genotypically by amino acids located in the V3 region of Env (Jensen and 
van 't Wout, 2003; Resch et al., 2001). T/F and chronic gp120s have shown similar requirements for 
elevated levels of CD4 (Alexander et al., 2010; Isaacman-Beck et al., 2009) but differences in CCR5 
usage have been determined (Parker et al., 2013). Most recently, Korber and colleagues (Gnanakaran 
et al., 2011) compared over 7,000 SGA derived env gp160 sequences from 275 acutely or chronically 
infected subtype B subjects and observed statistically robust signatures. The motif with highest 
statistical significance was in the signal peptide, which may affect Env expression and incorporation 
of Env into virions (Asmal et al., 2011). How these changes might affect HIV-1 transmission is 
currently unknown.  
 
T/F viruses from subtypes A, C and D have been determined as having more compact V1-V4 loops 
with a reduced number of glycans compared to chronic viruses, an observation less clear in subtype B 
viruses (Chohan et al., 2005; Derdeyn et al., 2004; Ping et al., 2013). DC-SIGN, the C-type lectin 
expressed on dendritic cells is able to bind virus via oligomannose residues which are expressed to a 
higher degree on T/F viruses (Geijtenbeek et al., 2000). This process of virus capture may contribute 
to direct infection of dendritic cells (Muratori et al., 2009), providing a mechanism of immune 
evasion. It has been suggested that the homing integrin α4β7 binds more efficiently to T/F viruses and 
that this difference is associated with decreased glycosylation of V1/V2 of gp120 (Nawaz et al., 
2011). Studies have shown that these characteristics provide T/F viruses with increased transmission 
fitness (Chohan et al., 2005; Wu and KewalRamani, 2006).  
 
Envelope proteins from newly transmitted viruses have been shown to retain neutralisation sensitivity 
to the transmitting partner’s antibodies as well as to CD4-binding-site monoclonal antibodies b12 and 
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VRC01 (Derdeyn et al., 2004; Wilen et al., 2011). Recent findings show that T/F viruses were more 
infectious and contained nearly 2 fold more Env incorporated per particle than the chronic controls 
were recently published (Parrish et al., 2013). Data suggest that T/F viruses have enhanced cell-free 
infectivity, improved dendritic cell interaction and relative IFN-alpha resistance. Given that HIV-1 
transmission is inherently inefficient and likely represents the most vulnerable point in the natural 
history of HIV-1 infection, identifying unique properties and potential vulnerabilities of T/F viruses 
remains an important objective for the development of prevention strategies. 
 
1.6 The mucosal immune system: structure and function 
The largest component of the mucosal immune system is the gut associated lymphoid tissue (GALT) 
that spans the gastrointestinal tract from the rectum to the oral cavity and serves to keep at equilibrium 
the essential functions of the absorption of nutrients and to protect from potential pathogenesis 
(Mowat and Viney, 1997). Several mechanisms exist within the mucosal immune system to protect 
from infiltration of pathogens such as a continuous epithelial physical barrier with tight cell junctions, 
a covering mucus layer, a variety of antimicrobial substances and the maintenance of environmental 
conditions (for example pH).  
 
Functionally, the mucosal immune system can be divided into inductive and effector sites. Inductive 
sites are the areas where antigens are collected from the lumen and immune responses initiated 
including the mesenteric lymph nodes, Peyer’s patches and isolated lymphoid follicles. Effector sites 
are regions where adaptive immune cells exert their immune pressure namely the epithelium and the 
lamina propria (Brandtzaeg et al., 2008). Anatomically however, lymphocyte populations can be 
categorised into those present in the epithelium (CD8
+
 T cells and Tϒδ cells) and those in the lamina 
propria (predominantly CD4
+
 T helper cells, CD8
+
 T cells, natural killer cells and B-cells) (Hein, 
1999).  
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The mucosal transmission event 
In contrast to the systemic immune system, most of the CD4
+
 T cells in the mucosal system are 
CCR5
+
, activated memory CD4
+
 T cells. These are preferential targets of HIV and SIV infection 
(Brenchley et al., 2004) and it is estimated that 60% of all mucosal memory CD4
+
 T cells are infected 
by HIV within the first few days following transmission (Mattapallil et al., 2005). HIV-1 traverses 
several tissue layers in the female genital tract before coming into contact with the appropriate target 
cells (Figure 1.4 Panel A) such as Langerhans cells or CD4
+
 T cells in squamous epithelium. CD4
+
 T 
cells can also be infected by viruses bound to submucosal dendritic cells. It is believed that a major 
site for HIV transmission in the female genital tract is the cervix; especially the endocervix and 
transitional zone which are only covered by a single layer of columnar epithelium (Grivel et al., 
2011).  This layer is less protective than the stratified epithelium of the vagina (Pudney et al., 2005). 
The vagina is covered by an exudate which is an effective barrier against many viruses and the upper 
genital tract is covered in mucus.  Soluble factors (such as SDF-1 which binds to CXCR4; defensins, 
complement proteins and surfactant proteins) found in mucus and the ability of mucus to trap virions 
may decrease infectivity and slow viral transmission by altering the surface charge of the gp120 timer 
(Lai et al., 2009).  
 
In the male genital tract, the penile foreskin and urethra harbour target cells (Figure 1.4 Panel B). The 
outer foreskin is heavily keratinized and is well-protected against pathogenic penetration (Ganor et al., 
2010). The inner foreskin and frenulum are covered in a thin layer of keratin and are sites of 
favourable target cells, such as Langerhans cells, which are presumed to be the first point of contact 
during penile transmission (Cohen et al., 2011). Virus-cell interactions in the male submucosa are 
likely to be comparable to the female genital tract with similar targets.  
 
The primary site of transmission in the gastrointestinal tract is the anorectal mucosa and to a lesser 
extent, the oral mucosa (Lackner et al., 2009). The anus is lined by several layers of stratified 
squamous epithelium which contains intraepithelial dendritic cells which may facilitate dissemination 
of virus (Shattock and Moore, 2003). The probability of infection through the rectum and colon is far 
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higher than the vaginal or penile route. The vulnerability of this tissue lies in the fact that only a single 
layer of columnar epithelium separates the lumen from the inner layers and may be damaged during 
sexual intercourse (Nazli et al., 2010). Furthermore, lymphocytes in this tissue are constitutively 
activated; providing a target population of highly susceptible cells. The oral mucosa does not appear 
to be a major route of HIV transmission, with the exception of mother-to-child transmission. Despite 
this, the palatine tonsil is a unique mucosal tissue as it has natural breaks in the barrier to expose 
underlying lymphocytes to the environment (Lackner et al., 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: HIV transmission through the mucosa 
HIV transmission across the (A) female and (B) male genital tract is shown here. While rectal 
transmission across thin columnar epithelium and thick mucus layer is comparative between sexes 
involving dendritic cells, CD4
+
 T cells and macrophages, transmission across stratified epithelium of 
the vagina and inner side of the foreskin differ in the presence of a mucus layer in the female genital 
tract. Dispersed within the stratified squamous epithelium are Langerhans cells (Cohen et al., 2011).  
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Given the multiple routes of transmission and the distinct histological features of the different tissues 
involved, it is not surprising that the identity of the initial cells infected with HIV remains elusive. 
Evidence to date suggests that CD4
+
 T cells and Langerhans cells are the primary targets (Hladik et 
al., 2007; van den Berg and Geijtenbeek, 2013) with an implication that dendritic cells may be the 
initial contact for HIV (Lackner and Veazey, 2007). Macaque studies suggest that mucosal infection 
may be dependent upon the ability of T/F viruses to infect resting CD4
+
 effector memory T cells 
(Haase, 2010). While the virus traverses the mucosal barrier within a matter of hours, the time for 
dissemination may be between 3 and 6 days. Following this initial step there is rapid dissemination 
into the draining lymph nodes and systemic circulation along with the establishment of viral 
reservoirs (Emau et al., 2006). The adjunctive damage to the mucosal tissue following HIV infection 
causes alterations in intestinal structure and leakage or translocation of gut bacterial products into 
sterile tissues, leading to further immune activation, increasing HIV replication (Brenchley and 
Douek, 2008). 
 
Preferential infection of the GALT by HIV 
While only 0.01-1% of peripheral CD4
+
 T cells are productively infected with HIV (Brenchley et al., 
2004), in striking contrast 60% of mucosal memory CD4
+
 T cells becoming infected at the time of 
peak viremia (Mattapallil et al., 2005). Regardless of the route of transmission, HIV-1 develops a 
rapid and extensive infection within the GALT which has been described as the principle and initial 
site of viral replication (Arthos et al., 2008; Brenchley et al., 2006; Lackner et al., 2009). The 
activated state of the GALT is thought to be as a result of constant antigenic exposure in the junction 
between the lumen of the gut and the epithelial layers, one of the possible reasons that viral 
replication is so high in this tissue (Ansari et al., 2011). The mechanism for this preferential cell 
tropism of HIV-1 for GALT is unknown; however it is hypothesised that the high frequency of 
CCR5
+
CD4
+
 T cells in GALT provides a rich target environment for HIV-1 replication (Nawaz et al., 
2011) and α4β7 expression on these T cells may facilitate virus infection and replication (Arthos et 
al., 2008; Kader et al., 2009). In addition the GALT tissue harbours in excess of 40% of all 
lymphocytes in the body (Hein, 1999). 
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Homing of T cells to the GALT 
As T cells only detect pathogens through direct contact with the MHC-presented antigen, they must 
traffic to the site of pathogenic exposure. Dendritic cells trap antigens in secondary lymphoid organs 
and naïve T cells exit the thymus and migrate preferentially to these regions; a process referred to as 
homing (Butcher and Picker, 1996). The encounter with antigen causes activation and proliferation of 
effector memory T cell clones that home to sites of inflammation where they come into contact with 
other cell types to elicit other immune responses. Following antigen clearance, the majority of effector 
cells die, some remain for long-term protection against repeated exposures to the antigen (Sallusto et 
al., 1999).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Homing of T lymphocytes 
Naive T cells home continuously from the blood to lymph nodes and other secondary lymphoid 
tissues. Homing to lymph nodes occurs in high endothelial venules (HEV), which express molecules 
for the constitutive recruitment of lymphocytes. On stimulation, T cells proliferate by clonal 
expansion and differentiate into effector cells, which express receptors that enable them to migrate to 
sites of inflammation (von Andrian and Mackay, 2000).  
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In order to leave the circulation and home to various tissues, leukocytes must engage sequential 
adhesion pathways (Figure 1.5). This sequence involves lymphocyte rolling, chemokine-mediated 
activation, firm adhesion to the vessel wall and finally transendothelial migration into the tissues. 
Molecules involved in the cascade include selectins, chemokines and their receptors, integrins and 
their immunoglobulin superfamily ligands (Berlin et al., 1995; Kim and Broxmeyer, 1999; von 
Andrian and Mackay, 2000). Specific to the gut, the homing receptors that are relied upon to maintain 
the levels of lymphocytes are largely the β7 containing integrins α4β7 and αEβ7 and the CCR9 
chemokine receptor and its ligand CCL25 (Berlin et al., 1993; Kunkel et al., 2000; Wagner et al., 
1996). Of particular interest in this study is the integrin α4β7. 
 
1.7 Integrin α4β7: regulation, structure and function 
Integrins are transmembrane cell adhesion receptors that consist of non-covalently associated α and β 
subunits that mediate cell-extracellular matrix (ECM) and cell-cell interactions (Pribila et al., 2004). 
Among the adhesion receptors, integrins are unique in the diversity of their ligands and mechanisms 
of attachment. Vertebrates express 18 α and 8 β subunits that combine to form 24 known integrins 
(Gorfu et al., 2009). Integrins are responsible for two forms of signalling processes: (i) “Inside-out” 
signalling involves the transport of proteins to the integrin cytoplasmic domains and multicomplex 
formation resulting in clustering of integrins and increased avidity for its ligand (Denucci et al., 2009) 
and (ii) “outside-in” signalling whereby cytoplasmic complexes link the integrin with the actin 
cytoskeleton and intracellular signalling pathways, allowing for the integrin signalling into the cell. 
Conformational changes to integrins can elicit cell-signalling events that increase affinity for their 
ligands, as well as promote cytoskeletal rearrangement and viral internalisation (Stewart and 
Nemerow, 2007).  
 
Unique amongst the integrins is α4β7. The α4 subunit associates with either the β1 subunit or with β7. 
The β7 subunit can also pair with the αE subunit, which is expressed on naïve CD8+ T cells and CD4+ 
T regulatory cells but not naïve CD4
+
 T cells (Lehmann et al., 2002; Masopust et al., 2006).  
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Functions of α4β7 
While selectins are the primary mediators of tethering and rolling during the homing process, α4β7 
uniquely mediates both rolling and firm adhesion and has a specialised structure to do so; with low 
affinity and high affinity forms triggered for different functions (Yu et al., 2012). α4β7 has been 
implicated in the formation of secondary lymphoid structures (Mebius et al., 1998), protective 
immunity against pathogens (Kuklin et al., 2001) and in the progression of gut inflammation; playing 
a central role in the development of inflammatory bowel disease (IBD) (Feagan et al., 2005), graft 
versus host disease (GVHD) (Ueha et al., 2007) and diabetes (Iwata et al., 2004). Certain studies have 
shown that there is a compartmentalised usage of adhesion molecules along the intestine with integrin 
being of less importance in the large intestine and essential in the small intestine (Bell and Else, 
2008).  
 
Ligands of α4β7 
The primary ligand for α4β7 is mucosal addressin cell adhesion molecule-1 (MAdCAM-1); an 
addressin that is expressed primarily on the high endothelial venules of the Peyer’s patches, 
mesenteric lymph nodes and the postcapillary venules of the lamina propria of the gut (Berlin et al., 
1993; Streeter et al., 1988). MAdCAM-1 is also expressed in the thymic medulla, tonsils, nasal 
associated lymphoid tissues, pancreas and brain (Briskin et al., 1997). MAdCAM-1 is highly 
expressed on the processes of follicular dendritic cells present in germinal centers, mesenteric lymph 
modes and Peyer’s patches and may be involved in the activation of B cells (Carrasco and Batista, 
2006).  MAdCAM-1 displayed variable expression on the genital tract (Johansson et al., 1999). Its 
expression is unregulated in areas of inflammation in GALT especially in the case of chronic 
inflammatory diseases (Kelly and Rank, 1997). In addition to the GALT, it is aberrantly expressed in 
the eyes, joints, liver and skin during active IBD (Adams and Eksteen, 2006) and upregulated in the 
genital mucosa following infection with Chlamydia trachomatis (Kelly and Rank, 1997). MAdCAM-
1 has also been implicated in the homotypic clustering of melanoma cells in malignancy (Leung et al., 
2003) and clearly has an extensive and entrenched role in immunity extending beyond the GALT.  
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MAdCAM-1, vascular cell adhesion molecule -1 (VCAM-1) and fibronectin all bind α4β7 through 
structurally homologous binding motifs (Jackson, 2002). The minimal binding epitope for MAdCAM-
1 is a tripeptide loop Leu-Asp-Thr (LDT), while fibronectin binding requires Leu-Asp-Val (LDV) and 
VCAM requires Ile-Asp-Ser (IDS). In all natural-ligand binding motifs, the aspartic acid residues are 
essential to binding, the removal of which abrogates the interaction (Jackson, 2002). However α4β7 
binds at a lower affinity to VCAM-1 and fibronectin compared to MAdCAM-1 (Andrew et al., 1994), 
MAdCAM-1 binds α4β7 by interacting with the metal ion at the metal ion-dependent adhesion site 
(MIDAS) in the β7 I domain (Sun et al., 2011) allowing for integrin activation and clustering as 
shown in Figure 1.6. The principal contact site for the natural ligands of α4β7 is present on the α-
chain (Zeller et al., 2001).  
 
 
 
 
 
 
 
  
 
 
 
Figure 1.6: Activation and binding of α4β7 to MAdCAM-1 
When activated, α4β7 present on the surface of lymphocytes binds to its putative ligand MAdCAM-
1in the presence of metal ions. Two sites of contact exist in both domains of MAdCAM-1; one of 
which is the minimal binding tripeptide motif LDT in the CC’ loop of MAdCAM-1 as shown in the 
green box (adapted from (Papst et al., 2012; Sun et al., 2011).  
 
Regulation of α4β7 expression 
Several levels of biological processes regulate α4β7 expression, including transcription, post-
transcriptional events, translation in endoplasmic reticulum, dimerization and transport to the cell 
 
 
LDT 
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surface (Humphries, 2000). Although the majority of circulating T cells express both α4 and β7 
subunits, they are mostly in an inactive conformation. As a result of contact with cognate antigen in 
the Peyer’s patches and mesenteric lymph nodes, dendritic cells present in the GALT induce rapid 
upregulation and induce a higher activation state of gut-homing receptors α4β7 and CCR9 by the 
action of all-trans retinoic acid (Iwata et al., 2004). CD103
+
 mucosal dendritic cells in the mesenteric 
lymph nodes and in the gut lamina propria but not in the skin or spleen express high levels of retinal 
dehydrogenase (RALDH), an enzyme that is essential for retinoic acid production from Vitamin A 
(Iwata et al., 2004; Jaensson et al., 2008; Johansson-Lindbom et al., 2005). However, in the absence 
of dendritic cells, retinoic acid alone is able to upregulate α4β7 and CCR9 expression (Arthos et al., 
2008). Retinoic acid increases α4 mRNA levels, while β7 and β1 levels remain constant (DeNucci et 
al., 2010). There are high amounts of intracellular β7 (in excess of α4 that serve as a reservoir for 
α4β7 pairing) but not β1 in naïve T cells; therefore overexpressed α4 increases α4β7 expression, 
without alteration in β1 expression (DeNucci et al., 2010). Another regulation mechanism explains 
that the Itg-α4 chain in T cells requires retinoic acid for transcription whereas the Itg-β7 genes require 
TGFβ for transcription (Kang et al., 2011). This upregulation has been described on CD8+, CD4+, B 
cells and natural CD4
+
 CD25
+
 FOXP3
+
 T regulatory cells (Johansson-Lindbom et al., 2005; Mora et 
al., 2003; Siewert et al., 2007). In contrast, a vitamin D metabolite suppresses retinoic acid induction 
of α4β7 and CCR9 while increasing the expression of skin homing receptors in T cells (Mora et al., 
2008). IL-7, a non-redundant cytokine essential for homeostasis of the T lymphoid compartment, is 
expressed by stromal cells as well as thymic and intestinal epithelial cells (Watanabe et al., 1995) and 
is under clinical trials as an immune-reconstitution agent in AIDS (Mackall et al., 2011). Recently, 
Cimbro and colleagues demonstrated that IL-7 induces expression and functional activation of α4β7 
in vitro and in vivo (Cimbro et al., 2012). While retinoic acid mediated upregulation of α4β7 requires 
TCR stimulation and occurs on naïve and memory T cells, IL-7 mediated upregulation does not 
require TCR stimulation, reflecting two mechanisms of α4β7 T cell homing indicative of different 
physiological states (Cimbro et al., 2012).  
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α4β7 signalling  
Integrin adhesiveness, central to the α4β7-homing function, is regulated by intracellular signalling 
pathways that are dependent on the cytoplasmic domains of integrins and enforce changes in the 
integrin conformation, clustering (Yauch et al., 1997), affinity and cell spreading (Krissansen et al., 
2006). Small GTP-binding molecules induce binding of α4β7 to its ligand MAdCAM-1 in hierarchical 
manner involving changes in receptor avidity because of ligand-induced clustering (Zhang et al., 
1999). The α4- chain has three LDV motifs which could support cell-binding to α4β7+ cells, thus 
offering an explanation for α4-triggered homotypic cell aggregation (Altevogt et al., 1995).  
 
1.8 α4β7 is an attachment factor for HIV 
Adhesion molecules were first implicated in HIV pathogenesis with the discovery that β2 integrins 
were involved in HIV-induced syncytium formation in T cells and monocytes (Hildreth and Orentas, 
1989). Since then, Arthos and colleagues showed that the HIV-1 envelope protein gp120 binds to and 
signals via the α4β7 integrin on CD4+, CD8+ T cells and NK cells and activates LFA-1 in an α4β7-
dependent way (Arthos et al., 2008). This is an important finding because in the tissue where HIV 
preferentially replicates, the virus’ envelope protein interacts directly with a homing receptor integral 
to CD4
+
 T cells in the tissue. This mechanism may account, in part, for the GALT being the region of 
rapid and preferential HIV infection, integral to the dissemination of the virus. 
 
Mechanism of α4β7-gp120 interaction 
The principal contact sites for the natural ligands of α4β7 are present on the α4-chain (Zeller et al., 
2001). By blocking α4β7 activity with anti-α4, β7 and α4β7 mAbs that target an epitope near 
MAdCAM-1 (Schiffer et al., 1995), Arthos and colleagues showed that gp120 binds to α4β7 at sites 
near the target of the natural ligands of the integrin. Present in the V2 loop of gp120 is a tripeptide 
consensus sequence consisting most frequently of Leu-Asp-Val (LDV) at positions 182-184 (by 
HXB2 numbering). In addition the aspartic residue in gp120 is conserved in 98% of gp120s present in 
the Los Alamos HIV database (Arthos et al., 2008; Kwong et al., 2002). The binding of the V2 loop to 
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α4β7 may facilitate viral entry by lowering the entropic barrier that slows the ligation of envelope 
spikes to CD4 (Kwong et al., 2002; Zhou et al., 2007). This interaction is highly conserved across 
subtypes of HIV as well as SIV.   
 
α4β7 co-localises with CCR5 and CD4 on both retinoic acid treated peripheral T cells as well as T 
cells derived from the gut, with the latter showing increased CD4 clustering (Arthos et al., 2008; 
Cicala et al., 2009). The position of α4β7 relative to CD4 and CCR5 is shown in Figure 1.7. Using 
acceptor-photobleaching Forster resonance energy transfer (FRET) and co-precipitation studies, β7 
was found to reside within 1.2 nm of CD4 and considering their relative height and the estimated 
diameter of  the gp120 trimer (Kwong et al., 2000), it is likely that the gp120 trimer will encounter 
α4β7 prior to CD4 (Cicala et al., 2009). HIV binding to α4β7 is independent of CD4 binding, unlike 
co-receptor (CCR5 and CXCR4) binding (Cicala et al., 2009). α4β7 extends more than 20nM from the 
cell surface (Chigaev et al., 2003), while comparatively CD4 extends 7nM from the surface (Wu et 
al., 1997). Unlike the HIV entry receptors CD4 and CCR5, α4β7 is not an absolute requirement for 
viral replication in vitro. This, coupled with its position on the cell surface indicates that α4β7 could 
serve as an attachment factor for HIV infection and it is likely that it binds gp120 prior to CD4 
engagement. This is in line with a structural analysis that places the V1/V2 region of gp120 (contains 
the tripeptide for α4β7 binding) at the apex of the trimeric spike (Liu et al., 2008; Mao et al., 2013). 
Different alleles of the ITGA4 gene, encoding for the α4 subunit of α4β7 have different affinity for 
natural ligands, anti-α4β7 monoclonal antibodies and gp120. This finding suggests that HIV-1 
acquisition, resistance to disease, progression, viremia control and CD4
+
 T cell depletion may be 
influenced by ITGA4 polymorphisms in primate species and humans (Darc et al., 2011).   
 
 
 
 
 
 
23 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Position of α4β7 relative to CD4 and CCR5 
The α4β7 integrin extends above the cell surface approximately 3 fold higher than that of CD4. CD4 
and α4β7 are very close and can be co-precipitated. V1/V2 loops that contain the α4β7 binding motif 
are predicted to be on the tip of gp120 and are shown in maroon here (Cicala et al., 2009).  
 
Effects of HIV- α4β7 binding 
Apart from the ability to take advantage of the homing function of α4β7 and facilitate dissemination 
of HIV-1 to the GALT, the effects of binding may be extensive. LFA-1 is an integrin that is linked 
directly to α4 (Chan et al., 2000) and is essential to immunological synapse formation (Bromley et al., 
2001). HIV has been found to commandeer LFA-1 to form virological synapses which facilitate cell-
to-cell transmission (Jolly and Sattentau, 2004; Piguet and Sattentau, 2004). Arthos and colleagues 
illustrated that LFA-1 can be activated by gp120 using a mechanism that is α4β7 dependent and that 
LFA-1, α4, CD4 and gp120 cluster at the interface of infected and uninfected cells (Arthos et al., 
2008). In addition, gp120 is able to drive homotypic clustering and clustering of homing receptors 
(Birdsall et al., 1997). α4β7 binding increases activation as well as the expression of LFA-1 (Arthos et 
al., 2008).  
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α4β7 and HIV-1 transmission 
Evidence suggests that the gp120-α4β7 interaction may be especially significant in the earliest stages 
of HIV infection. In SIV infected macaques, sub-optimally activated memory CD4
+
 T cells form the 
founder target population for infection (Li et al., 2005). In humans, non-activated cells in the gut show 
evidence for productive infection (Mehandru et al., 2007). In these resting cells LFA-1 is mainly 
inactive and represents a target for gp120-α4β7 mediated interaction (Tardif and Tremblay, 2005). 
Antigen-specific α4β7+ CD4+ T cells are found in the genital mucosa where CD4+ T cells are first 
infected following sexual intercourse (Hawkins et al., 2000; Kelly et al., 2009). α4β7, through its 
homing function, is functionally linked to each of the sites involved in acute infection. With the aid of 
α4β7, HIV is able to gain rapid access to compartments of immunity that have a high number of target 
cells and as a result, the probability of irreversible infection is greatly increased. 
 
It has been reported that α4β7 high CD4+ T cells are more susceptible to productive infection by HIV-
1 than those expressing low levels of the integrin, in part because this subset is enriched for activated 
CD4
+
 T cells, and in part because they express high levels of CCR5 and low levels of CXCR4 (Cicala 
et al., 2009). This phenotype extends to blood, rectum, colon and genital mucosa of the female 
reproductive tract (cervical cytobrush) (Cicala et al., 2009; Kelly et al., 2009). It has been reported 
that during the acute phase of SIV infection, α4β7 high CD4+T cells are preferentially infected and 
that α4β7+ T cells are depleted in lamina propria and rectal lymphoid nodes (Kader et al., 2009; Vajdy 
et al., 2000). In humans, circulating α4β7+ CD4+ T cells are preferentially depleted following acute 
HIV infection (Krzysiek et al., 2001). Prior to the onset of viral infection (except in the case of other 
inflammatory disease of sexually transmitted disease and other compounding factors), the fully 
activated CD4
+
 T cells are in the minority (Zhang et al., 2004b) and with most of these expressing 
α4β7, it is likely that α4β7 plays an important role in the establishment of infection. The genital 
mucosa does not contain organised immune-inductive sites but relies upon α4β7+ T cells to traffic 
from organised inductive sites including the Peyer’s patches (Mestecky and Fultz, 1999) and it is 
possible that the initial and most relevant site for the gp120-α4β7 interaction is the genital mucosa in 
the initial days following transmission. As a result of sexual transmission being a highly inefficient 
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process, any advantage would be of benefit for HIV replication. The impact of the α4β7-gp120 
interaction varies for different viral isolates, even for clones within the same individual at similar 
periods of pathogenesis (Arthos et al., 2008). This suggests that the stronger the affinity for α4β7, the 
higher the transmission fitness of the virus. Three early–transmitting gp120 monomers were found to 
have higher α4β7 reactivity than their matched chronic counterparts. To this end, Nawaz and 
colleagues showed that at the time of mucosal transmission selection for T/F viruses that have reduced 
glycosylation correlates with an increase in α4β7 reactivity and that this may be a transmission 
signature exploited for therapies (Nawaz et al., 2011). This effect appears to be linked to the change in 
conformation of V1/V2 and C3/V4 rather than steric occlusion (Nawaz et al., 2011). In the case of 
Chlamydia infection, antigen-specific α4β7+ T cells increase in number in the female genital tract 
homing to the GALT, suggesting that isolates with the ability to engage α4β7 are more likely to come 
into contact with rich target cells (Hawkins et al., 2000; Kelly et al., 2009; Kelly and Rank, 1997). 
Therefore, bottlenecks created as a result of sexually transmitted co-infections may determine α4β7 
reactivity at transmission.   
 
In contrast, Parrish and colleagues have described that in vitro anti-α4β7 mAbs had no inhibitory 
effect on viral replication and therefore no selective advantage offered by α4β7 during HIV 
pathogenesis with the exception of SF162, a subtype B virus (Parrish et al., 2012).While this result is 
pertinent, because much of gp120-α4β7 interaction hypothesis is based on binding studies, the chronic 
and T/F viruses studied were not matched and were of a small number with only six T/F and six 
chronic viruses examined. Furthermore concentrations of inhibitory mAbs used and determined as 
saturating in α4β7-binding assays increased HIV replication in many cases as a result of homotypic 
clustering triggered by α4β7-mAb binding.  
 
Despite this controversy, SIV infected rhesus macaques treatment with anti- α4β7 mAbs, displayed a 
decreased viral load and reduction of viremia and proviral DNA load in the GALT (Ansari et al., 
2011). This proof-of-concept suggests a role for α4β7 in HIV transmission. During acute SIV and 
26 
 
HIV infection α4β7 has been found to be upregulated on CD4+ T cells as well as NK cells (Cummins 
et al., 2001; Reeves et al., 2010), suggesting a role for the integrin in dissemination. 
 
1.9 α4β7 defines a subset of T lymphocytes highly permissive to infection 
α4β7 is expressed on naïve T and B cells at a low level (Erle et al., 1994). It is also expressed on NK 
cells, monocytes, dendritic cells, macrophages and eosinophils. The expression of this integrin is 
however enhanced on IgA expressing plasma cells and on memory gut-homing CD4
+
 subsets 
(Schweighoffer et al., 1993). α4β7 denotes a subset of CCR5 high memory CD4+ T cells that are  
strongly reactive for Ki67, a marker of cellular metabolism and activation (Cicala et al., 2009) evident 
and present in peripheral blood as well as in rectum, colon, female reproductive tract (Cicala et al., 
2009) and cerebrospinal fluid (Kivisakk et al., 2006).  
 
It has been reported that α4β7 high CD4+ T cells are more susceptible to productive infection by HIV 
than those expressing low levels of the integrin, in part because this subset is enriched for activated 
CD4
+
 T cells, and in part because they express high levels of CCR5 and low levels of CXCR4 (Cicala 
et al., 2009). Highly α4β7-expressing CD4+ T cells with a resting memory phenotype serve as the 
dominant target of SIV infection during acute infection (Kader et al., 2009).  
 
A delicate balance exists in the intestinal tract to maintain protection of the tissues without inducing 
autoimmune inflammation. This balance is disrupted in the GALT during HIV infection. At least two 
CD4
+
 T cell subsets have been found to maintain this balance and their disruption may be the cause of 
microbial translocation during HIV pathogenesis. These subsets, Th17 (pro-inflammatory) and T 
regulatory cells (anti-inflammatory) shown in Figure 1.8, are present in the GALT and genital 
mucosa, are regulated by retinoic acid and express α4β7, and as a result, are of interest in order to 
understand the initial dissemination of the virus to sites distal to the genital mucosa.  
 
 
27 
 
 
 
 
 
 
 
 
 
Figure 1.8: Development of Th17 and Treg CD4
+
 T cells 
Polarisation of naïve T cells to Th17 CD4
+
 T cells occurs via stimulation by TGF-β and IL-6 and Treg 
CD4
+
 T cells by TGF-β. Treg cells can also be induced by ATRA. Treg and Th17 cells exist in 
equilibrium with anti-inflammatory Treg cells supressing Th17 pro-inflammatory ability. Adapted 
from (Sethi et al., 2013). 
 
Th17 and T regulatory cells in HIV and immunity 
A) T helper 17 cells 
Th17 cells are CD4
+
 T cells that play a critical role in the maintenance of mucosal surfaces including 
enterocyte homeostasis and defence against extracellular bacteria and fungus.  Functioning in the 
mediation of inflammation (Bettelli et al., 2006) and the development of autoimmunity, these cells 
have also been linked with the recruitment of neutrophils and macrophages to the infected tissues and 
have been found in peripheral circulation as well as the genital mucosa (McKinnon et al., 2011). Th17 
cells produce IL-17 (a marker that typically identifies them in most phenotypic studies), IL-21 and IL-
22, but not interferon gamma or IL-4 (Steinman, 2007) They express the lineage specific transcription 
factor RORϒt (Ivanov et al., 2006) and most IL-17+ T cells are CCR6+ (Brucklacher-Waldert et al., 
2009; Singh et al., 2008). CCR6 is a marker necessary for cell migration into the Peyer’s patches of 
the small intestine (Wang et al., 2009a). A number of other markers for the Th17 subset have been 
identified but are not well-characterised including CD161 (Cosmi et al., 2008) and CD152 
(Brucklacher-Waldert et al., 2009). Th17 cells differentiate in the presence of TGF-β and IL-6 
(Mangan et al., 2006; Yang et al., 2008) and the impact of retinoic acid on their phenotype is 
controversial and requires further investigation.  
Thymus 
ATRA 
Pro-inflammatory 
Anti-inflammatory 
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Th17 cells are enriched in the lamina propria of the GALT (Ivanov et al., 2008). Interestingly, CCR5 
and α4β7 expression is substantially increased on Th17 cells present in the cervix compared to those 
in the blood (McKinnon et al., 2011). The high expression of IL-17 has been shown in multiple 
sclerosis, rheumatoid arthritis and IBDs, most of which are currently treated by blockade of α4β7 
(Tzartos et al., 2008). Currently little is known about the homing of Th17 cells to sites of 
inflammation in the intestinal tissues and the kinetics of α4β7 expression on these cells under 
conditions that favour the Th17 phenotype (Gorfu et al., 2009). Indeed cells that express IL-17 but not 
β7 exhibit a 50% decrease in trafficking to the GALT (Gorfu et al., 2009). Th17 CD4+ T cells require 
IL-7 for survival and expansion (Liu et al., 2010), an interleukin that has recently been described to 
upregulate α4β7 (Cimbro et al., 2012).  It has been reported that most Th17 CD4+ T cells express 
α4β7 (Ansari et al., 2011) and another study, suggested that α4β7+ are mostly Th17 CD4+ T cells 
(Kader et al., 2009). 
  
Multiple susceptibility factors for HIV are expressed in tandem on Th17 cervical T cells. These cells 
are depleted preferentially in cervical tissue and bind gp120 and as such, this population has been 
suggested as a founder target group for HIV transmission (McKinnon et al., 2011). Evidence suggests 
that Th17 cells are the most prominently depleted CD4
+
 T cell subset following HIV/SIV infection 
(Brenchley et al., 2008). Besides being highly susceptible to infection, the loss of Th17 cells provides 
a direct link between CD4
+
 depletion and immune dysfunction, as the major function for IL-17 is the 
strengthening of mucosal epithelial tight junctions (Blaschitz and Raffatellu, 2010). In nonhuman 
primates, depletion of Th17 cells following SIV infection was associated with loss of Salmonella 
typhimurium control leading to system leakage of bacterial components (Raffatellu et al., 2008). Th17 
cells are lost in the gastrointestinal tract of HIV individuals (Brenchley and Douek, 2008) but another 
study has shown that HIV infected individuals have higher IL-17 levels than healthy individuals 
(Maek et al., 2007). The loss of Th17 cells has been found to be predictive of systemic and sustained 
T cell activation (Favre et al., 2009). 
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Th17 cells themselves are highly susceptible to HIV infection and express high levels of CCR5 (El 
Hed et al., 2010). It has been shown that SIV replication in the infected rhesus macaque is limited by 
the size of the pre-existing Th17 cell compartment: those that had a higher representation pre-
infection (higher Treg: Th17 ratio) had a lower viral set point (Hartigan-O'Connor et al., 2012) and 
are therefore correlated with protection against replication acutely and for months following infection. 
In chronically infected HIV individuals the frequency of T cells is rapidly decreased and a higher 
frequency of viral DNA is found in Th17 cells (Gosselin et al., 2010). Indeed these cells may be 
restored via antiretroviral treatment if therapy is started at the time of infection (Alvarez et al., 2012; 
Macal et al., 2008). Since α4β7 is an attachment factor for HIV, preferential depletion of Th17 cells 
during HIV infection has been described as a result of α4β7 high expression on these cells (Kader et 
al., 2009). However, CCR6 being a marker of Th17 cells and critical for migration into the small 
intestine has been found to denote a subset that is highly permissive to HIV infection regardless of the 
expression of α4β7 (Monteiro et al., 2011). A recent study showed that Th17 CCR6+ T cells expressed 
higher levels of α4β7 and bound gp120 more extensively (Alvarez et al., 2013). Understanding the 
mechanism of Th17 cell depletion during HIV and the phenotype of those that express susceptibility 
markers such as α4β7, is imperative for the development of future therapies for restoration of immune 
function in HIV infected individuals.  
 
B) T regulatory T cells 
T regulatory cells (Tregs) serve to attenuate immune responses and remain in homeostasis with pro-
inflammatory Th17 cells by efficiently suppressing their effector functions (Crome et al., 2010). 
While the phenotypic markers expressed by Th17 cells are well defined, those of Treg cells are not. 
The most comprehensive definition of the phenotype currently used is CD25 high FOXP3
+
 
CD127neg/low CD4
+
 T cells, although the correlation between CD25 and FOXP3 in humans is far 
less prominent than in mice (Liu et al., 2006; Valmori et al., 2006). Recent findings however indicate 
that some Treg cells can produce IL-17 and IL-17 negative Treg cells can convert into IL-17 
producing cells (Auvert et al., 2005; Deknuydt et al., 2009). FOXP3
+
 T cells that are produced in the 
thymus from T cell progenitors are known as natural Treg cell. However FOXP3+ T cells known as 
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inducible Tregs are also found in the GALT, the development of which is mediated by ATRA 
secreted by GALT-dendritic cells in synergy with TGF-β (Sun et al., 2007). The phenotypic marker 
used to differentiate the latter from the former is the presence of Helios (Thornton et al., 2010), but it 
is controversial and therefore these two groups are not really differentiated in humans but rather in 
mice for passive immunotherapy of inflammatory diseases. This peripheral induction is accompanied 
by an increase in α4β7 expression to illicit enhanced homing to the GALT where inflammatory 
homeostasis is required (Benson et al., 2007). It is unknown whether Treg cells use conventional 
homing receptors such as α4β7 to migrate to the gut like effector cells (Gorfu et al., 2009). Gut 
homing deficient Treg cells are still able to elicit suppressive functionality in the GALT (Denning et 
al., 2005), this suggests that there are alternate routes of trafficking Treg cells to this region. About 
50% of FOXP3
+
 Treg cells express L-selectin which can bind MAdCAM-1 (Huehn et al., 2005). As a 
result the mesenteric lymph nodes may be a site where β7-deficient cells accumulate and inhibit the 
initial priming of pathogenic T helper cells.  
 
A significant drop in FOXP3
+
 Treg cells has been noted during SIV and HIV infected individuals 
(Andersson et al., 2005; Estes et al., 2006). However, a number of more recent studies reported an 
increase in Treg  T cell number following HIV infection has also been described in lymph nodes and 
duodenal tissue (Li et al., 2011a; Shaw et al., 2011) as well as a slight elevation in blood (Kinter et al., 
2004). Stage of infection is an important factor as well with studies reporting either a lower or higher 
Treg proportion during acute infection and the majority of studies showing an increase in Treg 
frequencies in chronic infection regardless of phenotyping strategy used (Chevalier and Weiss, 2013). 
Reports indicate that frequencies of Treg cells in the GALT are significantly higher than in the blood 
following HIV infection suggesting, homing of these cells (Rios et al., 2012). While agreement on the 
correct phenotypic markers for Treg cells is controversial, studies have shown that FOXP3 alone is 
increased and is a marker for HIV disease progression (Rallon et al., 2009; Suchard et al., 2010; 
Zhang et al., 2008). It is also possible that it is the relative balance of Treg and Th17 subsets, rather 
than either alone that drive HIV pathogenesis (Kanwar et al., 2010). Treg cells in HIV and SIV may 
decrease chronic immune activation which may slow disease progression (Kinter et al., 2004) or they 
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may inhibit antiviral responses, thereby increasing disease progression (Nilsson et al., 2006). While 
the latter is more widely accepted in the literature, discriminating clearly between which of these is 
occurring in vivo has been fraught with contradictions.  
 
Several studies have shown in vitro that Treg cells are highly susceptible to HIV infection (Chase et 
al., 2008; Moreno-Fernandez et al., 2009; Oswald-Richter et al., 2004). Moreover, HIV-1 infection in 
Treg cells has been described as increasing α4β7 expression (Ji and Cloyd, 2009) and survival 
(Nilsson et al., 2006). Studies have shown that antiretroviral therapy can restore Treg cell levels to 
that of a healthy control, similarly to Th17 cells (Epple et al., 2006; Montes et al., 2011).  
 
Taken together, these data suggest that Th17 and Treg CD4
+
 T cells may have a role in viral 
dissemination to secondary tissues following transmission. 
 
1.10 α4β7 as a therapeutic and vaccine target 
Integrins are attractive drug targets for interfering with cell proliferation, migration and tissue 
localisation. By modulating essential elements of the homing of naïve T cells or dendritic cells, 
clinicians might prevent, attenuate, or enhance immune responses to new antigens, such as allografts 
or vaccines. Because this treatment would not interfere with the responses of memory T cells, it 
should not be globally immunosuppressive and therefore may be a suitable approach (von Andrian 
and Mackay, 2000).  
  
One therapeutic option to prevent inflammatory disease is perturbing the de-adhesion of integrins by 
mutation, shown to decrease migration of leukocytes to inflamed tissue (Park et al., 2007; Semmrich 
et al., 2005). Natalizumab is a humanized antibody that is directed against α4β7 and α4β1integrins 
and has shown efficacy for the treatment of multiple sclerosis and Crohn’s disease (Ghosh et al., 
2003; von Andrian and Engelhardt, 2003). Interestingly, Natalizumab was removed from the market 
for a period because several patients who had received additional immunosuppressive therapy 
developed progressive multifocal leukoencephalopathy as a result of the reactivation of the John 
Cunningham (JC) virus (Langer-Gould et al., 2005), bringing into question the validity of this 
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treatment for other diseases. Such therapeutic targeting should take into account that there are 
multiple roles of adhesion molecules in the immune system and blocking them is likely to be a 
double-edged sword that may have effects ranging from lymphocyte costimulation, polarisation and 
survival. Humanised Act-1 (Vedolizumab) demonstrated efficacy in clinical trials for ulcerative colitis 
and Crohn’s disease (Feagan et al., 2005) and is the first antagonist showing a reduction of viral load 
in SIV infected macaques (Ansari et al., 2011). Interestingly, novel vaccine targets are also being 
investigated such as a strategy that targets ALDH1a2, a retinoic acid producing enzyme in GALT 
dendritic cells. Silencing the enzyme resulted in a decreased expression of α4β7 and redirected gp140 
specific immune responses from the gut to the genital tract, allowing for α4β7-low immune response 
(Zhu et al., 2013). 
  
α4β7+ T cells have been implicated in a number of therapeutic and vaccine strategies; the level of 
α4β7+ T cell expression in the blood has been investigated as a marker for tracking CD4+ T cell loss in 
the intestine as a result of SIV infection (Wang et al., 2009b). The failure of the STEP trial (a 
randomised vaccine trial of a T cell based vaccine aimed at limiting HIV replication) was attributed in 
part to the expansion of α4β7+ CD4+ T cells as a result of the use of Adenovirus type 5 vector for 
vaccination (Chakupurakal et al., 2010). The only HIV vaccine to show some level of protection, the 
RV144 Thai trial, showed antibodies to V1/V2 as a correlate of protection – the gp120 region in 
which α4β7 binding motif is present. Furthermore, Rolland and colleagues showed that vaccine 
efficacy directed at the tripeptide α4β7 binding motif was 78% if viruses were mismatched to the 
vaccine at position 181(Rolland et al., 2012). Indeed there are naturally occurring V2 antibodies in 
HIV infection that have been found to target the α4β7 epitope during HIV infection including 697-D, 
of which the epitope includes two residues of the LDV/I motif (Gorny et al., 1994; Gorny et al., 2012; 
Nakamura et al., 2012). A recent publication also showed that a mutation in the α4β7 binding motif 
dramatically increased the binding of several mAbs directed at V1/V2 (Mayr et al., 2013). It is 
becoming clear that blocking α4β7, its gp120 binding site or inducing antibodies specific for this 
region in a vaccine may be a viable option as a means to fight the scourge of HIV.  
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Aims and objectives 
Overall aim of this study 
The aim of this study is to investigate the role of integrin α4β7 at various stages of HIV pathogenesis, 
to define α4β7-expressing CD4+ T lymphocytes with focus on Th17 and Treg subsets and to 
determine how α4β7 expression affects permissiveness of these subsets to acute HIV infection.  
 
Rationale for this study 
The role of integrin α4β7 in HIV pathogenesis has been controversial, with gp120 monomeric 
proteins derived from early transmitting viruses showing increased binding to α4β7 (Nawaz et al., 
2011) . However, in a study by Parrish et al using infectious replicative virus, this observation could 
not be repeated. Using 6 unmatched T/F and chronic IMCs pairs they found no difference in their 
affinity for α4β7 (Parrish et al., 2012). While the binding of whole virions to the integrin is far more 
biologically relevant, determining the role of α4β7 in HIV pathogenesis in this manner with matched 
viruses longitudinally over time from several individuals is needed to adequately address this 
question.  
 
In addition, although α4β7 has been shown to define a subset of CCR5 high CD4+ T cells that are 
highly activated (Cicala et al., 2009), the relevance of this subset in the genital mucosa at the point of 
transmission and the GALT and the link between these two regions has not been fully elucidated.  
Two subsets that exist in equilibrium in these regions of mucosa have been determined as α4β7-
expressing; Th17 and Treg CD4
+
 T cells (Ji and Cloyd, 2009; Kader et al., 2009; McKinnon et al., 
2011). While the Th17 subset has been extensively linked with the integrin in a pro-inflammatory 
role, Treg CD4
+
 T cells have not been as widely investigated in this manner despite the fact that these 
cells are regulated by ATRA produced by GALT-dendritic cells, similar to the upregulation of α4β7 
(Kang et al., 2007). Establishing expression levels of the integrin on these subsets and how permissive 
they are to acute HIV infection, may provide a possible route of viral dissemination from the site of 
transmission. The elucidation of a clear role for α4β7 throughout the course of infection and viral 
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dissemination may allow for the integrin to be exploited either as a preventative target or as a therapy 
for HIV-infected patients to reduce the damaging effects of immune activation. 
 
Specific Aim 1: 
To examine the nature of the binding interaction between α4β7 and infective HIV virus, the 
dependence on α4β7 for viral replication at different stages of HIV-1 pathogenesis and factors 
responsible for differences between time points and individuals. 
 
Specific Aim 2:  
To determine the phenotype of α4β7 expressing CD4+ subsets under GALT conditions (mirrored via 
ATRA treatment) with specific focus on the Th17 and Treg subsets and examine how permissive they 
are to acute HIV infection.  
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CHAPTER 2 
THE DEPENDENCE ON α4β7 FOR VIRAL REPLICATION 
CHANGES OVER THE COURSE OF HIV SUBTYPE C 
INFECTION 
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2.1 Introduction 
Regardless of the route of transmission, HIV establishes a rapid infection in the GALT (Arthos et al., 
2008). In the case of sexual transmission, the genital mucosa does not contain organized immune-
inductive sites but relies upon integrin α4β7 to traffic from organised inductive sites including the 
Peyer’s patches, and mesenteric lymph nodes (Mestecky and Fultz, 1999). α4β7 was identified as an 
attachment factor for the envelope protein of HIV, gp120 (Arthos et al., 2008). Thus it is possible that 
the initial and most relevant site for the gp120-α4β7 interaction is the genital mucosa in the initial 
days following transmission.  
 
The natural ligands of α4β7 MAdCAM-1, VCAM-1 and fibronectin, arranged in order of preference 
for α4β7, all bind through structurally homologous binding motifs (Jackson, 2002). The minimal 
binding epitope for MAdCAM-1 is a tripeptide loop Leu-Asp-Thr (LDT), while fibronectin binding 
requires Leu-Asp-Val (LDV) and VCAM, Ile-Asp-Ser (IDS). In all natural-ligand binding motifs, the 
aspartic acid residues are essential to binding, the removal of which abrogates the interaction 
(Jackson, 2002). The importance of α4β7 in HIV transmission and pathogenesis is reflected in the 
ability of α4β7 to bind HIV and that the aspartic acid imperative for α4β7 binding on V1/V2 of gp120 
is conserved in 98% of HIV-1 isolates present in the Los Alamos HIV sequence database (Arthos et 
al., 2008). Of all the sequences in this database, 72% have a LDI/V motif however, this motif is less 
conserved in subtype C at 42% than in other subtypes (B: 76%, D: 79%, AE: 74%, A: 86%, AG: 
58%). Sequences from South Africa also show a decreased conservation of the LDI/V motif (47%) as 
compared to 85% of sequences from Malawi and 81% of sequences from Zambia. Although a highly 
resolved HIV trimer structure has not yet been elucidated, V1/V2 appears in a position that would 
allow for adequate binding in line with the trimer structure from Joseph Sodroski and colleagues as 
well as the V1/V2 structure on the gp120 monomer as determined by McKellan et al in 2011 (Mao et 
al., 2013; McLellan et al., 2011).  
 
The ability of α4β7+ T cells to home to secondary lymphoid tissues and the GALT (Berlin et al., 1993; 
von Andrian and Mackay, 2000) coupled with their presence at the site of sexual transmission (Kelly 
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et al., 2009; McKinnon et al., 2011), and their co-expression with multiple HIV susceptibility markers 
(Cicala et al., 2009) suggests a level of selective advantage offered by the integrin for viral 
replication. Data from SIV infected rhesus macaques show that following treatment with anti-α4β7 
mAbs there is a decreased viral load and proviral DNA load in the GALT (Ansari et al., 2011) 
corroborating a role for α4β7 in the facilitation of replication.  
 
In a study by Nawaz, et al, gp120s representative of early-transmitting viruses were found to have a 
higher affinity for α4β7 than those of chronic viruses with fewer glycans in V1/V2 and C3/V4 
associated with higher α4β7 reactivity. However, sample sizes were very small (3 in total) (Nawaz et 
al., 2011). Contrary to observations by Nawaz and colleagues, the effect of α4β7 on replication has 
been deemed to remain unaffected by shorter glycosylated V1/V2 loops in matched early (1-6 
months) and chronic (ranging between 24-47 months) viruses from eight individuals (Etemad et al., 
2013). Although intriguing, these data generalise early viral time points, do not consider T/F viruses 
and defined chronic viruses at different time points across individuals. Furthermore, a study by 
Parrish and colleagues investigated six T/F and four chronic infectious molecular clones to determine 
dependence on α4β7 for viral replication with the finding that there was no preferential affinity of the 
T/F replicative virus for the integrin (Parrish et al., 2012). Once again, sample sizes were small and 
were unmatched. Unmatched samples are not ideal for this comparison as they allow for the 
contribution of possible confounding factors. As such, the role of α4β7 longitudinally during the 
course of HIV infection and the factors that may define α4β7 reactivity have not been clearly 
elucidated. Whether the affinity for α4β7 can be defined as a transmission signature remains 
controversial.  
 
In this study, we used infectious viruses from 11 participants from the CAPRISA cohort, matched 
over a range of time points (T/F, 1/2, 6, 12 and 39 months post infection) to determine a role for α4β7 
in HIV pathogenesis. We postulated that the immune environment at the area of HIV transmission and 
tripeptide binding motif changes may influence the affinity of the T/F viruses for α4β7. These factors, 
as well as length and glycan density of the variable loops in gp120, distance of glycans from the 
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conserved aspartic acid in the tripeptide α4β7-binding motif and position of glycans were taken into 
consideration while assessing the effect of α4β7 on HIV replication and more specifically, the 
importance of α4β7 in the transmission event.  
 
2.2. Materials and Methods 
2.2.1. Ethical Considerations and Study Population 
Human samples were previously obtained from HIV women enrolled into the CAPRISA 002 Acute 
HIV Infection Cohort, established in 2004 (van Loggerenberg et al., 2008). Participants were derived 
from a prospective cohort of 245 high-risk HIV negative African women of which 62 became HIV 
infected and from whom stored material is available. Clinical sample collection was done at 
enrolment, weekly for 3 weeks, fortnightly until 3 months, monthly until 12 months, and quarterly 
thereafter. It is a well characterised cohort covering a large demographic area and despite the mobility 
of this sex worker cohort, the retention rate after 2 years was 86.1% (van Loggerenberg et al., 2008). 
Data including CD4 count, viral load and STI status were supplied by CAPRISA having been 
obtained as described previously (Mlisana et al., 2012; van Loggerenberg et al., 2008). Written and 
informed consent was obtained from all participants and the parent study received ethical approval 
from the University of KwaZulu-Natal (Ethics number: E013/04), University of Cape Town and 
University of Witwatersrand (Ethics Number: M040202) which is renewed annually. Ethics for my 
study was obtained from the Human Research Ethics Committee (HREC) of the University of the 
Witwatersrand M120221, the certificate of which follows in Appendix A.  
 
2.2.2. Isolation and stimulation of CD4+ T lymphocytes from whole blood 
CD4
+
 T cells were isolated from whole blood of healthy donors to a purity of 99%, obtained from the 
South Africa National Blood Service (SANBS), using RosetteSep Human CD4
+
 T cell Enrichment 
Cocktail (Stem Cell Technologies, Canada) as per the manufacturer’s protocol. ATRA (Sigma-
Aldrich, Missouri) was used to induce a gut-homing phenotype on the isolated CD4
+
 T cells in culture 
with the most physiologically relevant and optimum concentration determined as 10 µM following the 
39 
 
titration of ATRA in line with various studies (Arthos et al., 2008; Iwata et al., 2004; Kang et al., 
2011). In addition, 50 ng/ml OKT3 (anti-CD3 antibody) (eBioscience, California) and 20 U/ml IL-2 
(Roche Applied Sciences, Germany) were added to the CD4
+
 lymphocytes in RPMI media with 20% 
FBS and cultured for six days at 37˚C at 5% CO2 (Arthos et al., 2008). A control for upregulation of 
α4β7 was performed under the same IL-2 and OKT3 conditions but no ATRA was added. 
 
2.2.3. Flow cytometry surface staining 
The purity of the CD4
+
 T cell isolation and the upregulation of α4β7 was routinely confirmed by flow 
cytometry by staining with optimally titrated amounts of CD3-ECD (Beckham Coulter, France), CD4-
Qdot 605 (Invitrogen, Carlsbad, CA), Anti-Human CD49d (Integrin alpha 4) PE (eBioscience, CA) 
and Anti- Human/Mouse Integrin β7 FITC (eBioscience, CA) and Aqua Fluorescent Reactive Dye 
(Invitrogen, Molecular Probes, Carlsbad) was used to define cell viability. Fluorochromes were 
diluted in a 1% BSA/ PBS buffer up to a staining volume of 50 µl. 50 µl of cells were then added to 
the staining mixture and incubated in the dark for 30 minutes at 4 ˚C. After a series of washes with the 
staining buffer, live/dead staining with Aqua Fluorescent Reactive Dye was done as above. Following 
staining, cells were fixed in 0.1% paraformalydehyde in PBS. Figure 2.1 shows the gating strategy for 
α4β7+ CD4+ T lymphocytes. Fluorescence minus one controls (FMOs) shown in the Appendix (Figure 
B4) were used to define gates and compensation controls for multicolour staining were made fresh for 
each experiment were made using beads. Any direct comparisons were carried out on the same day, 
with voltages and resulting MFIs monitored over time by the use of peak 3 beads (BD).  Donors were 
designated responders and non-responders to the ATRA treatment based on the increase or no effect, 
respectively, of the ATRA treatment on the α4β7+ population of lymphocytes. 25% of the donors 
responded to ATRA treatment and only these donors were used in further experiments. Acquiring of 
all samples was performed on a FACSAria (BD Biosciences). All data analysis was done on FlowJo 
X software (TreeStar Ashland, OR). 
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Figure 2.1: Sequential gating strategy for α4β7
+
 CD4
+
 T lymphocyte analysis  
Panel A shows gating of the lymphocyte population based on size and scatter. Panel B shows the gate to 
eliminate doublets while Panel C shows the viability of this lymphocyte population (Aqua Vital negative). 
Panel D indicates percentage of CD3+ cells of the live cells, while Panel E indicates those CD3+ cells that are 
CD4+.Panel F shows α4β7
+
 CD4
+
 T lymphocytes as denoted by the red box with responders exhibiting α4β7  
CD4+ T cell expression at a mean of 50.43 ± 3.48%. 
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2.2.4 Production of infectious envelope clones and infectious molecular clones 
Replication competent viruses, defined here as infectious envelope clones or IECs, were constructed 
using env genes from 11 CAPRISA 002 participants designated as rapid or intermediate progressors 
and whether the participants go on to produce broadly cross neutralising antibodies (Table B1 in the 
Appendix). These IECs included T/F viruses, acute (1- 3 months) and chronic infection (6-39 months) 
virus clones shown in Table 2.1. A detailed description of all IECs in this study is indicated in Table 
B2 of the Appendix. These env genes were generated by single genome amplification (SGA) for 
previous studies and were ligated into a pcDNA3.0 vector by others in the laboratory (Keele et al., 
2008). The env gene sequences were amplified by PCR from these plasmids in this study with the 
reaction mixture as per Table B3 and Figure B1 of the Appendix. The presence of the correct size 
band was then confirmed by electrophoresis as shown in Figure 2.2B, following which the PCR 
products were purified by means of the Qiagen QIAquick PCR Purification Kit (Qiagen, Valencia, 
CA) as per the manufacturer’s protocol.  
 
Table 2.1: IECs from 11 CAPRISA 002 participants used in this study 
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Figure 2.2: Confirmation of components for infectious envelope clones 
A: Confirmation of pHIVΔenvBstEIInef-hisD plasmid cleavage by BstEII with lane A DNA 
Molecular Weight Marker X; lane B: uncut plasmid (> 12.2 kbp), with C and D exhibiting a 
linearilised plasmid (12 kbp) by EcoRI (positive control) and BstEII respectively. B: Confirmation of 
env gene PCR with lane A: DNA Molecular Weight Marker X; lane B: shows the negative PCR 
control and C-E show the env genes of clones x, y and z from 39 month post infection of individual 
CAP255 (3.5 kbp). 
  
Replicating viruses were prepared from specific envelope clones as described (Lu et al., 2004). The 
vector pHIVΔenvBstEllnef-hisD (a gift from Dr Kuritzkes), was constructed as described elsewhere 
(Lu et al., 2004). The plasmid was linearised in this study by means of the restriction enzyme BstEII 
with the reaction mixture as indicated in Table B4 in the Appendix. The reaction mixture of 100 μl 
was then reacted at 60˚C for 1 hour and compared with the migration of EcoRI digested plasmid as a 
positive control in gel electrophoresis (shown in Figure 2.2A) as it, in addition to BstEII, only cleaves 
the plasmid once. The PCR product was purified by means of the Qiagen Qiaex II Gel Extraction Kit 
as per the manufacturer’s protocol for desalting and concentrating DNA solutions (Qiagen, Valencia, 
CA). The digested backbone (750 ng) and the amplified env DNA (300 ng) were co-transfected with 
X-tremeGENE Transfection Reagent (Roche, Basel) into HEK293T cells seeded at 3 x 10
5
 cells/ml in 
12 well plates.  
 
In addition two infectious molecular clones or IMCs, matched to the IEC T/Fs from participants 
CAP210 and CAP239 and gifted to us by Prof Carolyn Williamson’s laboratory at UCT, were 
transfected in the same manner as IECs in our laboratory. They comprised a single plasmid and were 
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transfected at a concentration of 600 ng. Following incubation at 37 ˚C and 5% CO2 for 72 hours, the 
media was changed to fresh DMEM with 10% FBS. After a week of incubation in HEK293T cells, 1 
ml of the viral supernatant was spinoculated for 60 minutes at 1200g, 30˚C with activated CD8+ 
depleted PBMCs at a concentration of 5x10
6
 cells/ml. The following day, this centrifugation step was 
repeated. IMCs were grown in the same way, to ensure high titer of virus. A week later, an in-house 
p24 antigen ELISA was used to determine if there was viral growth over this time period. Viruses that 
displayed growth were then expanded into T25 flasks containing freshly isolated CD8 depleted 
PBMCs at 2 x10
6
 cells/ml and following several more days of incubation harvested 3 times. During 
harvesting, the viral supernatant was removed from the flask and filtered with a 0.45 nm micropore 
filter and aliquoted for freezing at -70˚C. 
  
In-house p24 ELISA 
The ELISA was performed as per protocol in (Moore et al., 1990) involving a chemiluminescent 
readout on the Wallac Victor II luminometer (PerkinElmer, Waltham, MA).  The assay is a twin 
sandwich enzyme-linked immunosorbent assay (ELISA) whereby the p24 antigen is captured from a 
detergent lysate of virions onto a polyclonal antibody absorbed to a solid phase. Bound p24 is 
detected with an alkaline phosphatase-conjugated anti-p24 monoclonal antibody while the primary 
coating mAb was D7320 Sheep anti-HIV p24 gag, affinity purified antibody (Aalto Bio reagents, 
Dublin) at 4μg/ml in a carbonate/bicarbonate buffer (Sigma-Aldrich, San Diego, CA). D7320 is a 
mixture of three sheep polyclonal antibodies raised against HIV peptides (specifically amino acids 
173-188; 226-237; 283-297). The p24 standard (Recombinant HIV-1-p24, Aalto Bio reagents) was 
diluted 1:31.25 in 1% Empigen/TBS and serially diluted 1:4 in 1% Empigen/TBS and along with the 
harvested viruses were incubated in the blocked plate for 3 hours. A negative control well was 
included (1% Empigen/TBS) as well as p24 positive controls.  
 
TCID50 Assay  
Both IECs and IMCs were titrated in luciferase reporter cell line JC53bl-13 (also known as TZM-bl) 
obtained from the NIH AIDS Research and Reference Reagent Program. Luciferase activity was 
measured in relative luminescence units (RLU) which is directly proportional to the number of 
44 
 
infectious virus particles present in the initial inoculum over a range of values. The TCID50 (50% 
tissue culture infectious dose) of each virus stock was determined in a single-cycle infection assay (2-
day incubation) in TZM-bl cells as developed by David Montefiori in 2004. This endpoint dilution 
assay quantifies the amount of virus required to infect 50% of host cells. The assay was read by a 
Wallac Victor II luminometer (PerkinElmer, Waltham, MA).  
 
2.2.5 Flow cytometry based α4β7-virus binding assays  
HEK293T cells were transfected with α4 and β7 encoding plasmids (Origene, Rockville, MD) with X-
tremeGENE and incubated at 37˚C with 5% CO2 for two days. The transfected cells were removed 
gently with 1mM EDTA/ PBS, following which the co-expression of α4β7 was determined by flow 
cytometry by staining with anti-human CD49d (Integrin alpha 4) PE (eBioscience, CA) and anti-
human/mouse integrin β7 FITC (eBioscience, CA). The gating strategy was done as shown in Figure 
2.3. Two forms of the binding assay were used; a (A) competition based assay and a (B) direct 
binding assay.  
 
 
 
 
 
 
Figure 2.3: Gating strategy for an α4β7 –dependent virus binding competition assay  
HEK293T cells transfected with α4β7 were gated to eliminate doublets, dead cells and distinguish 
α4β7+ cells outlined by the red box (second, third and fourth panels from the left respectively), gating 
for which was determined by FMO controls.  
 
(A) Competition α4β7 binding assay 
Based on the gp120- binding assays performed by Nawaz and colleagues in 2010, HEK293T α4β7-
transfected cells were incubated in the presence or absence with Act-1 (targets the α4β7 dimer) 
obtained from the NIH AIDS Research and Reference Reagent Program or HP2/1 (Beckman Coulter, 
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France) which targets the α4 subunit only, for 15 minutes and with or without IECs for 25 minutes. 
CAP88.1.00.17.5a (T/F) and CAP88.12.2F (12 month p.i) IECs were used in this assay as were 
matched CAP210 and CAP239 T/F IECs and IMCs. Cells were then stained with α4-PE and β7-FITC 
mAbs (eBioscience, CA) and a live/dead viability stain namely Aqua Fluorescent Reactive Dye 
(Invitrogen, Molecular Probes, Carlsbad). Percentage binding to α4β7 is defined as the percentage 
difference between the median fluorescence intensity (MFI) of PE and FITC of α4β7-transfected cells 
without an inhibitory mAb or virus and the MFI α4β7-transfected cells with an inhibitory mAb or 
virus represented in a formula below: 
 
 % binding to α4β7 =(MFI β7-FITC of untreated sample) – (MFI β7-FITC HP2/1 OR Act-1 OR virus samples) 
(MFI β7-FITC of untreated sample) 
 
(B) Direct α4β7 binding assay 
α4β7-expressing, HEK293T cells were incubated with or without HP2/1 or Act-1 for 15 minutes at 
4˚C and incubated with or without virus for 25 minutes without washing following mAb incubation. 
Viruses used were CAP88.1.00.17.5a (T/F) and CAP88.12.2F (12 month p.i) IECs were used in this 
assay as were matched CAP210 and CAP239 T/F IECs and IMCs. P24-  FITC (KC57, Beckman 
Coulter) was incubated with the virus-cell complex for 30 minutes at 4 ˚C as well as those cells 
without any virus added. Percentage p24 positive cells gated on total HEK293T cells were compared 
to those incubated with virus and those without as a representation of affinity of the virus for α4β7. 
  
2.2.6 α4β7 mediated virus capture inhibition assay 
In order to observe the effect that α4β7 has on the replication of HIV-1, an α4β7 mediated virus 
capture inhibition assay was performed. The assay was designed on the principle that the masking of 
the α4β7 integrin by a monoclonal antibody has been shown to have an inhibitory effect on viral 
replication (Cicala et al., 2009).  
 
Titration of α4β7-inhibiting mAbs HP2/1 and Act-1 
Both HP2/1 and Act-1 mAb concentrations were optimised by titration in the α4β7-mediated virus 
capture inhibition assay, noting the concentration at which effectiveness of blocking viral replication 
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was highest. In addition, a flow cytometry based competition assay was designed where 100 μl of 
ATRA treated CD4
+
 T cells seeded at 1x10
5
 cells/ml were incubated for 1 hour with the mAb using a 
range of concentrations (0.2 pM- 30nM for Act-1 and 2.2 pM – 30nM for HP2/1). An α4-PE labelled 
antibody was then used to stain the cells in 1% BSA/PBS. The difference between the MFI of α4-PE 
on CD4
+
 T lymphocytes without Act-1 or HP2/1 and the MFI of CD4
+
 T lymphocytes incubated with 
HP2/1 and Act-1 was used to represent the effect of the inhibitory mAbs as change in MFI.  
 
α4β7-inhibition assay  
25 μl ATRA-treated CD4+ T lymphocytes from a responder individual at 4 x 106 cells/ml were either 
incubated with 25 μl of media (virus control), 10 µg/ml anti-CD4 monoclonal antibody, 275 pM 
inhibiting monoclonal antibody HP2/1 (targeting α4 subunit) or 2.2 pM Act-1 (targets α4β7) for an 
hour at 37˚C at 5% CO2. 100 μl of titrated IECs and IMCs (25 TCID50) were incubated for 2 hours 
with the cells in a 96-well plate, followed by two washes with fresh IL-2 media (5% IL-2 at 200 U/ml, 
20% FBS and RPMI media) at 1200g for 5 minutes at 25˚C. Culture supernatant was harvested into 
1.25% Empigen/TBS solution and stored at 4˚C, without disturbing cells for a period of 10 days every 
2 days with replacement of fresh IL-2 media. P24 levels were assessed by the p24 ELISA as 
previously described. These experiments were repeated in triplicate.   
 
2.2.7 Statistics 
Paired data with only two groups were assessed by paired t test or Wilcoxon matched pairs signed 
rank test and in groups with three or more sets by the repeated measures one way ANOVA with 
pairwise comparisons adjusted for multiple comparisons using Tukey’s method. Unpaired data were 
assessed for significance by the Mann-Whitney test or the one way ANOVA and the Fisher exact test 
was used to determine the significance of categorical groupings. While Spearman’s correlation was 
use to assess linear correlations, multiple regression analysis was performed to assess the significance 
multiple factors (STATA 12). Observations of p < 0.05 were defined as significant. Statistics and 
graphs were done with GraphPad Prism 5 and STATA 12.  
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2.3 Results 
 
2.3.1 Titration of α4β7 inhibitory mAbs HP2/1 and Act-1 
In order to assess the saturating concentrations of the inhibitory mAbs Act-1 and HP2/1 to block 
α4β7, a flow-based competition assay between α4-PE and Act-1 or HP2/1 (Figure 2.4A and B i and ii) 
was used. The basis of a competition assay is that by binding to the same epitope or epitopes in very 
close proximity, the initial antibody will block the binding of the second fluorescently labelled 
antibody; resulting in a diminished signal (in this case PE-MFI) which is expressed as a change in PE-
MFI (Δ MFI of α4-PE). A range of concentrations were tested (0.2 pM- 30nM for Act-1 and 2.2 pM – 
30nM for HP2/1) , The highest concentration tested for both HP2/1 and Act-1was the most effective 
at competing with the α4 (CD49d) –PE mAb and decreased in their capacity to block α4β7 in a dose 
dependent manner (Figure 2.4 A and B). It was necessary to determine if the saturating concentration 
of the inhibitory mAbs determined in a binding assay translated to a decrease in viral replication. 
ATRA responder PBMCs were incubated with a range of HP2/1 or Act-1 mAb concentrations (0.2 
pM- 30nM for Act-1 and 2.2 pM – 30nM for HP2/1) and the CAP88.1.00.17.5A T/F IEC. Monitoring 
replication over 10 days by p24 ELISA revealed that the ability of Act-1 and HP2/1 to block 
replication by blocking α4β7 at 30 nM does not correlate with the level of saturation. 30 nM of Act-1 
and HP2/1 enhanced infection. Act-1 has been found to decrease heterotypic binding but increase 
homotypic binding at higher concentrations (Zeller et al., 2001) which may explain why it facilitates 
increased replication. Instead, a reproducible concentration at which replication can be inhibited was 
determined as 275 pM for HP2/1 and 2.2 pM for Act-1 (shown in Figure 2.4 C I and ii respectively). 
CAP88 T/F virus was used as a control virus as a result of showing a high affinity for α4β7 in a 
previous study (Nawaz, et al., 2011). The effect of HP2/1 and Act-1 on viral replication is only 
partial, while complete inhibition of viral replication results from treatment with an anti-CD4 mAb, 
corroborating that α4β7 is not essential for replication but rather offers a means for enhanced 
infection. In this study, the titration of the inhibiting mAbs was crucial to adequately determine the 
range of dependence on α4β7 for replication in further experiments.   
 
48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Titration of α4β7 inhibitors for maximal inhibition of viral replication 
(A) A decreasing shift in PE florescence relative to the experimental control (ATRA treated CD4
+
 T 
cells alone shown in black); is indicated in a dose-dependent manner between 0.0022-30 nM (i) 
HP2/1 and (ii) Act-1concentrations (red and blue graduations respectively). All samples were gated 
on single live CD4
+
 T lymphocytes. (B) Change in median fluorescent intensity (MFI) with the 30 nM 
being the most saturating concentration for blocking of the integrin by both mAbs. These results are 
representative of four repeated experiments, with the bars showing the mean and error bars, the SEM. 
(C) The same ATRA activated responders were infected with a T/F virus CAP88.1.00.17-5A and 
incubated with (i) HP2/1and (ii) Act-1 between 0.0022-30 nM (red and blue graduations respectively) 
and monitored over 10 days by p24-ELISA. The virus control (no inhibitory mAb) is shown in black 
and the infectivity control shown in grey. The optimum concentration for viral inhibition by HP2/1 is 
0.275 nM and Act-1 is 2.2 pM, while the viral replication is significantly upregulated at 30 nM in both 
cases. These results are representative of five independent experiments using 3 donors,with error bars 
indicating the SEM and points, the mean of three replicates.  
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2.3.2. α4β7 binds functional virus 
To verify that the infectious envelope viruses in this study bound α4β7, two binding assays were set 
up: a direct binding assay and a competition based assay similar to that described by Nawaz and 
colleagues. In both cases transfection of the HEK293T cells with α4 and β7 plasmids was confirmed 
by co-expression of α4-PE and β7-FITC in the experimental control (transfected with α4β7 as 
compared to the transfection control (was not transfected with α4β7) shown in red and black in Figure 
2.5. A negative virus control (was not transfected with α4β7 but was incubated with virus) was 
included in both assays to ascertain whether virus bound HEK293T cells in the absence of the α4β7 
integrin and to assess whether virus incubation increased non-specific florescence of the sample 
indicated in blue (Figure 2.5).  
 
 
 
 
 
 
 
 
Figure 2.5: Expression of α4β7 on the HEK293T cell line 
Gating was determined by both FMO controls and using a transfection control (HEK293T cells alone) 
indicated in black and a negative virus control (HEK293T cells incubated with virus) shown in blue. 
A positive experimental control (α4β7-transfected HEK293T cells incubated with virus) is shown in 
red.  
 
The direct binding assay was performed by incubating α4β7-transfected and untransfected HEK293Ts 
with CAP88 T/F and CAP88 12M IECs and visualising the virions that were bound following 
multiple washes by staining with p24-FITC (Figure 2.6A). Both CAP88 T/F and CAP88 12M IECs 
bound to α4β7+ HEK293T cells but not to α4β7- cells. Furthermore, the proportion of p24+ HEK293T 
cells was significantly decreased by treatment with α4β7 specific mAbs Act-1 and HP2/1 for the 
CAP88 T/F virus as shown in Figure 2.6B. Concentrations used for Act-1 and HP2/1 were those 
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optimal for blocking HIV replication, as these are most relevant for this study. The proportion of p24
+
 
cells was significantly higher when incubated with CAP88 T/F and 12 month IEC was also significant 
shown in Figure 2.6C; this finding mirrors binding observed using gp120 monomers from these same 
viruses in a previous study (Nawaz, et al., 2011).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Binding of IECs to α4β7 in a direct virus binding assay 
(A) p24
+
 HEK293T cells were distinguished in the negative control (HEK293T cells untransfected 
with α4β7 and incubated with virus) and HEK293T cells transfected with α4β7 (left and right panels 
respectively), matched for the virus of interest. (B) This increase is abrogated significantly by 
inhibition controls Act-1 and HP2/1 (blue and red bars), indicated by a decrease in the proportion of 
p24
+
 HEK293T cells (Repeated measures one way ANOVA with Tukey multiple comparisons post 
test). (C) The difference in proportion of p24
+
 cells between the CAP88 T/F and its 12 month clone is 
significant (p=0.0017;paired t test). These experiments consist of four replicates with bars indicating 
the mean of these and the error bar, the SEM. 
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The second binding assay was performed by incubating α4β7+ HEK293T cells with CAP88 T/F and 
12M IECs followed by incubation with α4-PE and β7-FITC mAbs. Percentage binding to α4β7 was 
represented by percentage difference between the MFI of the experimental control (not incubated with 
virus or inhibitory mAbs) and α4β7+ HEK293T cells incubated with virus or inhibitory mAbs HP2/1 
and Act-1 (Figure 2.7 B), Results recapitulated observations made in the direct binding assay: CAP88 
T/F and CAP88 12 month IECs bound to α4β7, with significantly more binding of the CAP88 T/F 
IEC to α4β7 as compared to CAP88 12 month IEC for β7-PE. .Positive controls Act-1 and HP2/1 also 
bound to α4β7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Binding of IECs to α4β7 in a competition flow assay 
(A) HEK293T cells transfected with α4β7 bound IECs representative of early (orange) and chronic 
(blue) infection as shown by the decrease in β7–FITC fluorescence relative to the experimental control 
(transfected 293s with no bound virus, red). HP2/1 and Act-1 binding were used as positive controls 
(light and dark green respectively) while the negative control was α4β7 untransfected cells incubated 
with virus. All populations were gated on α4β7+ live single 293s. (B) The percentage difference 
between the MFI of both α4-PE and β7-FITC (red and green respectively) and the experimental 
control were used calculate an inferred binding capacity. Difference between CAP88 T/F and CAP88 
12M binding was significant by competition with β7-FITC (p=0.002 for β7; Paired t test, n=3).   
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It has been suggested previously that as α4β7 is an attachment factor, it is likely that the integrin 
would play a greater role in facilitating viral replication when viral input is low (Parrish, et al., 2012). 
To this end, we sought to determine whether IECs CAP88 T/F and CAP88 12 months preferentially 
bound to α4β7 at lower viral inputs. This was not the case in either virus with all concentrations 
yielding similar levels of binding represented by α4-PE and β7-FITC within a range of 0.5 – 25 ng 
(Figure 2.8 A and B). 
  
 
 
 
 
 
Figure 2.8: Binding of IECs to α4β7 is not altered by viral input 
Percentage binding of (A) CAP88 T/F and (B) CAP88 12 month clone did not vary with amount of 
virus (ng) in an α4β7-dependent HEK293T cell assay when compared in terms of median 
fluorescence intensity of either  α4-PE or β7-FITC (Repeated measures ANOVA with Tukey multiple 
comparison post test). These data are representative of two independent experiments and bars indicate 
means while error bars indicate SEM. 
 
 
2.3.3. Influence of α4β7 on HIV replication changes longitudinally over time 
Following the finding that IECs were able to bind α4β7 and appear to do so differentially, similar  to a 
range gp120 monomers that have been tested (Nawaz, et al., 2011; Arthos, et al., 2008), we sought to 
determine whether α4β7 a) has a role in HIV replication and b) if so, whether the role changes over 
time.  
 
An α4β7-inhibition assay involving the incubation of ATRA treated CD4+ T cells with HP2/1 mAb 
(targets α4 subunit only; the point of contact for gp120) and Act-1 mAb (targets the α4β7) was 
performed. The cells were infected with viruses from 11 different individuals inclusive of time points 
from the point of transmission, 1 or 2 months post infection (p.i.) and chronic infection (6, 12 and 39 
months p.i.) and viral kinetic growth was monitored by p24 ELISA over 10 days. As described in 
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Chapter 2 Section 2. 3.1, titration of the inhibiting mAb was crucial to accurately determine the effect 
of α4β7 on HIV replication. Viral replication in the presence of 275 pM HP2/1 and 2.2 pM Act-1 
treated cells is similar at the point of exponential growth of the virus control. This is illustrated in 
Figure 2.9, using a T/F virus from participant CAP225. The use of HP2/1 and Act-1 mAbs head-to-
head is a control that confirms the inhibitory effect on viral growth is as a result of the advantage that 
α4β7 offers to replication. In addition, the effect of these inhibitory mAbs on virus replication is only 
partial while blocking the CD4 receptor completely abrogates viral replication. 
  
 
 
 
 
 
 
 
 
 
 
Figure 2.9: Act-1 mAb and HP2/1 mAb inhibit α4β7-dependent replication with similar efficacy 
Virus kinetic growth curves of a T/F from CAP225 without (green) or with an α4β7 inhibitory mAb  
Act-1 (blue) and HP2/1 (red) and an infectivity control in the form of an anti-CD4 mAb (grey) 
measured as p24 (ng/µl) over 10 days. Inhibition by Act-1 and HP2/1 at the point of exponential 
growth of the virus control was not significantly different represented by n.s at day 8 (Wilcoxon 
matched pairs signed rank test n = 3). This is representative of three independent experiments with 
dots representing the mean of three replicates and error bars representative of SEM. 
 
 
Comparison between the α4β7 reactivity of IECs and IMCs  
 
It has been suggested that viruses generated using a standard HIV backbone, as in this study, do not 
allow the effect of gene products other than Env to the T/F phenotype to be assessed and that the 
potential for the overexpression of Env in this model compared to naturally occurring viruses 
prohibits a meaningful assessment of virus–host cell interactions (Parrish et al., 2013). As a result it 
was necessary to compare the dependence of our unique IEC virus construction to the dependence of 
matching IMCs on α4β7. As IMCs consist of a proviral genome completely representative of the virus 
from a particular individual and IECs are only representative of a particular virus in terms of the env 
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gene. It is possible that a variety of factors purely related to the chosen virus expression system may 
influence the dependence on α4β7 including opportunistic recombination and higher expression the 
env glycoprotein compared to IMCs. As shown in Figure 2.10 both binding to and dependence for 
replication on α4β7 were not significantly different between matched IECs and IMCs for two 
participants (CAP210 T/F and CAP239 T/F viruses). This suggests that the IEC system is comparable 
to that of IMCs and is a suitable model for viral replication in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: IMCs and IECs have similar binding and replicative dependencies on α4β7  
(A) Direct p24 binding assay shows no significant difference between IEC and IMC binding to α4β7. 
(B) This is mirrored by the competition binding assay when competed with α4-PE (red) or β7-FITC 
(green). (C) Dependence on α4β7 for replication is not significantly different between IECs and IMCs 
(CAP210 and 239) in the case of both HP2/1 (red) and Act-1 (blue). All comparisons were non-
significant by the paired t test where each experiment is representative of 3 independent experiments.  
 
Longitudinal dependence of viruses on α4β7 for replication 
Of the IECs available in this study, three individuals (CAP88, CAP200, CAP206) have a completely 
representative data set; namely a T/F virus, a clone within 1 year of infection (1/2 months or 6 
months), a clone at 12 months and 39 months (those data sets in the black box in Figure 2.11). These 
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data show a similar pattern whereby the T/F virus has a higher dependence on α4β7 for replication 
which decreases after transmission and is maintained at these levels in the first year of infection and 
increases at 3 year p.i. As a result of the viruses in these three individuals being matched, this pattern 
is of particular relevance. Kinetic growth curves of virus clones of all individuals are shown in Table 
B2 of the Appendix and results are summarised in Figure 2.11. 
 
In order to determine why the dependencies of T/F viruses from CAP88, CAP200 and CAP206 on 
α4β7 differ the most dramatically from their next available viral clones (2 months p.i. in the cases of 
CAP88 and CAP206 and 6 months in CAP200 indicated in Figure 2.11) I aligned their gp160 
sequences (available from previous studies from our laboratory) to HBX2 (shown in Figure 2.12). 
This sequence is one that is used to standardise the numbering of sequence positions in an alignment. 
The alignment also shows the designation of the variable loops (V1-V5) and one constant region (C3) 
mentioned throughout this study. In addition, the position of N-linked glycans (indicated in red) was 
predicted by N-glycosite, a tool available on the Los Alamos National Database (Zhang, et al., 2004). 
While no common themes can be drawn from this analysis it is intriguing that the only changes in 
sequence in the case of the CAP88 T/F (88.2.00.17.-5A) and the 2 month clone, CAP88 2.00.B5 are 3 
amino acid changes in gp41, one of which (Leu 568 Arg) is highly conserved in the N-heptad repeat 
of gp41. Not only has the conservation of this residue been associated with membrane fusion (Dwyer 
et al., 2008) but it is a mutation that disrupts the very hydrophobic nature of this region. Furthermore, 
it has been associated with a reduction in the ability of gp120 expressing cells to fuse and form 
syncytia with target cells that express the appropriate receptors (Bar and Alizon, 2004). As a result of 
α4β7+ T cells being able to homotypically aggregate (Zeller et al., 2001) and the ability of the ability 
of the integrin to activate LFA-1 virological synapse formation, the reduction of the virus’ 
dependence on α4β7 appears to be as a result of the hydrophyllic nature of Arg 568 (present in 
CAP88.2.00.B5).  
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Figure 2.11: The role of α4β7 changes over time 
Virus clones derived from eight individuals including T/F viruses and 1-39 months post-infection (p.i.) time points were tested for their dependence on α4β7 for 
viral replication calculated as percentage inhibition by HP2/1 (red) and Act-1 (blue) expressed as percentage difference of p24 concentration between HP2/1 or 
Act-1 treated and untreated virus in exponential growth phase. The box denotes individuals CAP88, CAP200 and CAP206 with a complete data set namely T/F, 2 
months (absent in CAP200), 6, 12 and 39 months p.i. which follow a distinct pattern of α4β7 usage over time. Differences in dependence across all time points in 
each of these three individuals were significant by a repeated measures ANOVA for both Act-1 and HP2/1(*** p<0.0001) as well as between CAP88 T/F and 2 
months p.i, (***p<0.0001 for HP2/1 and **p<0.001 for Act-1) CAP200 T/F and 6 months p.i. (***p<0.0001 for HP2/1 and *p<0.01 for Act-1) and CAP206 T/F 
and 2 months p.i (***p<0.0001 for HP2/1 and **p<0.001 for Act-1), Pairwise comparisons were adjusted by the Tukey method. Bars represent means of between 
two and three independent experiments with the error bars indicating SEM. 
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Figure 2.12: Sequence alignment of CAP88, CAP200 and CAP206 gp160s  
The T/F and 2 or 6 month p.i. gp160 sequences of CAP88, CAP200 and CAP206 aligned to HBX2. 
Glycans are indicated in uppercase and highlighted in red. The α4β7 binding motif and CD4 binding 
sites are highlighted in grey and the non-synonymous sequence changes between CAP88 T/F and 2 
month, CAP200 T/F and 6 month and CAP206 T/F and 2 month highlighted in blue yellow and green 
respectively. Different structural regions of gp120 are denoted by coloured blocks and dots represent 
identities.  
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Three amino acid differences exist between CAP206 T/F and the 2 month clone, one of which is a 
glycan at position N461 in the 2 month clone. Situated in V5, a region linked to CD4-binding this 
forms part of the conformational epitope for the CD4-binding site mAb VRC01 (Li et al., 2011b). 
This change may result in a reduced affinity of the virus for α4β7 because CD4 is close enough to 
α4β7 on the cell surface for them to be co-precipitated (Cicala, et al., 2009). While differences in 
sequence between CAP200 T/F the 6 month clone are far more extensive (39 non-synonymous 
changes, consistent with the longer duration of infection), it is likely that the change of the α4β7-
binding motif from SDV to PDI at 6 months is significant and CAP200 is the only individual that has 
a non-synonymous motif change over time. All motif sequences are shown in the Appendix (Table 
B2).  
 
Although these changes are intriguing, many are unique to individuals and as a result it was necessary 
to determine factors inclusive of all individuals that may contribute to high α4β7 dependence for viral 
replication. The remaining five individuals depicted in Figure 2.11, which had matched T/F (CAP8 
and CAP256) or enrolment clones (CAP244 and CAP255) and chronic clones, with the exception of 
CAP177 which due to availability had no very early clone were used to assess overall patterns of 
α4β7-dependence as shown in Figure 2.13. Whether Act-1 (Figure 2.13 A) or HP2/1 (Figure 2.13 B) 
is used as the defining parameter, T/F viruses have a significantly higher dependence on α4β7 for 
replication and significantly lower than that of 39 month viruses. Strikingly, there is no significant 
difference in α4β7 dependence between T/F viruses and chronic clones at 6 and 12 months. Overall, 
this mirrors the finding that there is no difference between T/F viruses and chronic viruses in the first 
year of infection (Parrish, et al., 2012). Despite this, the pattern of dependence still suggests that α4β7 
may play an important role in transmission which diminishes shortly after infection. These data 
suggest that over time, the dependence on α4β7 for viral replication changes.  
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Figure 2.13: Pattern of α4β7 usage changes during different clinical stages of HIV  
T/F viruses (n=8)  had a significantly higher dependence on α4β7 for replication than acute viruses 
(n=5)  (1-3 months p.i.) as determined by both (A) Act-1 (***p<0.0001) and (B) HP2/1 mAb 
(**p<0.001 ), no significant difference compared to viruses from the first year including both 6 (n=6) 
and 12 months p.i. of chronic infection (n = 15) and a significant decrease compared to viruses 3 
years p.i. ( n=24, p<0.0001 for both Act-1 and HP2/1). Both data sets were analysed for significance 
by a one way ANOVA and pairwise comparisons adjusted for by Tukey’s method. 
 
2.3.4. Factors associated with high α4β7 dependence  
In order to determine why certain viruses have a higher dependence on α4β7 for viral replication, a 
number of additional viral factors were investigated. The reduced length and glycan density of the 
V1/V2 loop as well as C3/V4 has been associated with increased α4β7 binding (Nawaz, et al., 2011) 
although, a recent study by Etemad, et al., 2013 suggests that in matched samples this is not the case 
at least for the V1/V2 loop. We sought to determine what the association of length and glycan density 
in all variable loops as well as C3/V4 was with dependence on α4β7 for viral replication as seen in 
Figure 2.14 A and B. Sequences from previous studies in our laboratory corresponding to the env 
proteins of the viruses used in this study were analysed for number of glycans as predicted by the N-
glycosite tool from the Los Alamos National Database (Zhang et al., 2004a).  Several linear Spearman 
correlations were significant shown in grey blocks in Figure 2.14 including the glycan density of V2, 
V1/V2, V4 and C3/V4 and the length in amino acids of V1/V2 and C3/V4. However because of the 
interrelatedness of these regions, it was necessary to use a multiple regression to assess which of these 
associations are significant when others are kept constant. To limit multicolinearity, redundant 
variables were excluded from the data set (namely V1, V2 and V4 with only V1/V2, C3/V4 and V5 
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regions included) and glycan density and variable loop lengths were analysed separately because of 
their causal relationship. Overall V1/V2 length and glycan density were positively associated (β-
coefficient = 1.23 and 3.81 respectively) with the dependence on α4β7 for viral replication for Act-1 
inhibitory mAb. A complete data set of all lengths and glycan densities are shown in the Appendix 
(Table B2) but the sequences have not be included. In this data set, the region on which the α4β7 
binding site is present was most significantly associated with dependence on the integrin; similar to 
what has been hypothesised previously (Nawaz, et al., 2011).  
 
Owing to glycan density and length of the V1/V2 region having an association with the effect of α4β7 
on replication, we sought to determine whether the linear distance of the glycans from the α4β7 
binding motif in V1/V2 has an impact on the efficacy of the integrin’s effect on viral replication. To 
this end each individual viral clone was designated as exhibiting either high (green) or low (blue) 
α4β7 dependence for viral replication. This was done by comparing percentage dependence of each 
individual clone to the mean dependence on α4β7 (51.02 % with reference to HP2/1 mAb and 51.92% 
with reference to Act-1 mAb) with those above the mean designated as “high” and those below, 
“low”. A full list of designations can be noted in the Appendix (Table B2) with 27 sequences 
determined as having low α4β7 dependence and 33 designated as having high α4β7 dependence.  
 
The frequency of sequences (as a proportion of those viruses with a high or low α4β7 dependence 
respectively) expressing a glycan at a particular linear distance from the tripeptide minimal binding 
epitope for α4β7 in the V1/V2 loop is shown in Figure 2.15. This reflects the great variability of this 
region of gp120, in that only a small number of sequences (reflected by small percentages) have 
glycans at different linear distances from the motif which very few displaying common positions 
across a number of individuals. Glycans present 5 amino acids downstream and those 41 amino acids 
upstream from the motif are more frequent in viruses that have high affinity for α4β7 (8 versus 2 and 
9 versus 3 sequences respectively) while glycans 8 amino acid downstream are more frequent in 
viruses with low α4β7 affinity (7 versus 2 sequences) with the numbers of sequences indicated above 
the respective bars.  
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Figure 2.14: Association of length and glycan density of variable loops with dependence on α4β7 for replication  
Correlations between the (A) length and (B) glycan density of V1, V2, V1/V2, V3, V4, C3/V4, V5 and dependence on α4β7 for replication with reference to both 
HP2/1 and Act-1 inhibitory mAbs. Blocks shaded in grey are correlations that showed a significantly positive correlation (Spearman’s correlation) between the 
respective variables and yellow blocks are those associations that were significant by multiple regression. Beta coefficients, Spearmans coefficients and p values are 
shown above the respective blocks. 
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These differences are not significant using the Fisher exact test, nor is there a definite trend for 
positions closer to the motif to affect α4β7 reactivity either positively or negatively. While these 
numbers are small, the isolated cases where there are differences between viruses with high and low 
α4β7 dependence for replication suggest that glycans in specific positions within the gp120 protein 
might be of importance to α4β7 reactivity and perhaps in terms of their position in the trimer rather 
than their linear distance from the α4β7 binding motif.  
 
                                                                                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15: Distances of glycans from the α4β7 binding site in the V1/V2 loop of gp120 
The frequency of distances of different glycans across 60 viruses from 11 individuals from the α4β7 
binding motif is represented as a proportion of those viruses with high and low α4β7 dependence for 
viral replication (shown as green and blue bars respectively).  Numbers above the bars indicate the 
quantity sequences represented for each case.  
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While the observations made in terms of density of glycans are of importance, it is possible that the 
presence or absence of particular glycans within gp160 may influence α4β7 dependence for 
replication and that these appear largely unrelated to linear distance from the α4β7 binding motif. 
Using a similar stratification of α4β7 dependence for viral replication, the frequency of sequences that 
have glycans at positions in gp160 as aligned to HBX2 were expressed as a proportion of either high 
or low α4β7 dependent sequences as shown in Figure 2.16. While the whole of the gp160 sequence 
was investigated (Figure B3Appendix), only those that appeared different between the two groups 
across at least three individuals were deemed as relevant. These 12 glycan positions are include 130, 
150 (V1), 185 (V2), 234 (C2), 332, 334,339, 355, 362 (C3), 409 (V4), 448 (C4) and 462 (V5) shown 
in Table 2.2 while the location of these positions in the trimer is shown in Figure 2.17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16: Frequency of glycans in conserved regions of gp120 showing differences between 
high and low α4β7 dependence  
Frequency of glycans relative to the number of high or low α4β7 dependent viruses are shown in 
green and blue respectively, with those positions that show difference where high α4β7 dependent 
viruses have a higher frequency than low above the x axis and vis versa, below the axis. Significance 
was determined by the Fisher exact t test. 
High α4β7 dependence 
Low α4β7 dependence 
-100
-75
-50
-25
0
25
50
75
100
130 234
332
334
339
355 362 448
low > high
high > low
   **
   ** p < 0.001
*
   **
* p < 0.05
%
 F
re
q
u
e
n
c
y
64 
 
Table 2.2: Glycans associated with α4β7 dependence for viral replication 
Glycan numbers highlighted in green indicate those which are more prevalent in viruses with a high 
dependence on α4β7 for replication while those in blue are more prevalent in viruses with a low 
dependence. The number of sequences with the respective glycan across individuals is shown in bold  
and the frequency as a percentage of high and low dependent viruses indicated in italics. The number 
of individuals in which the glycan appears is also represented. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17: Position of glycans that impact on α4β7 reactivity in the gp120 trimer 
Here the most recently available trimer structure (Mao, et al., 2013) was used to model the positions 
of those glycans that are more frequently present in viruses with high α4β7 dependence (green) and 
those with low dependence (blue). The α4β7 binding motif is indicated in red and the position of the 
CD4 binding site indicated in purple. Positions of 130, 185 and 409 are not necessarily accurate as 
they are in the variable loops which are different lengths in different viruses. The V1/V2 structure is 
modelled on that proposed by McLellan, et al., 2011).  The model was created using the PyMOL 
Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC. 
Glycan Region of gp120 
Number of sequences  Number of 
individuals 
represented by 
sequences 
High α4β7 
dependence 
Low α4β7 
dependence 
130 V1 26 (79) 17 (63) 11 
150 V1 12 (36) 6 (22) 7 
185 V2 8 (24) 2 (7) 4 
234 C2 31 (94) 18 (67) 10 
332 C3 22 (67) 25 (93) 11 
334 C3 8 (24) 0 (0) 3 
339 C3 17 (52) 19 (70) 9 
355 C3 22 (67) 13 (48) 8 
362 C3 13 (39) 5 (19) 4 
409 V4 14 (42) 4 (15) 5 
448 C4 17 (52) 10 (37) 8 
462 V5 15 (45) 19 (70) 7 
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Of the 12 notable glycan positions, only three showed significant differences between the two groups 
in the conserved regions of gp120 including N234, N332 and N334 (Figure 2.16). In addition, 
position N409 was also found to be significant and other differences were also noted in the variable 
regions of gp120 (N150, N185 and N462). However the importance of these in α4β7 reactivity is less 
clear because of the extreme range of variable loop length and it is difficult to accurately determine 
the position of the glycan in gp120. Only two of the glycans in the conserved regions have a higher 
frequency in viruses with a low dependence on α4β7 namely N332 and N339 (and N462 in the 
variable loops) while the remaining 9 are present in a higher frequency in viruses with a high 
dependence on α4β7 (N130, N185, N234, N334, N355, N362, N409, N448). Only three of the latter 
are present in the V1/V2 loop (N150 and N185 with N130 present in the V1/V2 β sheet) and are 
situated near the α4β7 binding site. Several of these are in close proximity to CD4 contact sites 
including N130, N362 and N355 (Zhou et al., 2010) which may allow for conformational stabilisation 
of the CD4-gp120 and α4β7-gp120 interactions as a result of the close proximity of CD4 and α4β7 on 
the surface of the target cell; so close in fact that these receptors were able to be co-precipitated 
(Cicala, et al., 2009).  
 
N462 is a target for VRC01, a CD4 binding mAb, and is also located right next to a CD4 contact site 
in V5. However unlike the other glycans, this was found to be more frequent in viruses with low α4β7 
dependence. As such, it is possible that the presence of a glycan at this position may sterically impede 
the affinity of the virus for α4β7. N234 is a high mannose glycan, associated with DC-SIGN binding 
(Alexandre et al., 2012) and its removal has been found to have a significant reducing effect on 
infectivity and Env incorporation (Wang et al., 2013), possible reasons for its selection in viruses with 
a high affinity for α4β7. This glycan is also in the region where gp120 and gp41 are thought to 
interact (Yang et al., 2003). N448 is a conserved high mannose glycan (similarly to N234). These 
glycans are required for protein folding and stabilisation of protein conformation (Wyss et al., 1995) 
and have been found to be more extensively represented and conserved in T/F viruses (Go et al., 
2011) suggesting a link between these glycans and α4β7 in transmission.  
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The observation that N332 is more frequent in viruses with low α4β7 dependence is intriguing as it 
was found to be underrepresented in T/F viruses (Moore et al., 2012) and N332 knockouts have been 
found in our laboratory to have higher viral fitness than those with the glycan (Moore, unpublished). 
This suggests that this glycan may mitigate the selective advantage that α4β7 offers during 
replication. In addition, N334 is exclusive to high α4β7 dependent viruses which suggests that the 
shift in glycan not only confers resistance to PGT128 (Moore, et al., 2012) but may enhance α4β7 
affinity.  Glycans 339 and 332 are clustered together on gp120 (Scanlan et al., 2002) and may be the 
reason for N339 being expressed predominantly on those viruses with low α4β7 dependence. N339 is 
positioned in the α2 helix of C3. Overall these data suggest that glycans throughout gp120 and not just 
within V1/V2 are important in determining how dependent viruses are on α4β7 for replication.   
 
Of course it is possible that many other factors determine α4β7 reactivity and its influence on viral 
replication. Dependence on α4β7 for replication is significantly different between the various minimal 
tripeptide α4β7 binding motifs found across individuals in the first year of infection (Figure 2.18). 
Viruses expressing PDI/L or SDI/V motifs are significantly more dependent on α4β7 for replication 
than those expressing LDI/T/L. The difference is not significant between these three groups in the 
third year of infection (not shown). The tripeptide motif is highly conserved within an individual and 
as such differences do not explain changes in dependence longitudinally in individuals. Despite this, it 
is the first report of the sequence of the α4β7 motif affecting the dependence on the integrin for 
replication.  
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Figure 2.18: Different α4β7 tripeptide motifs affect dependence on α4β7 for replication in the 
first year of infection 
Tripeptide loops PDI/L (n = 18) and SDI/V (n = 8) are expressed on viruses with higher dependence 
on α4β7 for viral replication than those expressing LDI/T/L (n = 8) (** p<0.001 and *p< 0.01 
respectively; one way ANOVA, pairwise adjustments by Tukey method). Error bars represent the SEM 
and the lines represent the means.  
 
It was possible to correlate the dependence on α4β7 for replication with disease outcomes including 
CD4 count and viral load (Figure 2.19A and B respectively) matched for each time point. Raw data 
are in Table B2 in  the Appendix. No significant correlation with viral load (represented as log RNA 
copies/ml) was evident however a significant negative correlation was shown between α4β7 
dependence and CD4 count (represented as cells/μl). This suggests that as the disease progresses and 
CD4 counts decline, dependence on α4β7 for replication increases correlating in part with the 
observation that 3 years post infection, individuals had the highest dependence on α4β7. This 
correlation may also reflect that  in vivo at time points post infection where viruses that have high 
α4β7 dependence are dominant systemically, CD4 T cells may increase in their capacity to home to 
the GALT diminishing their presence in the blood. CD4 counts undertaken in the gut may reveal a 
positive correlation with α4β7 dependence of systemic viruses. These data were not available for 
analysis. This model does not include all T/F viruses as at the correlating time points, CD4 count was 
not performed.  
 
As shown in Table B1 in the appendix,  the individuals in this study have been stratified into rapid 
and intermediate progressors as well as those individuals that go on to develop broadly-cross 
neutralising (BCN) antibodies. No significant difference in dependence on α4β7 between rapid and 
intermediate progressors was noted at any time point examined (data not shown). 
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Figure 2.19: Correlation of HIV disease outcomes with dependence on α4β7 for replication 
(A) There is no significant correlation between α4β7 dependence and log viral load (RNA copies/ml) 
for either HP2/1(red, n= 60) or Act-1 (blue n=57) while there is a significant negative correlation (B) 
between α4β7 dependence and CD4 count (cells/μl) for both Act-1 and HP2/1.  
 
However, T/F viruses from individuals that go on to develop BCN antibodies showed a significantly 
lower dependence on α4β7 for replication than those that do not (Figure 2.20). Differences within the 
other time points were not significant. While this is not conclusive and requires further investigation, 
it is possible that the transmission event in individuals that go on to produce BCN antibodies is 
different to those that do not. These data suggest that BCN individuals do not make use of α4β7 to as 
great an extent as non-BCN individuals. As viral load has been associated with neutralisation breadth 
in BCN individuals (Doria-Rose et al., 2010; Gray et al., 2011) and α4β7 dependence does not 
correlate with viral load it is possible that α4β7 reactivity may be an additional factor responsible for 
initial differences in immunity. What does cause the difference is not known as very little is known 
about differences between BCN and nBCN individuals. This would need to be explored further but 
does suggest that BCN individuals have fundamentally different pressures at transmission that result 
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in viruses that have a decreased dependence on α4β7 for replication. It may be important to discern 
these pressures so we can improve the elicitation of effective BCN antibodiesin individuals. 
  
 
 
 
 
 
 
 
 
 
 
Figure 2.20: T/Fs of non-broadly cross neutralising (nBCN) individuals display higher 
dependence on α4β7 for replication than BCN individuals  
Individuals that produce broadly cross neutralising antibodies two years post infection display 
significantly lower dependence than nBCN individuals on α4β7 for replication but only at the T/F 
stage (BCN T/F n=4; nBCN n=4; ***p<0.0001, one way ANOVA, pairwise corrections by Tukey 
method). Dependence on α4β7 is noted here based on Act-1 and HP2/1 inhibition. 
 
2.3.5. The effect of STI status and cytokine milieu in the genital tract on the 
role of α4β7 in transmission 
 
When the dependence on α4β7 for replication is compared across all the T/F viruses the range is 
broad as shown in Figure 2.21 (22-68.8% for HP2/1 and 15.7-66.9% for Act-1). While overall T/F 
viruses displayed high α4β7 dependencies, we sought to investigate if the wide range could be 
explained by factors that would be relevant at the point of transmission.  
  
Following sequence analysis, the tripeptide α4β7 binding motifs present in the V1/V2 loop (shown in 
Figure 2.22A) could be used to stratify viruses with higher α4β7 dependence for replication (green) as 
compared to those with lower dependence (blue) (Figure 2.22 B). Those with high affinity had 
P/SDI/V binding motifs while those with low affinity had LDI/L motifs. While these differences may 
explain the variation in α4β7 dependence, it is important to consider the context in which transmission 
occurs. 
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Figure 2.21:  T/F viruses have a wide range of α4β7 dependencies for viral replication 
T/F viruses exhibited a wide range of dependencies on α4β7for replication with CAP88, 200, 206 and 
225 showing high α4β7 dependence (green) and the remaining four showing low α4β7 dependence 
(blue). Dependence was determined by Act-1 while bars represent the mean of four independent 
experiments, with error bars indicating SEM. 
 
 
 
HXB2           CTDLKNDTN------TNSSSGR----------MIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPID------NDTTS-----YKLTSC  
 
225.1.C.2.E11  CSNASP---------NNASLANLKVLNASYNDTIYQDGGVKSCSFNTTTEIRDKKQQVQAFFYKSDIALIN-----ATRSKD----EYILINC 
88.2.00.17-5A  CTNVTV---------VNATHTNKS-----MNGEIDMKEEMKNCSFKTTTGIRGKKQTEYALFYRPDIVPLS------KES-----SEYILISC  
200.1.06.B8a   CTN------------ANITKTKASK----GNLTTIMNEEVKNCSFNTTTEIRDKKQKAYALFYKSDVVLLQ------NDSKG--NGEYILINC  
206.1.02.B5    CTN------------ANISVTSVS------NDSRNMNEEIKNCSFNTTTEIRDKKQQVYALFYRSDVAPLS------KAN----SSEYILINC  
 
210.1.00.E8    CSDATY---------NNGTN---------------STDTMKICSFNATTELRDKKKKEYALFYRLDIVPLK------NESESQNFSEYILINC  
239.2.00.G3    CS-------------TNITKAN------------VTSEEMRSCSFNITTELRDKKQKVNALFYKLDIVPIN-----ESSSSS----EYRLVNC  
8.2.00.6F      CTNVYVNST---GNDTGGTYNN------------SVDGEMRNCSFKITTELKDKKQKVYALFYKLDIVSLD-----GNNES------YRLINC 
256.2.00.7C    CTTAKG---------INSTDNANATK--------KPNEEIKNCSFNTITEVRDKQKKEYALFYRLDLVSLNEGDSEGNSSRSGNFSTYRLINC  
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.22: α4β7 dependence variation of T/F viruses may be attributed in part to α4β7-
binding motif differences in the V1/V2 loop of gp120 
 (A) Sequence alignment of the V1/V2 loop of gp120 from the T/F with a highlighted α4β7-binding 
motif based on high (orange, n=4) or low dependence (green, n=6) on the integrin for replication 
graphically represented in B. LDI/L T/Fs have lower dependence on the integrin compared to those 
with P/SDI/V motifs (p=0.0286, Mann-Whitney test) 
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STIs have been identified as a major cause of inflammatory cytokine upregulation and immune cell 
recruitment to the genital mucosa (Levine et al., 1998). In addition to STIs and associated 
inflammation, bacterial vaginosis (BV) a syndrome characterised by a shift in vaginal flora 
composition (Fredricks et al., 2005), has been determined as a risk factor for HIV acquisition (Cohen 
et al., 2012; Nwadioha et al., 2011) as well as in a univariant analysis using the CAPRISA cohort but 
was not significant in a multivariant model (Mlisana et al., 2012). The homing function of α4β7, 
whereby cell subsets are able to traffic to the GALT and other extra-lymphoid tissues such as the 
genital mucosa, allows for cells predominantly of effector function to infiltrate inflamed tissue. Given 
this function and the integrin’s demonstrated role in supporting viral replication of HIV, it is possible 
that the STI status of the individual at the time of transmission as well as the cytokine milieu present 
at the site of sexual transmission may influence whether α4β7 has a large or diminished role in the 
establishment of infection. To this end we obtained clinical data from the CAPRISA 002 cohort on the 
presence of various STIs (Trichomonas vaginalis, Chlamydia trachomatis, HSV-2, Treponema 
pallidum, Neisseria gonorrhoea and Mycoplasma genitalium) as well as BV at the time of 
transmission in the 8 individuals with T/F viruses (Table 2.3). While no HSV-2, Treponema pallidum, 
Neisseria gonorrhoea and Mycoplasma genitalium was detected in these individuals, T. vaginalis, C. 
trachomatis and BV were present. Strikingly those individuals that tested positive for BV at the time 
of HIV transmission had a significantly higher dependence α4β7 than those that did not (Figure 2.23). 
These data suggests that BV creates a transmission bottleneck whereby viruses that have a high 
dependence on α4β7 for replication are selected although the numbers are small.  
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Table 2.3: STI status of individuals at the point of HIV transmission
†
 
Green shading indicates a group of T/F viruses that have dependence on α4β7 for replication below 
50%, while green shows those with high dependence. BV= Bacterial vaginosis, T. vaginalis = 
Trichomonas vaginalis, C. trachomatis = Chlamydia trachomatis.  
 
†
HSV-2, Treponema pallidum (Syphilis), Neisseria gonorrhoea, Mycoplasma genitalium were negative for all samples and 
therefore not included in the table 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.23: Bacterial vaginosis (BV) at the time of HIV transmission is associated with a high 
dependence of T/F viruses on α4β7 for HIV replication 
Individuals that were BV positive (n=4) at the time of infection have a significantly higher 
dependence on α4β7 than those that were BV negative (n = 4) (p = 0.0286; Mann-Whitney test).  
 
While it is not clear how BV may impact on the properties of viruses that establish infection, apart 
from an increase in the number of cells expressing α4β7 attracted to the genital mucosa in response to 
inflammation, a possible explanation is the cytokine milieu in a particular individual at the point of 
transmission that is present in the genital tract drives either expression of α4β7 or its ligand 
MAdCAM-1. We investigated the association between 31 inflammatory cytokines present in the 
cervicovaginal lavage (CVL) at the time of transmission of seven individuals with the matching T/F 
virus’ dependence on α4β7 for replication. The cytokine levels of the corresponding individuals were 
BV+ BV-
0
20
40
60
80
* p= 0.0286
%
 d
e
p
e
n
d
e
n
c
e
 o
n

4

7
fo
r 
re
p
li
c
a
ti
o
n
 (
A
c
t-
1
)
IL-1A IL-8 IL-7
Act-1
mAb
HP2/1
mAb
0 500 1000 1000 2000 .2 .4 .6
20
40
60
20
40
60
BV T. vaginalis C. trachomatis α4β7-dep (Act-1) α4β7-dep (HP2/1)
CAP 225 T/F x 60.08 68.61
CAP 88 T/F x x 66.85 64.08
CAP 200 T/F x 55.43 63.12
CAP 206 T/F x 48.76 50.55
CAP 210 T/F 39.28 47.10
CAP 239 T/F 29.73 31.34
CAP 8 T/F x 33.34 24.50
CAP256 T/F 15.72 22.00
73 
 
measured by luminex and the data obtained for another study (Masson, in review). The panel of 
cytokines tested included pro-inflammatory cytokines (IL-1α, IL-1β, IL-6, IL-12P40, IL-12P70, TNF-
α); chemokines (Eoxtaxin, Fractalkine, IL-8, IP-10, MCP-1, MIP-1 α, MIP-1β, MIP-3A, RANTES); 
innate cytokines (IFN-α); haematopoetic (G-CSF, GM-CSF, IL-7); growth factors (EGF,TGF- α, 
VEGF); adaptive cytokines (IL-2, IL-4, IL-5, IL-13, IL-15, IL-17, sCD40L) and anti-inflammatory 
cytokines (IL-10, IL-1Rα). Of these only three displayed significant positive correlations with 
dependence on α4β7 for replication IL-1α, IL-8 and IL-7 (Figure 2.24). IL-7 has been found to induce 
expression and activation of α4β7 (Cimbro, et al., 2012), while IL-8 has been linked with transient 
upregulation of α4β7 (Sadhu et al., 1998) and IL-1α is a potent inducer of inflammation and activation 
in endothelial cells, which may be responsible for the recruitment of α4β7 high cells to the region of 
initial infection.  
 
 
 
 
 
 
 
 
 
 
Figure 2.24: Levels of IL-1α, IL-8 and IL-7 in the CVL correlate with dependence on α4β7 for 
replication at time of HIV transmission 
Correlations and significance were calculated using Spearmans coefficient and each dot represents an 
individual.  
 
 
Taken together, these data suggest that the environment in which transmission occurs is important to 
determine whether α4β7 plays a definitive role in transmission.  
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2.4. Discussion 
In this study we investigated the role of α4β7 in HIV pathogenesis and the factors that determine α4β7 
reactivity. We show that infectious virus binds α4β7 and that there is a role for α4β7 in viral 
replication that changes over the course of infection. The dependence on α4β7 for replication was 
associated with V1/V2 glycan density and loop length and glycans N332, N234 and N334 and in 
addition CD4 count was negatively associated with α4β7 reactivity. We also found a striking 
association between the α4β7 binding motif sequence P/SDI/V on the virus and dependence on the 
integrin for replication as well as diagnosis of bacterial vaginosis in acute HIV infection. Furthermore 
elevated levels of IL-7, IL-8 and IL-1α in the female genital tract correlated with higher α4β7 
reactivity.  
 
While the α4β7 interaction with HIV has been investigated using primarily different gp120 monomers 
as opposed to infectious and replicative viruses, this study shows that infective viruses bind α4β7 by 
both a competition as well as a flow cytometry based binding assay. Nawaz and colleagues used 
CAP88 1.00.17-5A (T/F) and CAP88.12M.2.2F (12 months) to illustrate that gp120s of early 
transmitting viruses have a higher affinity for α4β7 than the gp120s of chronic viruses. In this study, 
using infectious viruses from the same individual (CAP88) a similar observation was made. This 
supports the hypothesis put forward in a recent study that although functional trimers on infectious 
viruses are likely to be different in conformation to monomers, α4β7 binding is not greatly different in 
either case (Etemad, et al., 2013). It is important to note that a larger number of trimers on the surface 
of HIV are non-functional (Moore et al., 2006) and while they may not participate actively in virus 
entry they are able to elicit potent immune responses and may play a role in α4β7 binding should 
V1/V2 be exposed optimally. In a recent study, a number of V2 directed mAbs were found to bind 
epitopes overlapping the α4β7 binding motif and mutations at this site dramatically altered binding 
affinity of these mAbs (Mayr, et al., et al., 2013). This indicates that this region on the trimer is 
optimally exposed in order to bind α4β7. In addition, others have submitted that being an attachment 
factor, the selective advantage of α4β7 in HIV replication would be most prominent at low viral titers 
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(Parrish, et al., 2012), however we found no difference in α4β7 binding within a range of virus 
concentrations.  
 
While a recent study investigated differences in α4β7 reactivity and dependence on the integrin for 
replication between T/F and unrelated chronic subtype C infectious viruses (Parrish, et al., 2012) and 
another used matched early (not T/F) and chronic infectious subtype A viruses (Etemad, et al., 2013), 
this is the first study that examines the dependence on α4β7 for viral replication longitudinally within 
the same individual. A previous study has pointed out that viruses generated using a standard HIV 
backbone, as in this study, do not allow the contribution of gene products other than Env to the T/F 
phenotype to be assessed and that overexpression of Env in this model compared to naturally 
occurring viruses prohibits a meaningful assessment of virus–host cell interactions (Parrish, et al., 
2013). While they discuss that these differences may skew biological findings and that full proviral 
IMCs are more relevant, we observed no difference in α4β7 binding or replication dependence on 
α4β7 in matched IMCs and IECs suggesting that our model was adequate for this study. In the case of 
individuals with complete data sets (CAP88, CAP200 and CAP206), a change in α4β7 dependence for 
replication was clear over time. The T/F virus was highly dependent on α4β7 in these three cases with 
a notable drop in dependence two months post  transmission. While a comparative analysis between 
the T/F gp160 and the matched 2 or 6 month clone of CAP88, 200 and 206 sequences revealed 
changes that may explain these differences (a change in the highly conserved region of gp41 which 
may impact on Env glycoprotein expression, a α4β7 binding motif shift and the addition of a glycan in 
V5, close to CD4 contact sites respectively), none of these changes were common across participants..  
 
Nevertheless, considering all 11 individuals and all 60 viruses, the shift in importance of α4β7 seems 
to correlate with the hypothesis that the integrin is necessary for initial viral dissemination to the 
GALT (Arthos, et al., 2008) and perhaps selected for during transmission. The T/F viruses were 
significantly more dependent on α4β7 compared to clones from 2 months post infection, by which 
time the virus has migrated to the target tissue (Brenchley and Douek, 2008) and perhaps α4β7 high 
affinity viruses are no longer selected for or that many of these replicative competent CD4
+
 T cells 
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(Cicala, et al., 2009) are severely and selectively diminished in number. In other studies a small 
sample of acute subtype A and C virus Envs bound α4β7 with high affinity, and in some cases, later 
virus strains showed significantly reduced binding (Nawaz et al. 2011), consistent with an early 
requirement for infection of α4β7-expressing cells that is dispensable once infection in the gut mucosa 
has been established. Strikingly, there was no significant difference in α4β7 dependence between T/F 
viruses and chronic clones at 6 and 12 months and this mirrors the finding that there is no difference 
between T/F viruses and chronic viruses in the first year of infection (Parrish, et al., 2012).  
 
A number of studies have investigated the density of glycans and the variable loop length of V1/V2 as 
a determining factor of α4β7 reactivity with conflicting outcomes. One study showed that the removal 
of glycans in this region by mutagenesis was associated with an increased binding affinity for α4β7 
(Nawaz, et al., 2011) and another illustrated that shorter, less glycosylated V1/V2 loops do not 
preferentially bind α4β7 (Etemad, et al., 2013). Results from this study support the latter in that α4β7 
dependence was associated with higher glycan density in V1/V2 and longer V1/V2 loop length. While 
glycans may offer stabilisation to the flexible V1/V2 loop perhaps enhancing α4β7 contact with the 
region, it is possible that density and length are not as important as the location of the glycans on 
gp160. This is reflected by the finding that glycans positioned 5 amino acids distal from the α4β7 
binding motif are present in a higher frequency in viruses that are highly dependent on α4β7 for 
replication. Although this observation was not statistically significant, this evidence corroborates the 
hypothesis that glycans may play a role in α4β7 interaction with gp120.  
 
While others have investigated the role of glycans in V1/V2 on α4β7 binding (Nawaz, et al., 2011; 
Etemad, et al., 2013), this is the first study to examine the importance of glycans throughout gp160 in 
this interaction. 9 notable glycans situated throughout gp120 were found to be present at a higher 
frequency in viruses that have a higher replicative dependence on α4β7. Of these only 2 were present 
in the V1/V2 region (N150 and N185) which is where the tripeptide α4β7 binding motif is located, 
and as previously shown (Figure 2.15), linear distance from the motif may impact on affinity of gp120 
for the integrin. Interestingly, glycans outside of V1/V2 showed the greatest differences between low 
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and high dependence on α4β7 for replication.  While Nawaz and colleagues showed that removal of 
N139, N145, and N184 increased α4β7 binding in a subtype C virus, none of these observations were 
reflected in frequency of these glycans in viruses with high α4β7 dependence.  Several other glycans 
are located near points of CD4 contact with gp120 (N130, N355, N362, N462) which may influence 
α4β7 binding as CD4 and α4β7 are in such close proximity they can be co-precipitated on the cell 
surface (Cicala, et al., 2009). Indeed the underrepresentation of N332 and a closely positioned N339 
in viruses with a high α4β7 dependence is intriguing as this glycan is diminished in T/F viruses 
(Moore, et al., 2012) and decreases the fitness of the virus (Moore, unpublished) correlating with the 
selective advantage α4β7 offers the virus during replication. Over all, these findings suggest that 
differences in sequences and glycan occupancy in V1/V2 alone cannot explain α4β7 reactivity and its 
changing role in replication and should not be used in isolation as a signature.  
 
Although viral load was not associated with α4β7 dependence for replication, CD4 count was 
negatively correlated. This is probably an artefact of the data that were available for specific time 
points. As can be noted in the Appendix Table B2, a number of transmission time points were not 
available as the CD4 count was not recorded. As such, the negative correlation reflects the increase in 
α4β7 dependence at 3 years post infection as previously mentioned. Interestingly, while rapid and 
intermediate progressors show no differences in α4β7 reactivity, viruses isolated from individuals that 
go on to produce BCN antibodies show a decreased dependence for α4β7 at transmission as compared 
to those that do not. While the only clinical outcome that broadly-cross neutralising capacity has been 
associated with is viral load (Doria-Rose, et al., 2010), and α4β7 dependence is independent of viral 
load it is possible that BCN individuals select against α4β7 at transmission as a result of their unique 
immune profile. While intriguing, this requires further investigation.  
 
This study is also the first to illustrate the effect of different minimal α4β7 binding motifs on α4β7 
reactivity during replication. As stated previously, α4β7 has three known natural ligands; MAdCAM-
1, fibronectin and VCAM-1 arranged in order of strongest affinity for the integrin to weakest 
(Jackson, 2002). In all of these there is a minimal binding tripeptide motif (LDT, LDV and IDS 
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respectively) of which the core aspartic acid is pivotal to function (Arthos, et al., 2008). Differences in 
the dependence on α4β7 for replication between different motifs were evident in viruses isolated from 
the first year of infection. Intriguingly, the viruses with motifs most closely resembling those of the 
natural ligand MAdCAM-1 (LDI/L/T) exhibit the lowest dependence on α4β7 for replication. α4β7 is 
unusual amongst integrins for its ability to mediate both rolling and firm adhesion (Bargatze et al., 
1995). The high resolution structure of MAdCAM-1recently reported suggests that it is the unusual 
flexibility of the integrin binding loop of this ligand that allows for these functions (Yu et al., 2013) 
not unlike the highly flexible V1/V2 loop of gp120 (McKellan, et al., 2011). The MAdCAM-1 
sequence of the integrin-binding CD loop is as follows SVQWRGLDTSLGAVQSDT with the 
minimal binding site for α4β7 shown in bold (Yu, et al., 2013). Within the binding loop downstream 
is another motif that is responsible for stabilisation of the interaction SDT (Yu, et al., 2013). Not only 
this, but using random peptidic libraries to generate potent inhibitors of the α4β7 integrin for 
treatment of gastrointestinal disease, a disulphide-bridged cyclic peptide containing the SDT-
tripeptide demonstrated a 10 fold selectivity favouring α4β7 over α4β1 binding and increased potency 
compared to other inhibitors (Dubree et al., 2002). The antagonists inhibit binding of α4β7 to 
MAdCAM-1 in vitro and lymphocyte accumulation in vivo. In addition, a SDV containing antagonist 
was also highly potent and interestingly more so than an LDT antagonists (Dubree, et al., 2002), 
mirrored by the observation in this study that viruses with SDI/V motifs have a higher reactivity with  
α4β7 as compared to LDI/T/V motifs. Viruses with PDI/L motifs were also more dependent on α4β7 
for replication than LDT like motifs and this may be as a result of proline bringing the virus into 
closer contact with α4β7 because of its hydrophobic and compact nature. These data suggests that a 
possible reason for the wide range of reactivities across individuals is that several viruses have 
selected for binding motifs that are preferential for α4β7 reactivity. It must be noted that within an 
individual over time, the α4β7 binding motif is highly conserved. It is rare for motif switching to 
occur and if it does, it appears to be largely driven by co-infection or super-infection. This suggests 
that the motif is selected for during transmission.   
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It has been hypothesised that α4β7 may have a role in transmission, as a result of observed 
preferential binding of gp120 monomers representative of early infection as compared to chronic 
infection (Nawaz, et al., 2011). While no difference in dependence on the integrin for replication was 
shown between T/F and chronic viruses at 6 or 12 months in this and other studies (Parrish, et al., 
2012; Etemad, et al., 2013), we showed that the effect that α4β7 has on replication decreases shortly 
after transmission. Despite this observation, there was a wide range of α4β7 reactivity for T/F viruses 
(22- 68.8% for HP2/1 and 15.7- 66.9% for Act-1). It is possible that the environment during 
transmission determines how great a role α4β7 plays during this time, suggesting that there may be a 
selective advantage for HIV to bind to α4β7. A result of this proposed bottleneck is that T/F viruses 
expressing P/SDV/I α4β7 binding motifs have significantly higher dependence on α4β7 for viral 
replication as compared to those expressing LDI/L as previously discussed.  
 
Inflammation in the genital tract has been implicated risk factors for HIV and as such contribute to a 
distinct bottleneck during transmission (Laga et al., 1993; Mlisana et al., 2012; Stamm et al., 1988). 
Intriguingly we noted that individuals with T/F viruses with high α4β7 reactivity were associated with 
BV diagnosis at the time of transmission. BV has been associated with changes in the genital cytokine 
environment that are distinct from that induced in STI infection inclusive of a mixed inflammatory 
profile with upregulated pro-inflammatory cytokines (IL-1α, IL-1β and TNF-β) and downregulated 
chemokines (IP-10, GRO, MDC and MIP-1α) (Ryckman et al., 2008); Masson, et al., in review), The 
difference in inflammatory profiles from those elicited in STIs is not clear and more importantly the 
disturbance of vaginal flora characteristic of BV has been associated with HIV acquisition (Taha et 
al., 1998). Our data may suggest that BV is associated with the transmission of viruses that have a 
higher dependence on α4β7 for replication by either enhancing the amount of α4β7+ T cells in the area 
of transmission or upregulating α4β7 expression on these cells. This may explain in part why BV is 
associated with enhanced acquisition and may suggest that α4β7 offers a selective advantage during 
transmission.  
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IL-1α, IL-8 and IL-7 in the CVL at the time of transmission were found to correlate significantly with 
the dependence of T/F viruses on α4β7 for viral replication in our system. IL-8 has been associated 
with transient upregulation of α4β7 (Sadhu, et al., 1998) and IL-7 has been found to induce expression 
and activation of α4β7 (Cimbro, et al., 2012) and IL-1α is a potent inducer of inflammation and 
activation in endothelial cells, which may be responsible for the recruitment of α4β7 high cells to the 
region of initial infection. While this remains to be confirmed in these data, the spontaneous rise in 
endogenous IL-7 during the progression to full-blown AIDS and the consequent upregulation of α4β7 
may explain the increase in viral replication dependence on the integrin 3 years post infection 
(Cimbro, et al., 2012). Owing to the small numbers available for analysis it is possible that there are 
many other cytokines that may be associated with α4β7 reactivity but have been excluded due to lack 
of significance. As such, it will be important to expand this analysis with the inclusion of more T/F 
viruses. Cumulatively, this confirms that the environment in which transmission takes place has a big 
impact on the transmission bottleneck which appears to determine α4β7 reactivity including BV 
diagnosis and elevated levels of IL-7, IL-8 and IL-1α.  
 
While the importance of α4β7 in HIV transmission and pathogenesis remains controversial in the 
literature, using a large panel of viruses we determined that the role of α4β7 changes over the course 
of infection in that shortly after transmission, dependence on α4β7 for replication declines. This 
correlates with HIV pathology; the virus would have a greater dependence on α4β7 important for 
wide-spread dissemination during transmission and acute infection, with the need for spread greatly 
decreased thereafter. We showed that multiple factors may determine high α4β7 reactivity throughout 
pathogenesis including but not limited to V1/V2 loop length and glycan density, distance of glycans 
from the α4β7 binding motif, glycan occupancy at positions N234, N334 and N332, low CD4 count 
and α4β7 binding motif sequence. We also showed that the environment at the site of transmission 
such as the diagnosis of BV and upregulation of cytokines IL-1α, IL-7 and IL-8 was associated with 
α4β7 reactivity.  
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Collectively, these data suggest that there is a role for α4β7 in HIV pathogenesis and that the 
interaction may be  selected for during transmission possibly as a result of a number of factors, one of 
which appears to be the presence of BV. As a result of the α4β7 binding motif being in a highly 
immunogenic region of gp120 and antibodies directed against this region associated with protection in 
the most effective vaccine trial to date, further understanding of the interaction between the virus and 
the integrin provides an arsenal for the development of future vaccine and therapeutic strategies.  
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CHAPTER 3 
EXPRESSION OF α4β7+ ON TH17 AND TREG CD4+ T 
LYMPHOCYTE SUBSETS AND PERMISSIBILITY FOR HIV 
INFECTION 
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3.1 Introduction 
Regardless of the route of transmission, HIV replicates rapidly in GALT several days after 
transmission. α4β7+ CD4+ T cells have been described as highly permissive to acute HIV and SIV 
infection as a result of their high activation level and expression of CCR5 (Cicala et al., 2009; Kader 
et al., 2009; Zhu et al., 2009). Not only are these cells readily infected by HIV and α4β7 is an 
attachment factor for gp120 (Arthos, et al., 2008) but they are able to home to sites distal from the site 
of transmission such as the GALT, Peyer’s patches, mesenteric lymph nodes and gut lamina propria 
(Gorfu, et al., 2009; Berlin et al., 1993; Kunkel et al., 2000; Wagner et al., 1996). In support of this 
route of viral dissemination, α4β7+ T cells as well as cells expressing the integrin’s putative ligand, 
MAdCAM-1, are found in the genital mucosa (McKinnon, et al., 2011; Kelly, et al., 2001).  
 
While a number of different T helper subsets have been defined, two of these function in the 
homeostasis of inflammation. This balance is disrupted in the GALT during HIV infection and this 
may be the cause of microbial translocation during HIV pathogenesis. These subsets, T helper 17 
(pro-inflammatory) and T regulatory cells (anti-inflammatory), are present in the GALT and genital 
mucosa, are regulated by retinoic acid (Elias et al., 2008; Uematsu et al., 2008) and express α4β7 
(Kader, et al., 2009). Th17 cells are involved in the maintenance of mucosal barriers and have been 
found to be preferentially depleted in acute HIV infection, compromising the integrity of the gut 
lining and allowing for leaking of lipopolysaccharides and consequent damaging immune activation 
(Brenchley, et al., 2008). A recent study indicated that Th17 cells express high levels of α4β7, CD4 
and CXCR4 but low levels of CCR5 ligands which makes them susceptible to HIV (Alvarez, et al., 
2013). Conversely, Treg CD4
+
 T cells function to attenuate immune responses including Th17 
inflammatory effects (Crome, et al., 2010) and have been found to increase in frequency following 
HIV infection (Chevailer, et al., 2013). Furthermore FOXP3, the defining transcription factor of Treg 
cells, has been suggested as a marker of disease progression (Suchard, et al., 2010). Both Treg and 
Th17 phenotypes of CD4
+
 T cells have been found to support HIV replication (El Hed, et al., 2010; 
Moreno-Fernandez, et al., 2009). 
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The founder target cell population of HIV has not been conclusively determined; however it is 
possible that the virus commandeers the natural homing mechanism to the gut by binding to α4β7, 
after which it reaches a highly permissive target population. Chapter 2 discusses evidence for a role 
for α4β7 in HIV pathogenesis and suggests that shortly after transmission, α4β7-dependent infectivity 
decreases. At this point the virus has already disseminated to the GALT. The phenotype of the α4β7-
expressing cells that may support dissemination and their suitability to such a function has not been 
investigated in the context of HIV.  
 
In this study we sought to determine the effect of all-trans retinoic acid (ATRA) on the frequency of 
Th17 and Treg CD4
+
 T subsets in the peripheral blood from healthy donors in order to mimic the 
GALT environment where dendritic cells secrete ATRA to upregulate homing receptors (Iwata, et al., 
2004). We also sought to directly compare the susceptibility of Th17 and Treg CD4
+
 T subsets to 
harbour HIV infection as well as their relative expression of the homing receptor α4β7. The 
comparison between Treg and Th17 cells in this respect is a novel one. These findings along with the 
natural functions of these subsets may allow for the elucidation of new routes of viral dissemination 
which can be targeted to prevent the systemic spread of the virus from the genital tract and the 
establishment of latent reservoirs.  
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3.2 Materials and Methods 
3.2.1 Isolation and stimulation of CD4+ T lymphocytes from whole blood 
CD4
+
 T cells were isolated as described in Chapter 2 from healthy donors from the South African 
National Blood Bank using the RosetteSep Human CD4
+
 T cell Enrichment Cocktail (Stem Cell 
Technologies, Canada) as per the manufacturer’s protocol. Cells were cultured in the presence or 
absence of ATRA (Sigma-Aldrich, Missouri) to upregulate the expression of α4β7 (a gut-homing 
molecule) and to mimic the GALT environment in vitro on the isolated CD4
+
 T cells in culture. The 
most physiologically relevant and optimum concentration of ATRA was determined as 10 µM 
following titration. 50 ng/ml OKT3 (anti-CD3 antibody) (eBioscience, California) and 20 U/ml IL-2 
(Roche Applied Sciences, Germany) were added to the CD4
+
 lymphocytes in RPMI media with 20% 
FBS and cultured for six days at 37˚C at 5% CO2. The purity of the CD4
+
 T cell isolation and the 
upregulation of α4β7 was confirmed by flow cytometric staining with optimally titrated amounts of 
CD3-ECD (Beckham Coulter, France), CD4-Qdot 605 (Invitrogen, Carlsbad, CA), Anti-Human 
CD49d (integrin alpha 4) PE (eBioscience, CA) and anti-human/mouse integrin β7 FITC 
(eBioscience, CA) and Aqua Fluorescent Reactive Dye (Invitrogen, Molecular Probes, Carlsbad) was 
used to monitor cell viability. The gating strategy was as indicated in Figure 2.1 in Chapter 2. The 
samples from the donors were designated responders and non-responders to the ATRA treatment 
based on the increase or no effect, respectively, of the ATRA treatment on the α4β7+ population of 
lymphocytes. 
 
3.2.2 Th17 and Treg phenotyping of CD4+ T cells by flow cytometry 
In order to determine the nature of the subset on which α4β7 is prominent, Th17 and Treg subsets, 
were investigated. Surface staining was performed as described above, while cells for intracellular 
staining for FOXP3 and IL-17 was initially activated with phorbol 12-myristate 13-acetate (PMA) at 
10 ng/ml, Ionomycin (500 ng/ml) and Brefeldin A (10 μg/ml) for a period of 4 hours. Unstimulated 
cells were used to determine the level of background staining. Both PMA and ionomycin were used to 
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activate the T cells in order to stimulate the production of the chemokine IL-17. Fluorochromes were 
diluted in a 1% BSA/ PBS buffer up to a staining volume of 50 µl. 50 µl of cells were then added to 
the staining mixture and incubated in the dark for 30 minutes at 4 ˚C. Staining was then completed as 
per the manufacturer’s protocol (One-step protocol for intracellular (nuclear) protein, eBioscience) 
and the FOXP3 Staining Buffer Set (eBioscience, San Diego) was used to provide the optimum 
buffering system for staining of the FOXP3 transcription factor. For cell surface staining, 
CD195/CCR5 PE-Cy5 (BD Pharmingen, San Diego, CA), CD3-ECD (Beckham Coulter, France), 
CD4-Qdot 605 (Invitrogen, Carlsbad, CA), anti-human CD49d (Integrin alpha 4) PE (eBioscience, 
CA) and anti-human/mouse integrin β7 FITC (eBioscience, CA), mouse anti-human CD196/CCR6 
PerCP-Cy5.5, mouse anti-human CD45RA APC-H7, CD25-AF700 (BD Biosciences), CD127-PE-
Cy7 (BD Biosciences) were used. Intracellular markers included FOXP3-V450 (BD Horizon) and IL-
17-AF642 (BD Biosciences). Following staining, cells were fixed in 0.1% paraformalydehyde in PBS. 
Th17 CD4
+
 T cells were delineated as CCR6
+
 IL-17
+
 CD4
+
 T lymphocytes, as shown in Figure 3.1. 
Treg CD4
+
 T cells also shown in Figure 3.1 were of CD25
high
 (gated on the highest 2% of the CD25
+
 
CD4
+
 population) FOXP3
+
 CD127
-
 CD4
+
 T lymphocytes. Both defined populations were analysed for 
expression of α4β7, CCR5, CD45RA. In addition IL-17+ and FOXP3+ populations were analysed for 
the expression of α4β7, CCR5, CD45RA as a consequence of the controversial nature of defining the 
Th17 and Treg T subsets. α4β7+ CD4+ T cells were also assessed for Treg, Th17 and IL-17/FOXP3  
expression indicated by the dashed arrows in Figure 3.1. Acquiring of all samples was performed on a 
FACSAria (BD Biosciences). All data analysis was done on FlowJo X software (TreeStar Ashland, 
OR). 100000 events were acquired in each experiment.  
 
3.2.3 Flow sorting of CD4+ T lymphocytes 
In order to test the permissibility of α4β7+ populations to infection, ATRA treated CD4+ T cells were 
stained as previously described (Chapter 2 Section 2.2.3) and sorted on the FACSAria into four 
populations (i) α4-β7- (ii) α4-β7+ (iii) α4+β7- and (iv) α4+β7+ CD3+ CD4+ T cells. These populations (at 
4 x 10
6
 cells/ml) were then infected with a transmitted/founder (T/F) infectious envelope clone (IEC) 
(CAP88.2.00.17-5A) produced as discussed (Chapter 2 Section 2.2.4) and following a 2 hour 
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incubation at 37˚C and 5% CO2, the cells were washed twice with 1% BSA/PBS. The cells were 
harvested over 10 days into 1.25% empigen, and a p24 ELISA was done as discussed in Chapter 2 
Section 2.2.4 to measure HIV infection. 
 
 
 
 
  
Figure 3.1: Gating strategies for Th17, Treg, IL-17 or FOXP3 expressing 
α4β7+CD4+ T cells 
Dashed arrows indicate α4β7+ T lymphocytes gated as α4β7+ CD4+ CD3+ live 
single lymphocytes (black box) and then defined as Th17 cells (green arrows) 
based on dual expression of CCR6 and IL-17. The Treg subset was defined as 
CD25
high
 FOXP3
+
 CD127
-
 population (blue arrows) and IL-17 and FOXP3 
expression (purple arrows) was also determined. The solid arrows show those 
populations gated on CD4+ T lymphocytes. Treg, Th17, IL-17/FOXP3 and naïve 
CD4+ T cells were then gated for α4β7 while CD45RA- and memory CD45RA+ 
(red arrows) CD4 T cells were gated for Th17 and Treg and then assessed for α4β7 
expression.   
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3.2.4 Permissiveness of α4β7+ Treg and Th17 CD4+ subsets to HIV infection 
Following the isolation of CD4
+
 T cells from healthy donors and culturing with ATRA as previously 
described (Chapter 2 Section 2.2.2), the lymphocytes were infected with a T/F IEC (CAP88. 2.00.17-
5A) as previously described (Chapter 2 Section 2.2.6). Subsequently, after three days of incubation at 
37˚C, the cells were washed and resuspended in 1% BSA/PBS and stained to denote Th17 and Treg 
subsets and their α4β7 expression as previously described. In addition, viral replication was noted by 
intracellular p24 staining (following the same intracellular staining protocol as per the manufacturer 
of eBiosciences FOXP3 intracellular staining kit), with Act-1, HP2/1, CD4 and uninfected controls. 
This extensive panel enabled us to confirm how the expression of Treg and Th17 markers and α4β7 
are affected on HIV infected cell populations as well as the comparative level of p24 in these cells. 
This enabled us to investigate the impact of HIV infection on Treg and Th17 CD4
+
 T cells and the 
effect of α4β7 expression in these subsets. 
 
3.2.5 Statistics 
The Wilcoxon matched-pairs signed rank t test or paired t test was performed on paired sample 
comparisons while independent sample comparisons were done using the Mann-Whitney test of 
Friedman’s test. p > 0.05 was used to define a significant observation.  
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3.3 Results 
3.3.1 ATRA changes the phenotypic profile of CD4+ T cells 
CD4
+
 T lymphocytes from healthy donors were incubated with ATRA at varying concentrations (1 
µM, 100 nM, 10 nM) to optimise upregulation of the α4β7 integrin, a marker of the gut-homing 
phenotype. In line with previous studies (Arthos, et al., 2008; Kang, et al., 2011), 10 nM, a 
concentration similar to that found at physiological conditions in the GALT, was the most effective at 
upregulating α4β7 expression represented in Figure 3.2 by the greatest shift in β7-FITC fluorescence 
(yellow) compared to ATRA untreated cells (grey).  
 
 
 
 
 
 
 
 
 
Figure 3.2: Determination of optimal ATRA concentration for activation of CD4
+
 T 
lymphocytes 
ATRA concentrations of 1 µM, 100 nM and 10 nM are indicated in yellow, orange and red 
respectively with the untreated control displayed in grey and the staining control in black. 10 nM 
showed the greatest upregulation of α4β7. CD4+ live T lymphocytes were gated for α4β7 and 
increases in α4β7 represented by increases in β7-FITC fluorescence. 
 
 
Interestingly, approximately 25% of donors responded to ATRA treatment in terms of the 
upregulation of α4β7 as shown in Figure 3.3 in line with findings from others (Arthos, et al., 2008). 
Only those individuals that responded in this way were included in this study. Untreated non 
responders and responders exhibited a mean expression of 33.19 ± 2.91 % and 31.33 ± 2.94 % 
respectively. ATRA treatment of responders increased α4β7 expression significantly (Paired t test at 
95% confidence interval (c.i.) by 20% to a mean of 50.43 ± 3.48%.). Results show that in response to 
ATRA treatment, there was an upregulation in α4β7 expression on CD4+ T cells (number per cell 
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represented by median fluorescence intensity) and an increase in frequency of α4β7 expressing CD4+ 
T cells (Figure 3.4A and B). This is not the only receptor that comes into contact with HIV that is 
affected by ATRA treatment. CCR5 expression is also increased significantly (Figure 3.4C) on the 
surface of CD4
+
 T cells. This, along with α4β7 upregulation may explain in part why CD4+ T cells 
that are treated with ATRA show higher levels of infectivity over ten days than those that are not 
(Figure 3.4D).  
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Characterisation of a Responder and Non-Responder to ATRA Treatment 
CD4 cells were treated with ATRA for 6 days and stained for β7. Red lines represent ATRA treated 
samples, blue lines represent untreated controls with an FITC- unstained control displayed in grey. An 
example of a responder is shown in Panel A and a non-responder in Panel B.  
 
Treg CD4
+
 T cells (defined in this study as CD25
high
 FOXP3
+
 CD127
-
 were increased in frequency 
following treatment with ATRA represented in terms of absolute numbers of the total lymphocyte 
population (Figure 3.5A). To corroborate our gating strategy, we also investigated the level of 
expression of FOXP3 (the master transcription regulator of this subset) and the number of FOXP3
+
 
CD4
+
 T cells and found that this marker is also upregulated by ATRA. Conversely, Th17 (defined by 
CCR6
+
 IL-17
+
 expression as in Singh, et al., 2007) and IL-17
+
 CD4
+
 T cells were not significantly 
affected by ATRA treatment (Figure 3.5C). Ionomycin/PMA treatment is required to stimulate cells to 
release large amounts of  IL-17 while very low background levels were noted in unstimulated cells 
(Figure 3.5B). 
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Figure 3.4: ATRA upregulates α4β7 and CCR5 expression on α4β7+ CD4+ T cells and enhances 
permissibility to HIV infection 
ATRA significantly upregulates (A) α4β7 expression on CD4+ T cells (p=0.0156, Wilcoxon matched-
pairs signed rank test; n=7) and (B and C) CCR5 expression on α4β7+ CD4+ T cells (p=0.008, 
Wilcoxon matched-pairs signed rank test; n=7). Replication of HIV is enhanced by ATRA treatment 
of CD4
+
 T cells (D) Detection of p24 antigen occurs more rapidly and to higher levels in the ATRA 
treated cultures (red line) compared to untreated cultures (blue line) and CD4 inhibition control 
(purple) over 10 days of culture. The difference in infection is significant at day 6 (p = 0.004, paired t 
test). This figure is representative of four independent experiments with three replicates at each time 
point.  
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Figure 3.5: ATRA upregulates FOXP3 expression and Treg frequency but has little effect on the 
Th17 phenotype  
(A) ATRA significantly upregulates FOXP3 (MFI determined on FOXP3+ CD4+ population) and the 
Treg phenotype (CD25
high
 FOXP3
+
 CD127
-
 CD4
+
 T cells) as gated on CD4
+
 T cells as indicated by 
absolute numbers of cells. (B) Representative plot of IL-17 and FOXP3 gated on CD4
+
 T cells 
showing cells unstimulated with PMA and ionomycin and stimulated cells untreated and treated with 
ATRA respectively. (C) Th17 cells defined as CCR6
+
 IL17
+
 CD4
+
 T lymphocytes and IL-17
+
 T 
lymphocytes were not significantly affected by ATRA treated. ATRA treated and untreated matched 
individuals were compared by Wilcoxon matched-pairs signed rank t test; (n=7) with n.s. referring to 
non-significant where p>0.05.  
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3.3.2 Treg and Th17 CD4+ T cells express high levels of α4β7  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Phenotypic characteristics of α4β7+ CD4+ T cell subsets from healthy donors 
(A) The α4β7+ CD4+ T subset, shown in the first pie chart consists of other CD4 subsets (black), and a 
small percentage comprising Treg (blue) and Th17 (green) CD4
+
 T cells. In this population, the 
proportion of Treg CD4
+
 T cells is significantly higher than Th17 CD4
+
 T cells (p=0.012, Paired t test; 
n=12). α4β7 is expressed to similar levels on Th17 and Treg CD4+ T cells as shown by the green and 
blue  portions of the second and third pie charts (p>0.05,paired t test; n=12) respectively. The grey 
portions represent the proportion of Treg or Th17 CD4
+
 T cells not expressing α4β7. (B) α4β7 
expression was gated on naïve or memory Treg or Th17 CD4+T cell populations and was highest on 
the naïve Treg CD4+ T cell population (p=0.006; repeated measures one way ANOVA; n=12). 
 
In a number of defined responders treated with ATRA (mimicry of the GALT environment), the 
expression of α4β7 on Th17 and Treg subsets was determined to assess the potential homing ability of 
these cells to the gut. Sixty percent of Treg CD4
+
 T cells were found to express α4β7 and form a 
larger proportion of α4β7 CD4+ T cells as compared to Th17 cells (Figure 3.6A). This further suggests 
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that ATRA favours a Treg phenotype and that both Th17 and Treg subsets are able to home to the 
GALT. When the memory marker CD45RA was used to discriminate between naïve and memory T 
cells, the Treg naïve CD4
+
 T cell population was found to express significantly more α4β7 than other 
populations (Figure 3.6B). This suggests that this phenotype maybe particularly well suited to home 
to and attach to HIV preferentially allowing for wide-spread dissemination shortly after transmission. 
 
3.3.3 α4β7+ CD4+ T cells are highly permissive to infection 
While many have described that α4β7 defines a subset of cells that is highly permissive to HIV 
infection, it has been based on infection in culture (Cicala, et al., 2009). We sought to determine 
whether α4+β7+ sorted subsets were more permissive to infection in pure populations. We sorted CD4+ 
T cells into (i) α4+β7- (ii) α4+β7+ (iii) α4-β7+ and (iv) α4-β7- populations and infected them with 
CAP88 T/F IEC and monitored p24 over 10 days (Figure 3.7 A). Not only was the α4+β7+ population 
(shown in red) more permissive to infection than the other α4β7 populations, but was more permissive 
to infection than the unsorted CD4
+
 T cell population (shown in black) (Figure 3.7B). CCR5 has often 
been used to define HIV permissive subsets of cells as it is an essential receptor for HIV replication 
(Samson et al., 1996). α4β7+ CD4+ T cells also express significantly higher levels of CCR5 than α4β7- 
CD4
+
 T cells (Figure 3.7C) which may explain why this subset is highly permissive to HIV infection.  
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Figure 3.7: α4β7+ CD4+ T lymphocytes are significantly more permissive to HIV infection than 
α4β7- subsets 
(A) α4+β7+ / α4+β7-/ α4-β7+ and α4-β7- CD4+ T lymphocytes were sorted by flow cytometry and 
following infection with CAP88 T/F α4+β7+ (red) shows higher p24 than α4β7- subset (blue) 
(significant at day 6 *p <0.01;Friedman test adjusted for multiple comparisons using Dunn’s test ) 
with a CD4 control indicating blocking of infection (grey). p24 levels were determined by in-house 
p24 ELISA. This is representative of 3 independent experiments with 4 replicates in each. An 
unsorted population of CD4
+
 T cells was also infected (black) and its permissiveness to infection 
compared to sorted populations as in (B). Percentage difference in infectivity was calculated as the 
difference in p24 between the sorted population and CD4
+
 unsorted population as a proportion of the 
latter. (C) CCR5 expression was significantly higher on α4β7+ as compared to α4β7- CD4+ T cells 
(p<0.0001,repeated measures one way ANOVA with Tukey multiple comparisons post test; n=16). 
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3.3.4 Treg and Th17 CD4+ T cells are highly permissive to acute infection 
In order to determine the permissibility of Treg and Th17 subsets to HIV infection under GALT 
conditions, CD4
+
 T cells isolated from healthy donors that responded to ATRA by upregulation of 
α4β7 were infected with CAP88 T/F and subjected to p24 intracellular staining (Figure 3.8B) and 
Th17/Treg CD4
+
 phenotyping after 3 days. As CD4 was rapidly downregulated following infection as 
noted in Parrish, et al., 2012 and in Figure 3.8 A, populations were not gated on this marker but were 
gated on CD3
+
 T cells as a representation of CD4
+
 lymphocytes. As these cells were 98-99% pure for 
CD4 lymphocytes after CD4 enrichment (data not shown), this gating strategy is unlikely to affect 
results.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Alteration in gating strategy to define infected Th17 and Treg T lymphocytes 
(A) CD4 is downregulated on the surface of purified CD4 T lymphocytes following infection with 
HIV and as a result all subsets were gated on the CD3
+
 T cell subset alone. The blue population shows 
the CD3
+
 T lymphocytes incubated with anti-CD4 mAb, while red is the infected cells and green the 
uninfected cells. (B) p24 was stained for and was clearly enhanced in the infected samples (right 
panel) as compared to the uninfected samples (left panel). 
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The gating strategy was as per Figure 3.1 for Th17 and Treg subsets with p24+ cells serving as the 
third possible parent gate (shown Figure 3.10B). In some cases where specified, p24+ cells were gated 
from Treg or Th17 parent population (Figure 3.10 C) or from the Treg α4β7+ or Th17 α4β7+ 
populations (Figure 3.10 E).  
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
Figure 3.9: Effect of HIV infection on Treg and Th17 phenotypes 
(A) FOXP3
+
 CD4
+
 T cells (p = 0.02) and Treg CD4
+ 
T cells (CD25
high
 FOXP3
+
 CD127
-
) (p =0.008) in 
the first and last panel respectively were significantly increased in number following infection. 
FOXP3 expression (MFI determined on FOXP3+ CD4+ T cells) is unchanged following infection 
(middle panel). HIV infection decreases (B) Th17 marker IL-17 expression (p = 0.03), the frequency 
of IL-17 expressing cells (p = 0.002) and Th17 (CCR6
+
 IL-17
+
) T cells (p = 0.02) were decreased 
following infection. All statistical comparisons were done with a Wilcoxon matched-pairs signed rank 
t test where n=5 
 
Five individuals were used to examine the effect of HIV infection on the frequency of Th17 and Treg 
subsets. Treg CD4
+
 T cells were upregulated and we also confirmed that FOXP3
+
 (the master 
regulator of Treg subsets) CD4
+
 T cells were also increased in number. The median fluorescence 
intensity of the FOXP3 marker did not change during HIV infection in vitro, an indication that 
expression itself was not affected (Figure 3.9.A). Interestingly, the frequency of Th17 and IL-17
+
 
CD4
+
 T cells decreased 3 days post infection as did IL-17 expression per cell (Figure 3.9B). This 
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suggests that not only are these cells depleted, but those that remain have decreased IL-17 expression. 
This rapid decline has been noted in vivo, with data suggesting that Th17 cells are the most 
prominently depleted CD4
+
 T cell subset following HIV/SIV infection (Brenchley, et al., 2008). In 
addition, Treg cells have shown to be increased in number following HIV infection (Li, et al., 2011; 
Shaw, et al., 2011). The observation that FOXP3, a regulator of Treg function, is unchanged after 
three days of incubation with virus is in line with other studies that show that suppressive function of 
Treg cells is maintained following infection (Angin et al., 2012; Kared et al., 2008).  
 
In addition, Treg (CD25
high 
FOXP3
+
 CD127
- 
CD4
+
 T cells) were found to be highly permissive to HIV 
infection with 71.15% of this population found to be p24 positive (Figure 3.10C), with a significantly 
higher proportion of p24
+ 
CD4
+ 
T cells being Treg cells as compared to Th17 cells (Figure 3.10B). 
Despite the significant differences in infectivity, Th17 and Treg CD4
+
 T cells express similar levels of 
CCR5 (Figure 3.10D) but as described (Chapter 3 Section 3.3.2), Treg CD4
+
 T cells express slightly 
higher levels of α4β7 than Th17 CD4+ T cells although this was not significant. There may be other 
susceptibility markers that were not investigated that may explain these differences. Interestingly 
α4β7+ Treg and α4β7+ Th17 CD4+ T cells show similar levels of infectivity 3 days post infection 
(Figure 3.10E) despite the fact that Th17 CD4
+
 T cells express significantly higher levels of CCR5 
compared to Treg CD4
+
 T cells (Figure 3.10F). Act-1 and HP2/1 mAbs that target the α4β7 integrin 
were able to partially inhibit HIV infection of CAP88 T/F as shown in Chapter 2 and CD4 abrogated 
HIV replication (Figure 3.10A) confirming the dependence on the integrin for viral replication.  
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Figure 3.10: p24 levels in Treg and Th17 CD4
+
 
T lymphocytes  
(A) CD4
+
 T lymphocytes were incubated with 
CAP88 T/F virus and HP2/1, Act-1 and anti-CD4 
mAbs and p24 levels compared to virus control 
Infectivity is expressed as % p24
+
 CD4
+
 T cells 
(Repeated measures one way ANOVA, pairwise 
comparisons adjusted for by Tukey’s method) (B) 
Of the total p24
+
 CD4
+
 population both Treg and  
α4β7+ Treg T lymphocytes make up a larger 
proportion of cells compared to Th17 cells and  
α4β7+ Th17 cells respectively (***p<0.0001, 
paired t test). (C) Treg CD4
+
 T cells express 
significantly higher p24 levels than Th17 cells 
three days p.i. (p=0.014; paired t test) but (E) 
show similar levels of infection when gated 
relative to α4β7 where n.s.= non-significant (p > 
0.05;paired t test) and n = 5. (D) CCR5 expression 
was similar on Treg and Th17 CD4
+
 T cells 
(p>0.05, paired t test; n=16) and (F) CCR5 
expression is significantly higher in α4β7+ Treg 
CD4
+
 T cells compared to α4β7+ Th17 CD4+ T 
cells (p=0.022, paired t test; n=9).   
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3.4 Discussion 
In this study we describe the phenotypic properties of Treg and Th17 CD4
+
 T subsets that express 
high levels of α4β7. Studies have shown that dendritic cells in the GALT secrete all trans retinoic acid 
(ATRA) which upregulates α4β7 on CD4+ T cells (Iwata, et al., 2004). In this study, we describe how 
ATRA and therefore the GALT environment may influence the phenotype of these subsets 
irrespective of α4β7 upregulation; with the number of Treg and FOXP3+ CD4+ T cells increasing with 
ATRA treatment and Th17 and IL-17
+
 CD4
+
 T cell number remaining unchanged. Expression of 
FOXP3, α4β7 and CCR5 were upregulated by ATRA treatment as was the permissiveness of 
infection. In addition, Treg CD4
+
 T cells express slightly more α4β7 than Th17 CD4+ T cells. α4β7+ 
and Treg CD4
+
 T cells were highly permissive to infection by a T/F virus.  
 
Understanding the effect that ATRA has on Treg and Th17 subsets and the markers CCR5 and α4β7 
may elucidate their role in the GALT and their possible involvement in HIV infection. The 
upregulation of α4β7 and other homing receptors like CCR9 by retinoic acid produced by GALT 
dendritic cells has been well documented (Iwata, et al., 2004; Arthos, et al., 2008) and was confirmed 
in this study using ATRA. CCR5 was also upregulated on CD4
+
 T cells as a whole as well as on Treg 
and Th17 subsets (data not shown), an observation previously only noted on CCR6
+
 and not CCR6
-
 
CD4
+
 T cells (Monterio, et al., 2011). Strikingly, we found that permissiveness to HIV infection 
increases with ATRA treatment, an observation that together with elevated levels of α4β7 and CCR5 
may explain the rapid HIV replication and depletion of CD4
+
 T cells that is characteristic of acute 
infection in the GALT (Brenchley and Douek, 2008). ATRA has been found to suppress the 
differentiation of naïve CD4
+
 T cells into Th17 T cells, and enhances their differentiation into 
inducible FOXP3
+
 regulatory T cells (Johansson-Lindbom, et al., 2005; Elias, et al., 2008). Our 
results reflect this, showing an increase in the frequency of both Treg and FOXP3
+
 CD4
+
 T cells with 
little effect on the Th17 phenotype. The fact that FOXP3 expression and frequency is also upregulated 
suggest that the increase in frequency of Treg CD4
+
 T cells is not as a result of the upregulation of 
activation markers. In addition the ATRA induced upregulation of Treg cells improves the 
suppressive function of Treg cells in acute inflammation (Menning et al., 2010). The differentiation of 
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naïve T cells into Treg cells by retinoic acid has the same mechanism as the retinoic acid activation of 
α4β7 by binding to the retinoic acid receptor-α on cells (RARα) (Hill et al., 2008). Furthermore 
ATRA can increase the expression of gut- homing molecules like α4β7 and CCR9 on these inducible 
and natural T regulatory cells (Siewert, et al., 2007, Sun, et al., 2007). Interestingly, the lamina 
propria of the small intestine exhibits a higher proportion of Treg cells compared to other tissues (Sun, 
et al., 2007). Despite retinoic acid inhibitory signals however, Th17 cells are found in the intestinal 
mucosa (Mucida et al., 2007). A recent study suggested that a low concentration of retinoic acid is 
required for Th17 cell differentiation (Uematsu, et al., 2008), but is not reflected in our data. Despite 
the blocking of Th17 differentiation by ATRA, α4β7 and other gut-homing receptors are still 
upregulated on these cells (Cha et al., 2010; Ikeda et al., 2010). It is possible therefore that retinoic 
acid may be required to induce gut-homing receptors but not pro-inflammatory Th17 responses. 
Alternatively, antigen-presenting cells that induce Th17 cells may be different from those that induce 
gut homing receptors in Treg cells. 
 
As one of the mechanisms of Treg induction overlaps with that of α4β7 upregulation in the GALT, it 
is not surprising that we found α4β7 to be present on Treg CD4+ T cells. The level of expression of 
α4β7 on Treg CD4+ T cells however was slightly higher than on Th17 CD4+ T cells, a subset 
previously described as mostly expressing α4β7 (Ansari, et al., 2011). Whether increased expression 
of the α4β7 integrin on one subset gives the population a higher propensity to home to the target tissue 
is unknown. Another study, suggested that α4β7+ CD4+ T cells are mostly Th17 cells (Kader, et al., 
2009) however this was not examined in cells under GALT conditions and our results demonstrate 
that a significantly larger, but still very small proportion of α4β7+ CD4 T cells are Treg CD4+ T cells 
as compared to Th17 CD4
+
 T cells. This reveals a significant caveat in this, and many other studies, 
where cells from peripheral blood are used to assess homing capabilities and functional properties of 
cells. Although this study does mimic the GALT environment in terms of the effect of ATRA, the 
ideal samples would be from gut tissue. It is interesting that CD45RA
+
 (Naïve) Treg CD4
+
 T cells 
expressed the highest levels of α4β7 in this study. Naïve Treg cell counts have been reported to be 
significantly reduced in HIV-infected patients, a reduction exclusively restricted to the acute infection 
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phase, while no difference is observed in chronically infected patients (Simonetta et al., 2012). It is 
possible that this subset may be important in the dissemination of HIV from the genital mucosa to the 
GALT as a result of its high α4β7 expression and its depletion in peripheral blood only during acute 
infection.   
 
α4β7 has been described as defining a highly permissive subset of T lymphocytes (Cicala, et al., 
2009) and this was confirmed in this study by sorting α4β7 populations and examining, in the absence 
of contaminating populations, the relative levels of p24 over 10 days. Not only this, but α4β7+ CD4+T 
cells expressed higher levels of CCR5 than α4β7- subsets. This suggests that this integrin does offer 
some selective advantage to HIV infection. Moreover, a recent study in rhesus macaques has shown 
that the number of α4β7+ CD4+ T cells at the site of transmission is a risk factor for productive HIV 
infection (Martinelli et al., 2013). 
 
We also examined how permissive Th17 and Treg subsets are to HIV infection by incubating these 
cell populations with a T/F virus in an in vitro culture system, a novel comparison not present in the 
literature. Several studies have shown in vitro that Treg cells are highly susceptible to HIV infection 
(Oswald-Richter, et al., 2004; Chase, et al., 2008; Moreno-Fernandez, et al., 2009). Other studies have 
demonstrated that Th17 cells are depleted preferentially in cervical tissue and have been identified as 
a founder target cell subset for HIV transmission (McKinnon, et al., 2011). Evidence suggests that 
Th17 cells are the most prominently depleted CD4
+
 T cell subset following HIV/SIV infection 
(Brenchley, et al., 2008). It is unclear in the literature whether Th17 cells are preferentially infected 
by virus (Kader, et al., 2009; El Hed, et al., 2010) or indirectly destroyed by bystander effects 
(Brenchley, et al., 2008). Our results seem to reflect the latter in that Treg CD4
+
 T cells were 
substantially more permissive to acute infection by a T/F virus as compared to Th17 CD4
+
 T cells 
even though these cells expressed similar levels of CCR5. Preferential infection of  Th17 cells is not 
always found in viremic individuals (Brenchley, et al., 2008) and it has been hypothesised that the 
loss of Th17 cells is due to the fact that they are more susceptible to cell death caused by activation 
than Treg cells (Kanwar, et al., 2010). Treg and FOXP3 CD4
+
 T cells and were not found to be 
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depleted as was the case with Th17 cells. However in culture, this observation may reflect the in vivo 
scenario where Treg cells have been found to increase in number following infection (Li, et al., 2011; 
Shaw, et al., 2011; Nilsson, et al., 2006).  It has been shown that Treg suppressive capacity does not 
seem to be affected by HIV infection as Treg cells isolated from acutely infected HIV individuals 
suppress effector T cells proliferation as efficiently as Treg cells isolated from healthy donors (Kared, 
et al., 2008). This may be mirrored in the observation that FOXP3 expression per cell is unchanged 
following infection in this study as FOXP3 is essential for Treg immunosuppressive function. The 
rapid depletion of Th17 CD4
+
 T cells reflects the pathology of the HIV as noted in vivo. Besides being 
highly susceptible to infection as previously mentioned, the loss of Th17 cells in the GALT 
environment provides a direct link between CD4
+
 depletion and immune dysfunction. These cells 
function in the maintenance of the GALT mucosa, primarily through the function of IL-17 which is 
responsible for the strengthening of mucosal epithelial tight junctions (Blaschitz and Raffatellu, 
2010). The expression of IL-17 per cell downregulated after infection may suggest a reduced function 
of these cells in maintenance of mucosa integrity. Despite a higher level of infectivity noted in Treg 
CD4
+
 T cells as compared to Th17 CD4
+
 T cells after 3 days, it was clear that slightly elevated levels 
of  α4β7 in the former is not the reason for this observation as α4β7+ Treg and α4β7+ Th17 CD4+ T 
cells showed high and similar levels of infection. Although this study uses in vitro culture, it mimics 
the in vivo scenario closely and may give valuable insight into the role of α4β7 in dissemination in the 
first few days of infection, providing details of a target for prevention of chronic HIV. 
 
The effect of ATRA on Th17 and Treg cells as well as the role of Treg subsets in HIV has been 
conflicting. These conflicts exist largely as a result of the lack of a clear phenotypic profile and 
homogenous markers for Treg cells. Treg cells are often identified as expressing high levels of CD25 
(Dieckmann et al., 2001; Jonuleit et al., 2001) which is unreliable as CD25 expression is not unique to 
Treg cells but is also a marker of immune activation. The most reliable and widely published 
phenotype, also used in this study, is a combination of CD25 high FOXP3
+
 (a transcription factor was 
identified as an essential and specific factor for Treg cell development and function) and CD127
-
 
(Simonetta, et al., 2013). This phenotype is unlikely to be all encompassing as CD127 is found to be 
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downregulated on activated cells (Simonetta, et al., 2013) and some studies describe a distinct lack of 
correlation between CD25 and FOXP3 in human cells and elect to use FOXP3 alone to represent Treg 
cells (Suchard, et al., 2010). As a result of this we elected to use both the classical phenotypic profile 
and FOXP3 exclusively in our analyses to control for effects of activation on the markers. 
 
Although many studies have examined the importance of Th17 cells in HIV as a possible founder 
target population of cells for HIV, as a result of their preferential depletion in genital tissue, their high 
expression of α4β7 (allowing for homing to the gut, a site of rapid HIV infection), high expression of 
CCR5 and presence in the GALT tissue (McKinnon, et al., 2011), few have examined Treg CD4
+
 T 
cells as conduits for viral dissemination. We have shown evidence in this study to suggest that this 
may be the case and that during HIV acute infection Treg cells may be uniquely suited to fulfil this 
niche. Treg cells express high levels of α4β7, which not only allows migration of the cells to the 
GALT but binds gp120 itself (Arthos, et al., 2008). They are induced by ATRA in vitro as shown in 
this study and in the GALT (Hill, et al., 2008; Siewert, et al., 2007), a mechanism that also controls 
α4β7 upregulation (Iwata, et al., 2004) but did not affect Th17 expression in this study. These cells are 
highly permissive to HIV infection and express similar levels of CCR5 compared to Th17 cells but 
appeared to be expanded following infection while Th17 cells were depleted in vitro in this study and 
in vivo in others (Brenchley, et al., 2008; Suchard et al., 2010). Interestingly, it has been suggested 
that Treg cells could represent a preferential cellular reservoir of viral infection because of their 
apparent survival following HIV infection (Tran et al., 2008). As a result, Treg cells may be better 
suited to disseminating virus because they may survive long enough to do so while in contrast, Th17 
cells deplete rapidly in at least 3 three days. Interestingly, the lamina propria of the small intestine and 
part of the GALT exhibits a higher proportion of Treg cells compared to other tissues (Sun, et al., 
2007) and have been found in the genital mucosa (Jiang and Kelly, 2011), the site of sexual 
transmission. Therefore infection of Treg cells shortly following transmission may provide an 
effective mechanism of HIV dissemination by exploiting α4β7 homing to the GALT. Further 
exploration of this mechanism in vivo and in tissue explants may ultimately contribute to the 
exploitation of certain targets for prevention and treatment strategies.  
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CHAPTER 4: DISCUSSION 
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The role of integrin α4β7 in HIV transmission and pathogenesis is controversial. Not only can α4β7 
bind gp120 (Arthos, et al., 2008) and defines a subset of cells highly permissive to HIV infection 
(Cicala, et al., 2009), but it may allow for viral dissemination to the GALT, the site of initial and rapid 
replication, by the natural homing of T lymphocytes to this region (Berlin et al., 1993; Kunkel et al., 
2000). Gp120 is likely to also signal through α4β7 and LFA-1 and may increase viral transmission 
from cell to cell by homotypic clustering and formation of virological synapses (Arthos, et al., 2008; 
Birdsall, et al., 1997). Moreover antibodies directed at the V1/V2 region, epitopes of which overlap 
the α4β7 tripeptide binding motif, have been described as a correlate of protection for the RV144 
vaccine Thai trial (Haynes, et al., 2012) and blockade of the α4β7 integrin in rhesus macaques 
reduced SIV viral load (Ansari, et al., 2011). A recent study however showed very little effect of α4β7 
on HIV viral replication and no difference between α4β7 usage between T/F and chronic viruses using 
a very small sample of unmatched viruses for comparison (Parrish, et al., 2012). In this dissertation 
we aimed to use a larger panel of viruses from 11 individuals in the CAPRISA 002 cohort to examine 
the dependence on α4β7 for HIV replication and to determine the factors that may influence this 
reactivity. We also aimed to determine which T subsets that have been previously found to be in the 
GALT and genital tract express the highest levels of α4β7 which may allude to a novel route of viral 
dissemination from the site of transmission to the GALT.  
 
In Chapter 2 we describe a role for α4β7 in HIV subtype C infection that changes over time and varies 
across individuals. In three individuals, dependence on α4β7 was higher using T/F viruses and 
decreased sharply during acute infection (1-3 months post-infection). This seems to reflect the in vivo 
observation that T lymphocytes downregulate α4β7 once the cells have migrated to the target tissue in 
the GALT (Menning et al., 2010; Wang et al., 2009b). α4β7 dependence showed an increasing trend 
in chronic infection over time which was slight in the first year. The spontaneous rise in endogenous 
IL-7 during the progression to full-blown AIDS and the consequent upregulation of α4β7 may explain 
the increased dependence on the integrin 3 years post infection (Cimbro, et al., 2012). We show that 
factors that influence α4β7 reactivity include glycan distance from α4β7-binding motif, glycan density 
and variable loop length in the V1/V2 region. In addition, several glycans positioned in conserved 
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regions of gp120 including N234, N332 and N334 showed significant differences in frequency 
between viruses with high and low α4β7 reactivity. Differences in frequency of glycans in the variable 
loops including V1/V2, V4 and V5 were also found between the two groups. This is the first study to 
examine the effect of position of glycans in the whole of gp160 on α4β7 reactivity. Although reduced 
glycosylation in V1/V2 has previously been shown to increase gp120-α4β7 binding (Nawaz, et al., 
2011), and another study showed that α4β7 binding does not select for shorter less glycosylated 
V1/V2 loops (Etemad, et al., 2013) we observed a positive correlation between glycan density and 
α4β7 dependence for replication. We therefore hypothesise that it may be more pertinent as to where 
the glycans are and less about how many there are that affect α4β7 reactivity.  
 
Strikingly there was an association between high dependence of α4β7 for replication at transmission 
and those T/F viruses that have a S/PDI/V α4β7 binding motif as well T/F viruses found in individuals 
diagnosed with bacterial vaginosis during acute infection. Not only this, but several cytokines in the 
CVL of these individuals during early infection (IL-8, IL-7 and IL-1α) positively correlated with α4β7 
dependence for replication. These data suggest that the affinity for α4β7 may be determined by the 
transmission environment and that BV may create a bottleneck which selects for viruses that have a 
high α4β7 reactivity perhaps by increasing the number of α4β7+ CD4+ T cells in the transmission 
tissue either by expression of particular cytokines or upregulation of α4β7 ligand MAdCAM-1. BV 
has shown to increase risk of HIV acquisition in several cohorts (Cohen, et al., 2012; Nwadioha, et al., 
2011) but was only significantly associated with risk by univariant analysis in the CAPRISA 002 
cohort (Mlisana, et al., 2012). This, along with the observation that T/F viruses have higher 
dependence on α4β7 than acute viruses, suggests that α4β7 may have a role in transmission.  
 
In order for α4β7 to have any effect on transmission, and to disseminate virus to regions with cells 
highly permissive to HIV infection such as the GALT, α4β7 + T cells would need to be present at the 
site of transmission. The ligand for α4β7, MAdCAM-1 has been found to be expressed in the female 
genital tract and upregulated in the case of chlamydia and vaginal candidiasis which would recruit 
α4β7+ T cells to vaginal sites (Kelly et al., 2001; Wormley et al., 2001) and a number of α4β7+ T cells 
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have been described in this region including Th17 expression in the cervical tissue (McKinnon, et al., 
2011). Moreover, a recent in vivo study using rhesus macaques showed that susceptibility to SIV was 
directly correlated with the number of α4β7+ T cells present in the rectum (Martinelli, et al., 2013).  
Before the discovery of α4β7-gp120 interaction, it was unclear how the T/F virus could bypass the 
unactivated cells and infect those that allow for robust productive infection, this interaction allows for 
a possible mechanism (Cicala, et al., 2009).  
 
In Chapter 3 we sought to describe the subsets of CD4
+
 T cells on which α4β7 is most prominently 
expressed. Treg and Th17 subsets were examined because they are both present in the GALT and 
genital tract and both have important roles in HIV pathogenesis. In addition ATRA is necessary for 
Treg induction as well as α4β7 upregulation (Sun, et al., 2007; Elias, et al., 2008; Iwata, et al., 2004) 
as reflected in our study, with little effect on Th17 phenotype. Treg CD4
+
 T cells expressed slightly 
higher levels of α4β7 as compared to Th17 cells. In addition, Th17 cells in this and other studies were 
shown to rapidly deplete following HIV infection (Brenchley, et al., 2008), while Treg CD4+ T cell 
were shown to expand (Li, et al., 2011; Shaw, et al., 2011; Nilsson, et al., 2006). Despite this, Treg 
CD4
+
 T cells were significantly more permissive to infection as compared to Th17 CD4
+
 T cells 
which may be as a result of Treg cells being more resistant to apoptosis (Kader, et al., 2009; El Hed, 
et al., 2010 Kanwar, et al., 2010) as it has been suggested that Treg cells may form part of a latent 
reservoir during latent infection (Tran, et al., 2008). Due to high levels of α4β7 expression and the 
ability to bind gp120, presence in both the genital tract and the GALT, regulation by ATRA similar to 
α4β7 upregulation, expansion following HIV infection and elevated permissiveness to acute infection 
Treg cells may be a robust vector from the genital mucosa to the GALT shortly after transmission. 
This subset may be better suited for this role as compared to Th17 CD4
+
 T cells which are more 
susceptible to either depletion by HIV or bystander effects. There are other mechanisms of 
dissemination; one such example is the conserved trafficking signal in gp41 (711-714) which in SIV 
contributes to targeting mucosal tissues (Breed et al., 2013) but this has not been extensively studied.  
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Pitfalls of the study and further recommendations 
While this study is the largest assessment of α4β7 dependence on HIV replication to date, only a 
limited number of time points within individuals were available for analysis and as such not all 
individuals had complete data sets. In addition, analyses involving T/F viruses were limited by the 
number that have been produced for other studies with several individuals not being sampled early 
enough to infer the T/F viruses. Future directions may include expanding the data set to limit skewing 
by the increased numbers of chronic time points available. In order to prove that the α4β7-binding 
motif may impact on α4β7 reactivity we are currently mutating the tripeptide motif sequence to assess 
whether higher binding can be conferred to low α4β7 binding viruses by changing the motif sequence 
(e.g. LDI mutated to PDI). We will assess binding capability as well as how the motif affects α4β7 
dependence on virus replication. We are currently investigating the association between the P/SDI/V 
motif and BV diagnosis as well as cytokine expression in the CVL in the CAPRISA 002 and 004 
cohort in order to make use of larger sample size. A large caveat to the study is using peripheral blood 
cells and treating them with ATRA to mimic the GALT environment. Multiple studies have shown 
that intrinsic differences exist within tissues compared to peripheral blood (McKinnon, et al., 2012; 
Cohen, et al., 2010) and it is possible that expression levels of homing receptor would be different in 
gut tissue compared to ATRA treated peripheral cells. The ideal sample tissue would therefore be gut 
tissue. In addition, because the infection of cells was done in vitro culture, an artificial situation where 
cells are dying and not recirculating, the ideal model for infection would be an in vivo model such as 
infecting mucosal tissue explants or rhesus macaque infection, although findings from this study 
mirror the in vivo situation. As a result of the phenotype of cells changing over time in a culture, it 
would be necessary to confirm the result from this study in HIV infected individuals to reduce the 
influence of the artifacts of culture conditions. Finally, the analysis of Treg cells as a whole has been 
controversial a result of the lack of a clear phenotypic profile and homogenous markers for Treg cells, 
but until another reliable marker is determined, this study uses the best available definition as CD25 
high FOXP3
+
 CD127
-
 CD4
+
 T cells.  
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Future avenues of research may include how much of role α4β7 signalling plays in cell-cell 
transmission and the determination of frequency of higher α4β7 binding motifs in unbiased and large 
population sequences. With improved studies and expansion of our sample size, it is possible that 
α4β7 may be a good target for the prevention of HIV transmission or reduction of the severity of 
inflammation.  
 
Conclusion 
In conclusion, this dissertation describes a dependence on integrin α4β7 for HIV replication which 
changes over time in addition to its’ function as a homing receptor that is responsible for the 
trafficking of lymphocytes into the GALT and also serves as an attachment factor for gp120. α4β7 is 
not essential to establish HIV infection but the observation that α4β7 dependence changes over time 
and that there are factors that correlate with this change suggests that HIV obtains a selective 
advantage from the utilisation of the integrin. Factors that influence this interaction include glycan 
position, glycan density, variable loop length and P/SDV/I sequence of the α4β7-binding motif. The 
transmission bottleneck that seems to select for viruses that have high α4β7 reactivity may include 
bacterial vaginosis and elevated levels of IL-8, IL-7 and IL-1α in the genital tract. α4β7+ Treg CD4+ T 
cells may be one of the initial populations to be infected follow HIV transmission and are well-suited 
to a function of viral dissemination to the GALT. This dissertation suggests that the role of α4β7 in 
HIV pathogenesis and perhaps more importantly transmission could be targeted to diminish the risk of 
HIV infection either by blockade of the integrin itself, already licensed for multiple sclerosis 
therapies, or by directing responses to the α4β7 binding motif in future vaccine trials.  
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Appendix B: Supplementary data  
 
Table B1: Characteristics of the HIV infection of individuals in this study 
 
Individual Disease progression*
 
BCN/nBCN
† 
CAP8 Rapid BCN 
CAP88 Intermediate nBCN 
CAP177 Rapid BCN 
CAP200 Rapid nBCN 
CAP206 Rapid BCN 
CAP210 Rapid nBCN 
CAP225 Intermediate nBCN 
CAP239 Intermediate BCN 
CAP244 Rapid nBCN 
CAP255 Rapid BCN 
CAP256 Rapid BCN 
 
*Rapid progressors were defined as having two consecutive CD4 counts < 350 cells/µl within the first 
2 years of infection 
† 
Individuals that produce broadly-cross neutralising antibodies were defined by the ability of patient 
sera to neutralize 40% of viruses from different subtypes 
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GD = glycan density      * Viral load measured as RNA copies/ml     n.d. = not determined      ϯ CD4 count measured as cells/µl 
 
 
Time point V1 GD V1 length V2 GD V2 length V1/V2 GD V1/V2 length V3 GD V3 length V4 GD V4 length C3/V4 GD C3/V4 length V5 GD V5 length gp160 GD α4β7-binding motif Log Viral Load CD4 count HP2/1 mAb Act-1 mAb
8.2.00.6F TF 4 28 1 39 5 67 1 35 4 29 7 80 1 4 30 LDI 5.32 n.d. 24.50 33.34
8.3.16.1 56 WK/ 12M 4 28 2 39 6 67 1 35 3 23 6 74 1 4 31 LDT 4.59 332 40.53 35.48
8.4.25.T25 171WK/39M 6 37 2 39 8 76 1 35 2 24 5 75 1 5 32 LDI 5.33 201 63.30 58.40
8.4.25.C10 171WK/39M 5 37 2 39 7 76 1 35 6 30 9 81 1 4 34 LDI 5.33 201 69.00 76.70
88.2.00.17-5A TF 4 28 0 39 4 67 1 35 3 22 5 75 2 7 28 PDI 4.47 963 64.08 66.85
88.2.00.B5 5WK/1M 4 28 0 39 4 67 1 35 3 22 5 75 2 7 28 PDI 4.47 963 23.30 22.90
88.3.44.4C 30WK/ 6M 4 28 0 39 4 67 1 35 3 22 6 75 2 7 28 PDI 4.66 686 42.96 38.16
88.12.23.7A 57WK/12M 4 28 0 37 4 65 1 35 3 23 6 76 2 7 29 PDI 5 520 30.33 48.01
88.12.17.7F 57WK/12M 4 28 0 37 4 55 1 35 3 22 6 74 2 7 29 PDI 5 520 33.55 43.42
88.12.46.4B 57WK/12M 4 26 1 39 5 65 1 35 3 24 6 76 2 7 30 PDI 5 520 36.14 43.32
88.12.2F 57WK/12M 4 26 1 39 5 66 1 35 3 22 6 74 2 7 29 PDI 5 520 52.00 43.39
88.12.45.10B 57WK/12M 4 26 1 39 5 65 1 35 3 22 6 74 2 7 30 PDI 5 520 43.41 51.31
88.12.21.10D 57WK/12M 4 28 1 38 5 66 1 35 3 24 6 76 2 7 30 PDI 5 520 54.72 43.48
88.4.25.D5.4 173WK/39M 3 27 2 37 5 64 1 35 4 25 7 75 1 5 29 PDI 5.25 633 74.80 63.51
88.4.25.G3 173WK/39M 5 39 2 37 7 76 1 35 4 27 6 77 1 5 31 PDI 5.25 633 73.23 87.69
88.4.25.A3.3 173WK/39M 5 32 2 39 7 71 1 35 3 22 6 72 1 5 29 PDI 5.25 633 71.95 55.77
177.3.7AS 28WK/6M 3 18 2 39 5 57 1 35 3 20 5 72 2 7 24 PDI 5.18 444 48.38 40.87
177.3.7F.1 28WK/6M 3 18 2 42 5 60 1 35 3 20 5 71 2 5 25 PDI 5.18 444 31.03 37.07
177.12.11.3A 54WK/12M 3 26 2 42 5 62 1 35 3 17 5 69 2 7 25 PDI 4.62 370 31.77 49.81
177.12.47.6F 54WK/12M 4 25 2 42 6 67 1 35 3 20 4 71 2 5 27 PDI 4.62 370 53.32 46.52
177.12MO.1.10D 54WK/12M 5 26 2 42 7 68 1 35 3 20 5 71 2 5 28 PDI 4.62 370 44.13 48.79
177.4.25.1.11E 172WK/39M 4 27 3 42 7 69 1 35 4 23 6 75 2 7 33 PDL 4.62 293 73.45 66.43
177.4.25.28.7A 172WK/39M 6 33 3 42 9 75 1 35 3 20 5 72 2 7 33 PDI 4.62 293 63.81 65.94
200.1.06.B8A TF 3 27 2 42 5 89 1 35 3 28 5 80 1 6 26 SDV 5.6 n.d 63.12 55.43
200.3.08.1H 21WK/5M 4 27 2 39 6 66 1 35 3 28 5 80 1 6 28 PDI 5.13 414 29.64 31.32
200.3.16.10 54WK/12M 4 27 2 39 6 66 1 35 4 28 7 80 2 6 31 PDI 4.86 367 47.45 43.37
200.3.16.13 54WK/12M 4 27 2 39 6 66 1 35 4 28 5 80 1 5 28 PDI 4.86 367 50.51 48.88
200.3.16.4 54WK/12M 4 27 2 39 6 66 1 35 4 28 7 80 1 5 30 PDI 4.86 367 53.82 48.60
200.4.25.C2.1 176WK/39M 3 24 3 39 6 63 1 35 5 28 8 80 2 6 33 PDI 5.55 193 67.83 76.62
200.4.25.E1 176WK/39M 3 24 2 39 5 63 1 35 3 23 6 75 2 8 30 PDI 5.55 193 69.84 85.57
206.1.02.B5 TF 3 25 2 40 5 65 1 35 4 25 6 77 0 7 25 SDV 5.29 n.d 50.55 48.76
206.8W.24 8WK/2M 3 25 2 40 5 65 1 35 4 25 6 77 1 7 26 SDV 5.57 365 25.23 22.99
206.6M.B4 33WK/8M 3 25 2 38 5 63 1 35 4 25 6 77 1 4 26 SDV 5.14 325 27.96 39.89
206.6M.B14 33 WK/8M 3 25 2 38 5 63 1 35 4 25 6 77 1 4 27 SDV 5.14 325 36.78 29.54
206.12M.13 56WK/ 12M 3 25 3 48 6 73 1 35 3 25 5 77 1 3 28 SDV 5.32 297 29.39 34.75
206.12M. 18 56WK/ 12M 3 25 2 37 5 62 1 35 4 25 6 77 1 4 27 SDV 5.32 297 25.39 35.96
206.39M.A4 173WK/39M 3 25 1 45 4 70 1 35 4 27 6 77 1 5 27 SDV 5.76 469 68.80 78.05
206.39M.F4 173WK/39M 3 25 1 45 4 70 1 35 3 22 5 74 1 5 26 SDV 5.76 469 61.30 70.70
206.39M.C10 173WK/39M 3 25 2 45 5 70 1 35 4 24 6 76 1 5 29 SDV 5.76 469 71.10 n.d.
206.39M.E3 173WK/39M 3 25 2 45 5 70 1 35 3 27 5 79 1 6 27 SDV 5.76 469 60.45 55.11
206.39M.E12 173WK/39M 3 25 2 45 5 70 1 35 4 28 6 80 1 3 28 SDV 5.76 469 69.80 n.d.
210.1.00.E8 TF 2 19 3 44 5 64 1 35 6 39 9 91 2 8 33 LDI 5.67 332 41.10 39.28
239.2.00.G3 TF 2 18 2 41 4 59 1 35 5 31 8 83 1 9 29 LDI 4.98 845 31.34 29.73
244.2.00.D3 8WK/2M 6 42 2 39 8 81 1 35 5 29 7 81 1 7 29 LDI 4.28 557 24.30 23.63
244.4.25.B34A 178WK/42M 3 27 2 39 5 66 1 35 5 31 7 83 1 6 29 LDI 3.73 335 61.35 63.81
244.4.25.A36A 178WK/42M 4 27 2 39 3 66 1 35 5 36 8 88 2 7 32 LDI 3.73 335 54.75 72.12
255.2.00.5 8WK/2M 3 24 3 43 6 67 1 35 4 27 7 79 1 5 29 LDI 5.29 693 15.70 22.31
255.4.25.3D 176WK/39M 7 35 3 41 10 76 1 35 5 31 7 83 1 5 34 LDI 3.95 226 74.95 82.34
255.4.25.26 176WK/39M 6 38 2 41 8 79 1 35 5 35 9 87 1 6 33 LDI 3.95 226 60.80 49.96
255.4.25.34.7D 176WK/39M 7 38 3 43 10 81 1 35 4 31 8 83 1 7 33 LDI 3.95 226 73.60 69.85
225.1.C.2.E11 TF 4 34 2 41 6 75 1 35 4 23 7 75 2 7 30 SDI 7.8 n.d 68.61 60.08
256.2.00.7C 6WK/2M 3 26 2 50 5 76 1 35 3 31 5 83 1 6 27 LDL 4.75 689 22.00 15.72
256.2.06.C7 15WK/3M 3 22 2 42 5 64 1 35 4 31 7 82 2 6 30 LDI 6.38 555 27.52 21.59
256.4.25.10 176WK/39M 3 20 3 49 6 69 1 35 5 31 8 82 1 6 31 LDL 5.01 275 65.85 75.64
256.4.25.11 176WK/39M 3 20 3 49 6 69 1 35 5 30 8 81 0 5 29 LDL 5.01 275 75.73 85.87
256.4.25.4E 176WK/39M 4 28 3 49 7 77 1 35 5 30 8 81 1 7 31 LDL 5.01 275 75.90 61.47
256.4.25.F10 176WK/39M 3 24 1 47 4 71 1 35 5 30 8 81 0 5 27 LDL 5.01 275 65.35 70.49
256.4.25.E1 176WK/39M 3 24 1 47 4 71 1 35 5 30 7 81 1 5 28 LDL 5.01 275 52.30 75.13
256.4.25.H1 176WK/39M 3 24 2 47 5 71 1 35 4 31 6 82 2 7 29 LDL 5.01 275 57.15 67.63
256.4.25.F1 176WK/39M 4 28 3 49 7 77 1 35 5 30 8 81 0 5 30 LDL 5.01 275 60.20 n.d.
* ϯ 
Table B2: Properties of IECs used in this study 
 
High α4β7 dependence Low α4β7 dependence 
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Table B3: PCR Reaction mixture for env gene amplification from pcDNA3.0 vector 
COMPONENT AMOUNT (μl) 
Sterile Water (Sigma-Aldrich, San Diego) 
50 mM MgSO4 (Invitrogen, Carlsbad) 
20 pmol Env M primer (Rev) 
TAGCCCTTCCAGTCCCCCCTTTTCTTTTA 
20 pmol Env A  primer 
TGCTGCTCCCAAGAACCCAA 
5 U/µl Platinum Taq DNA Polymerase High Fidelity 
(Invitrogen, Carlsbad) 
10 x High Fidelity PCR Buffer (Invitrogen, Carlsbad) 
600 mM Tris-SO4 (pH 8.9) 
180 mM Ammonium Sulfate 
Env DNA 
0.2 mM dTNPs (Invitrogen, Carlsbad)
1
 
39.75 
2 
0.5 
 
0.5 
 
0.25 
 
5 
 
 
1 
1 
1 
Formed by 10 μl  of each of the dTNPs in 60 μl of sterile water 
 
 
 
 
 
 
 
Figure B1: PCR cycle for the amplification of env genes from pcDNA 3.0 vector 
 
Table B4: Reaction mixture for the digestion of pHIVΔenvBstEllnef-hisD backbone 
COMPONENT AMOUNT (µl) 
10x Buffer D (Promega, Madison,WI) 
10 mg/µl Acetylated BSA 
(Promega, Madison,WI) 
10 U/µL BstEII (Promega, Madison,WI) 
Sterile water (Sigma-Aldrich, San Diego) 
pHIVΔenvBstEllnef-hisD vector 
10 
1 
 
5 
44 
40 
TOTAL          100 
 
94˚C  
5 min 
94˚C  
15 sec 
55˚C  
30 sec 
68˚C  
4 min 
68˚C  
15 sec 
10˚C  
  ∞ 
35 Cycles 
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Figure B2: α4β7 mediated virus capture 
inhibition assay 
Virus growth kinetic curves of CAP8, 88, 
177, 200, 206, 210, 225, 239, 244, 255 
and 256 viruses completed in triplicate; in 
the presence or absence of HP2/1 mAb 
(red),  Act-1 mAb (blue) or CD4 mAb 
(grey) demonstrate their inhibitory effect 
on the replication of T/F, early and 
chronic clones. Data are representative of 
two independent experiments, with the 
curves representative of the mean p24 
readings and error bars indicating the 
SEM. 
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Figure B3:  Glycan positions in gp160 and their frequency in viruses with high and low α4β7 dependence 
The frequency of glycans at positions in gp160 across 60 viruses from 11 individuals from the α4β7 binding motif are represented as a proportion of those 
viruses with high and low α4β7 dependence for viral replication (shown as green and blue bars respectively). Those glycan positions where high and low α4β7 
dependencies differ across at least three different individuals are highlighted in yellow. Positions of glycans within the structure are indicated below the axes. 
High α4β7 dependence 
Low α4β7 dependence 
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Figure B4: FMO controls for α4-PE and β7-FITC  
Plots showing (A) PE FMO only stained with β7-FITC, (B) FITC FMO only stained with α4-PE 
and (C) α4β7 populations gated on CD4+ T cells stained with both α4-PE and β7-FITC 
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List of Corrections 
 
Internal examiner 
A: Flow cytometric plots 
 
1. Figure 3.1-parent population labelled as CD3+CD4+ live single lymphocytes but Treg 
plot on right hand side clearly shows positive and negative cells. CD4 should be 
removed from the parent block if the plots were not gated on CD4
+
 events. 
 
The flow plot referred to here does show only positive CD4+ T cells because the PBMCs 
used in this study were enriched for CD4 expression with a purity of 99%, as mentioned on 
page 38 paragraph 3. These PBMCs were gated on CD4 initially to exclude any outliers 
and we confirmed the purity of this singleCD4 population via various gating analyses. This 
gating strategy is shown on page 40 panel E.  
 
2. Figure 3.1 Treg gating.  
The gating strategy that was used in this study was optimised to demonstrate the cells with 
the highest FOXP3 MFI, as this is currently the most specific marker for suppressive 
Tregs. Using CD127 instead of CD25 to set the gate is far more difficult. CD127 
expression is downregulated extensively when T cells are activated, especially following 
HIV infection, making it difficult to discern a distinct population. As a result, most studies 
still choose to use the highest 2% of the CD25
+
 population using the whole CD4
+
 T 
population as a reference. The CD25 gate was not set on the CD4
+
 CD25
+
 plot but rather 
this plot was used only as a frame of reference to work out CD25 high positioning. This 
gate was then imposed and set on the FOXP3 CD25
HI
 parameter. To avoid confusion the 
arrow between the CD4/CD25 plot and the CD25/FOXP3 gate has been removed on page 
87 as these plots do not follow on from one another (i.e the CD25 high gate set on the 
CD4/CD25 plot is not the parent population for the FOXP3/CD25 plot). Rather these gates 
were simultaneous and the FOXP3/CD25 plot is representative of all CD4
+
CD3
+
live T 
cells.  
 
3. Figure 3.1 Why is IL-17 expression in the left hand plot labelled “Th17” clearly less 
than that of the lowest plot labelled “FOXP3/IL-17”?  
This figure has been replaced with the correct image on page 87. 
 
4. Figure 3.1 Flow gating of Th17 and Tregs: Legend: last line 
Many of the comments that follow on from this one appear to stem from the inaccurate 
representation of the gating strategy of Treg and Th17 cells in Figure 3.1. Many comments 
address the fact that α4β7 was the parent gate. This was only true in some cases. The gating 
strategy included the Treg, Th17 and FOXP3/IL-17 gated off α4β7+ CD4+ T lymphocytes 
(now shown in the Figure 3.1 as dashed arrows) but also included CD4
+
 T lymphocytes 
gated for Th17, Treg and IL-17/FOXP3 which were then assessed for α4β7 expression as 
illustrated by the solid lines. The previous figure only made the prior gating strategy 
apparent. The corrected figure is on page 87. 
 
5. For publication purposes the candidate has sufficient data to answer another 
pertinent question-namely of the Treg and Th17 subsets, how many are α4β7 
positive? 
This question has already been investigated and is on page 93 (Figure 3.6 pie chart two and 
three). 
 
And is this the same or different with or without HIV infection in the culture? 
This has been investigated (Figure 3.9 page 97) and the misunderstanding stems from the 
inaccuracy of communicating the gating strategy as mentioned in the previous point. The 
example used to illustrate this by the examiner has therefore not been addressed because 
 
 
the effect of ATRA on the IL-17 expressing phenotype has been investigated and on total 
CD4
+
 T cells and not on the α4β7 subset as suggested by the examiner (Figure 3.5 page 
92).  
 
6. Figure 3.6 on page 93 and section Heading 3.3.2….. 
This heading and legend is correct, once again a misunderstanding evolving from the 
incorrect communication of the gating strategy, which has now been clarified. α4β7 was 
not the parent gate when determining whether α4β7 was expressed on Th17 and Treg T 
cells (Figure 3.6 second and third pie chart). However when determining what proportion 
of α4β7 expressing cells are Th17 and Treg (Figure 3.6 first pie chart), α4β7 was the parent 
gate. This applies to the comment on this figure’s legend as well.  
 
Similarly naïve Treg CD4 T cells express the highest level of α4β7-this gating has not 
been shown. Confirm which parent gate. 
The gating strategy used to generate the data shown in Figure 3.6 B (page 93) has been 
added in Figure 3.1 on page 87 and it now has been specified in the legend of Figure 3.6 
that the parent population naïve Treg CD4
+
 T cells. 
 
The final comment for page 93 last paragraph has been addressed previously. 
 
7. Figure 3.7C. Why are the other two subsets not shown?  
The other two subsets were not shown for simplicity but have now been added in on page 
95 
 
8. Figure 3.7A: Please specify method of measurement of p24 in legend 
Corrected on page 95 Figure 3.7 legend as being performed by in-house p24 ELISA. 
 
9. Figure 3.9 and text, page 97-how was median florescence intensity of FOXP3 
measured? On which subset and from which plot? Also for Figure 3.5 page 92 
Both figure legends have been corrected to say that MFIs were done on FOXP3
+
 CD4
+ 
T 
cells.  
 
10. Figure 3.10 legend 
As mentioned in correction 4, the gating strategy has been amended in Figure 3.1 to 
indicate that Th17 and Treg subsets were either the parent populations or were gated from 
the α4β7+population. The gating strategy was as per Figure 3.1 for Th17 and Treg subsets 
with p24
+
 cells serving as the third possible parent gate (shown Figure 3.10B). In some 
cases where specified, p24
+
 cells were gated from Treg or Th17 parent population (Figure 
3.10 C) or from the Treg α4β7+ or Th17 α4β7+ populations (Figure 3.10 E). This 
explanation has been inserted on page 97 first paragraph. 
 
11. Page 101 discussion of CD45RA+ naïve Treg-gating not shown.  
This has been corrected as per correction number 6. 
 
12. Section 3.3.4 on page 96 
The examiner expresses concern about the methodology of assessing the susceptibility of 
Treg and Th17 subsets to HIV infection as a result of changing phenotype following 
culture. While this is certainly valid, the incubation time was only 3 days and was not an 
extended culture. In addition this study sought to mimic the environment of the GALT as 
gut samples were unavailable. While the response without ATRA could have been of 
value, this was not the scope of the project and may be covered in work going forward. The 
sorting of Tregs was in the original protocol but was removed after extensive literature 
review revealed that the reliability of such sorts is highly questionable. In addition many 
Treg cells with the markers that the examiner alludes to (CD25 and CD127) express IL-17, 
therefore sorting using these markers wouldn’t be sufficient to distinguish Tregs from Th17 
 
 
cells. In addition, sorting both these populations based on surface markers is very 
imprecise as a result of having intracellular markers as their defining characteristics. These 
concerns were also addressed in the final discussion of this study. 
 
13. Page 50 and 51: Binding of IECs to α4β7 in a competition assay.  
The readout of this experiment is represented as “% binding to α4β7 by competition” with 
either virus or α4β7 inhibitory mAb. This calculation is done by the formula on page 45 as 
correctly determined by the examiner. As mentioned in the text in the first paragraph on 
page 45 “Percentage binding to α4β7 is defined as the percentage difference between the 
median fluorescence intensity (MFI) of PE and FITC of α4β7 transfected cells with and 
inhibitory mAb OR VIRUS as represented in the formula below.” The formula was aimed 
as being an example of one of these scenarios (i.e measuring the competition between Act-
1 and HP2/1 and the fluorescent antibody β7-FITC). However to make this point clear, the 
formula has been corrected to include “viruses”.  
 
It should be noted that the text does not state that the α4β7 inhibitory mAbs, fluorescent 
α4β7 mAbs AND the virus are incubated all together as alluded to by the examiner, but 
rather the Act-1 or HP2/1 mAbs and the fluorescent mAbs OR the virus and the fluorescent 
mAbs were incubated together. The HP2/1 and Act-1 mAbs were simply used as controls 
to illustrate that they were competing with the α4-PE and β7-FITC antibodies to a 
saturating degree. If virus bound to α4β7 in this assay and then was treated with 
fluorescently labelled α4 and β7 mAbs and compared to a control which had no virus, one 
would expect a decrease in MFI of α4-PE and β7-FITC relative to the control as the virus 
has already occupied the sites where the fluorescent mAbs would bind. These unbound 
fluorescent mAbs were then washed away and the readout relative to a control diminished.  
 
Considering that in the titration experiment (Figure 2.4C), increasing amounts of 
blocking antibody did not correlate linearly with decreasing fluorescence of the 
integrin on the cells, why should increasing amounts of virus result in decreasing 
fluorescence of the integrin? 
Figure 2.4B on page 48 shows that increasing amounts of the blocking antibodies did 
correlate linearly with decreasing fluorescence of the integrin, with the readout being 
represented as change in MFI. Figure 2.4 C to which the examiner refers, is unrelated to 
flow cytometry. This, as described in the legend is an alternate approach to achieve the 
same goal of antibody titration. While the effect was linear in the flow cytometry assay, it 
was not in the cellular assay. This is likely to be because of flow cytometry measuring 
binding capacity and the replication assay taking into account all signalling pathways. 
Even though the concentration is saturating for binding it is not saturating to diminish 
replication.  
 
Why would the gating be on α4β7 positive cells only? 
It should be remembered that the cells used for this assay were HEK293T cells which do 
not naturally express α4β7. Assessing the whole population is not valid as the rest of the 
cells do not even express the receptor of interest. Assessing the whole population does not 
change the result and will introduce errors because of incomplete transfection (i.e. only the 
α4 subunit being transfected).  
 
14. Page 52 Figure 2.8. Would viral binding throughout the 10 day culture period 
necessarily affect binding of the fluorescent monoclonal on the day of staining? 
This titration experiment, as mentioned in this chapter, was not based over a 10 day period. 
This was binding done with a 15 minute incubation time with the virus and an additional 
half an hour with fluorescent mAbs as detailed on page 45. The questions that are posed by 
the examiner that follow this assumption of a 10 day assay are therefore not relevant here. 
Any assays with a readout of “% dependence on α4β7 for replication” are indicative of an 
assay as detailed on page 53.  
 
 
 
15. Fluorescence minus one controls. 
The FMO controls have now been included as Figure B4 in the appendix on page 138. As 
α4β7 is an integrin and is present as a dimer, the expression pattern of the integrin on flow 
cytometry plots therefore appears as a diagonal as the subunits are expressed 
simultaneously. Although the diagonal is often a sign of poor compensation, this is how the 
data looks. Samples that were directly compared (HIV infected versus HIV uninfected or 
ATRA- and ATRA+ samples) were always run head to head. In addition fresh 
compensation was done with each new experiment and compensation matrixes were not 
reused on different days. This point has been added in Section 2.2.3 page 39. 
 
16. Was any effort made to standardise MFIs of the instrument and assays over time? 
A standard positive control across experiments was not used but any experiments where 
head to head comparisons were required were run on the same day, limiting the need to 
stringent standardisation. The flow cytometer is however stringently monitored for change 
in voltage over time by peak fluorescence beads.  
 
 
 B: Statistics 
 
1. All instances of “Mann-Whitney t test” have been changed to “Mann-Whitney test” as have 
the Fisher exact test and Wilcoxon matched pairs sign rank test.  
 
2. All statistics has been revisited and changed as follows: 
Figure 2.6B: Repeated measures one way ANOVA with Tukey multiple comparisons post 
test 
Figure 2.6C: Paired t test 
Figure 2.7B: Paired t test 
Figure 2.8A and B: Repeated measures one way ANOVA with Tukey multiple comparison 
post test 
Figure 2.9 Wilcoxon matched pairs signed rank test 
Figure 2.10 A-C Paired t tests 
Figure 2.11 Repeated measures one way ANOVA with Tukey multiple comparison post test 
Figure 2.13: One way ANOVA with Tukey multiple comparison post test 
Figure 2.18: One way ANOVA with Tukey multiple comparison post test 
Figure 2.20: One way ANOVA with Tukey multiple comparison post test 
Page 89 last paragraph: Paired t test 
Figure 3.4: Paired t test 
Figure 3.6 A Paired t test 
Figure 3.6 B Repeated measures one way ANOVA 
Figure 3.7 A: Friedman’s test adjusted for multiple comparisons by Dunn’s post test 
Figure 3.7 C: Repeated measures one way ANOVA with Tukey multiple comparisons post 
test 
Figure 3.10 A: Repeated measures one way ANOVA, pairwise comparisons adjusted for by 
Tukey’s method 
Figure 3.10 B-F: Paired t test 
 
3. Figure 3.6 – concern about the gating strategy has been addressed in the previous section 
 
4. Figure 3.10B- the pale green and purple bars are proportions of the dark green and 
purple bars and shouldn’t be on the same set of axes 
Both of these population subsets were gated initially on p24
+
 CD4
+
 T cells.  
 
C: General comments 
 
 
 
1. Limitations of sample group 
The aim of this study was to understand longitudinally what occurs in an individual with 
regards to α4β7 utilisation and not to access intricacies of transmission. In addition, the 
CAPRISA cohort does not have the donor matched pairs available and as a result this 
would have been an impossible study.   
 
2. Page 75 “The T/F virus was highly dependent…with a notable drop in dependence 
following transmission”. Specify the time after transmission at which there was a 
notable drop. 
This has been corrected as “with a notable drop 2 months post transmission” on page 75 
second paragraph.  
 
3. Overstatements 
The several overstatements as defined by the examiner have been corrected on page 33 last 
paragraph, page 79 first paragraph, page 79 second paragraph, page 79 second paragraph. 
All have been edited to contain the words “may, possible and may be”.  
 
4. Headings in Chapter 2.2.5  
The heading on page 44 has been changed to “2.2.5. Flow cytometry based α4β7-virus 
binding assays”. In addition the competition binding assay has been labelled as A and the 
direct binding assay as B. These assays are both flow based assays, hence the heading. The 
competition assay is based on competition between virus or HP2/1 or Act-1 and the 
fluorescent mAbs α4-PE and β7-FITC, with binding represented as any decrease in 
fluorescence relative to the sample untreated with virus. The direct binding assay was done 
using virus that is labelled with a fluorescently labelled p24 mAb and binding there is 
represented as an increase in number of p24
+
 T cells. The α4β7 mediated virus capture 
inhibition assay is not a flow based assay but is cellular in nature hence a new section title.  
 
5. The difference between data included in Figure 2.18 and 2.22B regarding α4β7 
binding motifs was not clear to me 
The first figure includes all viruses isolated within the first year of infection as stated in the 
legend and the second figure is only inclusive of T/F viruses and is also described in the 
legend. 
 
6. Page 41 section 2.24. until page 43 first paragraph for previous studies: specify which 
work was done by the candidate. 
Single genome amplification and cloning of the env gene into the vector was done by 
others in the laboratory. The env genes were amplified by PCR from these in this study by 
the candidate. The backbone for IEC construction was gifted to the laboratory by Dr 
Kuritzkes but the digestion and consequent transfection was done by the candidate. The 
CAP210 and CAP239 IMC plasmids were gifted to the laboratory by Dr Carolyn 
Williamson but were transfected by the candidate. This has been made clear in the text. 
 
The TCID50 assays were all done by the candidate but as they were only used to titrate the 
input of virus to a TCID50 of 25 for assays, showing these data does not add anything to 
the manuscript.  
 
7. Page 52 Section 2.3.3. The data from this section is only present in the appendix and is 
difficult to absorb at a glance. 
Data from this section is not only presented in the Appendix as suggested by the examiner 
but is rather summarised in Figure 2.11 and 2.12 with an index of % dependence on α4β7 
for replication.  
 
8. HXB2 – No introduction given to reader about consensus sequence. Should be 
explained. Also not on abbreviation list.  
 
 
HXB2 is not a consensus sequence but rather an HIV sequence that is used to standardise 
numbering in sequences. This is explained on page 55 in paragraph 2.  
 
In addition there is no abbreviation for HXB2.  
This is a strain name.  
 
9. Page 57 Figure 2.12: Glycans have been highlighted in red. Is there a reference for a 
method used for its determination? 
The determination of potential N-linked glycans was done using a tool from the Los 
Alamos National Database, N-Glycosite. This is detailed on page 55 in the second 
paragraph.  
 
Page 60 Glycan density is discussed in the first paragraph. Where is the glycan data 
from?  
How the glycan density was determined has been added in the first paragraph of page 59.  
 
10. Page 5- Introduction to N-linked glycans. Candidate should give more of an 
introduction to the nomenclature. 
The two major types of glycosylation are now described in the first paragraph of page 6 
 
11. Page 77 -“…may have a highly individual specific signature and is highly dependent 
on the immune system” – What is the basis for the statement regarding the immune 
system? Too vague.  
This sentence has been omitted. 
 
12. Page 79 – last paragraph “ our data suggest that BV..” This sentence implies 
causation, but all data are correlative. 
Changed to “BV is associated with the transmission of viruses that have...” 
 
13. Page 88- section 3.2.4.- The measurement ng/ml was omitted. 
 
14. Absolute numbers for Figure 3.9 and Figure 3.5 
Absolute numbers were taken as the frequency of a particular cell population represented 
by cell number as opposed to a percentage. This has been added on page 90 last paragraph.  
 
D: Unclear separation of viral and host on phenotypes 
 
1. Abstract first paragraph: “may indicate the founding phenotype for HIV infection” 
changed to “ may indicate the phenotype of the first host cells infected by HIV”.  
 
2. 2nd page of the abstract paragraph 1 “In addition, Th17 cells in this and other studies 
were shown to rapidly deplete following HIV infection while Treg CD4
+
 T cell were 
shown to expand” was corrected to include in vitro. 
 
3. Specific aim 1 page 34: Changed from “the role of α4β7 at different stages of HIV-1 
pathogenesis” to “ the dependence on α4β7 for viral replication at different stages of HIV-1 
pathogenesis”.  
 
4. Chapter 2 heading page 35: changed from “The role of α4β7 changes over the course of 
HIV subtype C infection” to “The dependence on α4β7 for viral replication changes over 
the course of HIV subtype C infection”  
 
 
 
5. Page 37 middle paragraph changed from “Whether α4β7 can be defined as a transmission 
signature remains controversial” to “Whether the affinity for α4β7 can be defined as a 
transmission signature remains controversial.” 
 
6. Discussion page 74 2ndsentence. There are a mixture of host and viral factors that are 
associated with α4β7 dependence and as a result this sentence was not edited. 
 
7. Page 77 2nd paragraph “As such, the negative correlation reflects the increase in α4β7 at 3 
years post infection as previously mentioned” was changed to “As such, the negative 
correlation reflects the increase in α4β7 dependence at 3 years post infection as previously 
mentioned”.  
 
The CD4 query is addressed in the external examiners responses.  
 
Page 77 2
nd
paragraph “Interestingly, while rapid and intermediate progressors show no 
differences in α4β7 reactivity, individuals that go on to produce BCN antibodies show a 
decreased dependence for α4β7 at transmission as compared to those that do not” was 
changed to “ Interestingly, while rapid and intermediate progressors show no differences in 
α4β7reactivity, viruses isolated from individuals that go on to produce BCN antibodies 
show a decreased dependence for α4β7 at transmission as compared to those that do not.” 
 
8. Page 78 line 2 “Differences in the dependence on α4β7 for replication between different 
motifs were evident in the first year of infection” changed to “Differences in the 
dependence on α4β7 for replication between different motifs were evident in viruses 
isolated from the first year of infection.” 
 
9. Page 79 last paragraph: The association between BV and α4β7 dependence is likely to be 
as a result of host environment shaping the viral affinity. This may be because BV is 
increasing the expression of α4β7 on the T cells during inflammation and this provides an 
advantage to the viral replication of HIV and the virus adapts accordingly. This is however 
only a theory as BV cells were not investigated in this study as pointed out by the 
examiner.  
 
10. Page 80 paragraph 1: “IL-1α, IL-8 and IL-7 were found to correlate significantly with the 
dependence of T/F viruses on α4β7 for viral replication in the CVL at the time of 
transmission” was changed to “IL-1α, IL-8 and IL-7 in the CVL at the time of transmission 
were found to correlate significantly with the dependence of T/F viruses on α4β7 for viral 
replication in our system.” 
 
11. Page 84 paragraph 2: “In this study we sought to determine the effect of all-trans retinoic 
acid (ATRA) on the frequency of Th17 and Treg CD4
+
 T subsets in the peripheral blood of 
healthy donors in order to mimic the GALT environment where dendritic cells secrete 
ATRA to upregulate homing receptors (Iwata, et al., 2004)” was corrected to be “In this 
study we sought to determine the effect of all-trans retinoic acid (ATRA) on the frequency 
of Th17 and Treg CD4
+
 T subsets in the peripheral blood from healthy donors in order to 
mimic the GALT environment where dendritic cells secrete ATRA to upregulate homing 
receptors (Iwata, et al., 2004).” 
 
12. Page 100 paragraph 1: “In addition, Treg CD4+ T cells express slightly more α4β7 than 
Th17 CD4
+
 T cells. α4β7+ and Treg CD4+ T cells were highly permissive to acute 
infection” was changed to “In addition, Treg CD4+ T cells express slightly more α4β7 than 
Th17 CD4
+
 T cells. α4β7+ and Treg CD4+ T cells were highly permissive to infection by a 
T/F virus.” 
 
 
 
13. Page 106 paragraph 1: “”We also aimed to determine which subsets present in the GALT 
and genital tract express the highest levels of α4β7 which may allude to a novel route of 
viral dissemination from the site of transmission to the GALT” was changed to “We also 
aimed to determine which T subsets that have been previously found to be in the GALT 
and genital tract express the highest levels of α4β7 which may allude to a novel route of 
viral dissemination from the site of transmission to the GALT.” 
 
14. Page 110 conclusion: “In conclusion, this dissertation describes a role which changes over 
time for integrin α4β7, a homing receptor that is responsible for the trafficking of 
lymphocytes into the GALT and also serves as an attachment factor for gp120” was 
changed to “In conclusion, this dissertation describes a dependence on integrin α4β7 for 
HIV replication which changes over time in addition to its’ function as a homing receptor 
that is responsible for the trafficking of lymphocytes into the GALT and also serves as an 
attachment factor for gp120.”  
 
15. Chapter heading for chapter 3 on page 82 has been changed from “The role of α4β7+ 
CD4+ T lymphocyte subsets in early viral dissemination” to “Expression of α4β7 on Th17 
and Treg T lymphocytes and permissibility for HIV infection.” 
 
E. Minor errors 
 
1. Abstract bottom paragraph of first page 
Sentence has been shortened and in the following line “of” replaced with “on”. 
 
2. CVL  
Has been added to abbreviation list and written in full in the abstract. 
 
3. Page 2 of abstract last paragraph 
“This population of T cells may be more suitedfor this function than Th17 CD4+ T cells 
which are more susceptible to either depletion by HIV or bystander effects” changed to 
“This population of T cells may be more suited for this function than Th17 CD4+ T cells 
which are more susceptible to depletion either by HIV or bystander effects.”  
 
4. Page 3 line 5 
“The level of efficacy was modest at 31.2% and efforts to understand how to improve the 
vaccine regimen is on-going” was changed to “The level of efficacy was modest at 31.2% 
and efforts to understand how to improve the vaccine regimen are on-going.” 
 
Page 3 line 8 
“immune systems” changed to “immune system’s” 
 
5. Page 16 first line 
“As T cells only detect pathogens through direct contact with the antigen, they must traffic 
to the site of pathogenic exposure” changed to “As T cells only detect pathogens through 
direct contact with the MHC-presented antigen, they must traffic to the site of pathogenic 
exposure.” 
 
6. Figure 1.8 not referenced page 27 
Adapted from Sethi, et al., 2013 
 
7. Page 28 1st paragraph 
The high expression of IL-17 has been shown in multiple sclerosis, rheumatoid arthritis and 
IBDs, most of which are currently treated by blockade of α4β7 has been amended with a 
reference Tzartos, et al., 2008. 
 
 
 
8. Page 29 last paragraph 
“FOXP3+ T cells that are produced in the thymus from T cell progenitors are known as 
natural Treg cells as well as in the GALT mediated by ATRA secreted by GALT-dendritic 
cells in synergy with TGF-β (Sun et al., 2007) from naïve CD4+ T cells known as inducible 
Treg cells (Kang et al., 2007) ” was changed to “FOXP3+ T cells that are produced in the 
thymus from T cell progenitors are known as natural Treg cell. However FOXP3
+
 T cells 
known as inducible Tregs are also found in the GALT, the development of which is 
mediated by ATRA secreted by GALT-dendritic cells in synergy with TGF-β (Sun et al., 
2007).” 
 
9. Page 30 last paragraph 
“A significant drop in FOXP3+Treg cells has been noted during SIV and HIV infected 
individuals (Andersson et al., 2005; Estes et al., 2006), but a number of more recent studies 
reported an increase in Treg T cell number following HIV infection has also been 
described in lymph nodes and duodenal tissue (Li et al., 2011a; Shaw et al., 2011) as well 
as a slight elevation in blood (Kinter et al., 2004)” was changed to “A significant drop in 
FOXP3
+
Treg cells has been noted during SIV and HIV infected individuals (Andersson et 
al., 2005; Estes et al., 2006). However, a number of more recent studies reported an 
increase in Treg  T cell number following HIV infection has also been described in lymph 
nodes and duodenal tissue (Li et al., 2011a; Shaw et al., 2011) as well as a slight elevation 
in blood (Kinter et al., 2004).” 
 
10. Page 32 2nd paragraph 
“α4β7+ T cells has been implicated in a number of therapeutic and vaccine strategies,” 
changed to “α4β7+ T cells have been implicated in a number of therapeutic and vaccine 
strategies” 
 
11. Page 33 Rationale- IMC has been added to abbreviation list 
 
12. Page 45 2nd paragraph –p.i. has been added to the abbreviation list 
 
13. Page 53 top line, the line does not make sense with the suggested correction. 
 
14. Units have been corrected on figure legend of 2.4 page 48 
 
15. The study referred to here was referring to CCR5 ligands and not the receptor as suggested 
by the examiner. This has remained uncorrected. 
 
16. The colour of the CD4 control in Figure 3.4 page 91 has been changed in the legend from 
grey to purple 
 
External Examiner 
 
1. The examiner expresses confusion at how the term bottleneck is used in the text. As a 
result several sentences have been changed to ensure that the meaning of bottleneck refers 
to the selection of virus strains and not the infecting strains themselves: 
 
“While it is not clear how this bottleneck arises apart from an increase in the number of 
cells expressing α4β7 attracted to the genital mucosa in response to inflammation,” on page 
72 last paragraph has been changed to “While it is not clear how BV may impact on the 
properties of viruses that establish infection, apart from an increase in the number of cells 
expressing α4β7 attracted to the genital mucosa in response to inflammation” 
 
 
 
“It is possible that the bottleneck created during transmission determines how great a role 
α4β7 plays during this time, suggesting that there may be a selective advantage for HIV to 
bind to α4β7” has changed to “It is possible that the environment during transmission 
determines how great a role α4β7 plays during this time, suggesting that there may be a 
selective advantage for HIV to bind to α4β7.” Page 79 paragraph 1 
 
“Collectively, this data suggests that there is a role for α4β7 in HIV pathogenesis and that 
the interaction is selected for during transmission by a number of bottlenecks, one of which 
is the presence of BV” was changed to “Collectively, this data suggests that there is a role 
for α4β7 in HIV pathogenesis and that the interaction may be selected for during 
transmission possibly as a result of a number of factors, one of which appears to be the 
presence of BV.” Page 81. 
 
 
Was there any impact of α4β7 dependence on the nature of the bottleneck? 
As the examiner points out, this study only looked at cases where successful transmission 
has occurred. Of the viruses that have successfully established infection, there are 
differences in α4β7 dependence. These differences are associated with the particular α4β7-
binding motifs, the presence of BV at the time of transmission and the cytokine 
environment. I don’t believe that the findings in this study can conclusively answer this 
question. The fact that T/F viruses appear to have a higher dependence on α4β7 for viral 
replication as compared to viruses isolated from the first year of infection suggests that 
α4β7 dependence may have an impact on the bottleneck. However it is also possible, and 
more likely in my opinion, that other correlative factors are the cause of the α4β7 
dependence and not that the α4β7 dependence is the cause of the bottleneck. α4β7 
dependence appears to be a selective advantage because it does allow for rapid 
dissemination throughout the body and α4β7 is present on many different cell types, but 
based on the evidence shown in this study, these outcomes are likely to be an effect of 
random factors. As the examiner points out, many people do believe that transmission is a 
stochastic process and as the body of work here suggests, α4β7 is most certainly not the 
determining factor for transmission to occur. 
 
2. The term Mann-Whitney t test is confusing. 
This was addressed in comments from the internal examiner, see “statistics”. Where the 
term Mann-Whitney t test has been used in the text, it has been replaced with Mann-
Whitney test as this test should not be referred to as a t test.  
 
Also it seems that in some instances where this test is used, it should be an actual 
parametric student’s t test. 
All statistics have been reassessed and corrections are shown in “statistics” in the 
comments from the internal examiner. 
 
3. CD4 decline analysis and Figure 2.11 and Figure 2.14 re-analysis with repeated 
measure statistics 
This has been done as specified previously in the internal examiner comments under 
statistics. 
 
With respect to the CD4 decline: is α4β7 dependence result likely to result in more gut 
homing or more gut CD4 depletion? Is this the difference in CD4 decline a cause or 
effect? 
This correlation may also reflect that in vivo at time points post infection where viruses that 
have high α4β7 dependence are dominant systemically, CD4 T cells may increase in their 
capacity to home to the GALT diminishing their presence in the blood. CD4 counts 
undertaken in the gut may reveal a positive correlation with α4β7 dependence of systemic 
viruses. These data were not available for analysis. It is likely that this association is an 
 
 
effect of α4β7 dependence, although clearly α4β7 dependence is not the cause of mass 
CD4 depletion over the course of infection. This explanation has been added on page 67 
first paragraph. 
 
4. The word data should always be plural 
Instances where data was not plural has been corrected. 
page 71 last paragraph 
page 77 second paragraph 
page 78 last paragraph 
page 80 paragraph 1 
page 81 
Figure B2 legend 
Abstract last page 
page 37 paragraph 1 
page 38 paragraph 2 
page 66 paragraph 1 
page 67 paragraph 1 
 
5. How many of the α4β7 changes over time could be driven by neutralising antibody 
escape? Are these likely to be “α4β7 escape?” The BCN correlation in Figure 2.20 not 
well explained.  
While this an important question to answer, this is beyond the scope of this project and is 
likely to be the subject of further studies in our laboratory. As neutralising antibody escape 
is evident in the V2 region of gp120 (the region in which α4β7 is present), it is plausible 
that some differences in α4β7 dependence may be as a result of escape. The V2/V3 region 
is often referred to as being the shield for HIV’s inner core and as a result is frequently the 
target of antibodies. This hypothesis cannot be corroborated however by the correlation as 
shown in Figure 2.20. This result simply shows that viruses isolated at transmission from 
individuals that go on to develop BCN antibodies have lower dependence on α4β7 to 
replicate. As a result of broadly neutralising antibodies only appearing on average two 
years after infection and a difference only noted at the stage of transmission, it is unlikely 
that this is as a result of broadly neutralisation pressure. What does cause the difference is 
not known as very little is known about differences between BCN and non-BCN 
individuals. This would need to be explored further but does suggest that BCN individuals 
have fundamentally different pressures at transmission that result in viruses that have a 
decreased dependence on α4β7 for replication. It may be important to discern these 
pressures so we can improve the elicitation of effective BCN antibodies in individuals. 
This additional point has been included in the last paragraph of page 68.  
 
6. In few places there are too many concepts packed into 1 paragraph.  
The one paragraph on page 65 has been split into separate paragraphs and additional 
explanation has been added to the paragraph on page 68.  
 
7. Were Mg and Ca++ used in buffers? This should insure integrins are in their 
activated forms. 
Yes, all physiological buffers used in this study contained Mg and Ca++, however were not 
included during the process of flow cytometric staining as they were found to interfere with 
staining and decrease the viability of the cells.  
 
8. The examiner expresses concern that the analysis with the α4β7 binding motifs is de-
emphasised in the text and should be bought to the forefront in a publication. 
The examiner’s comment has been noted and in the upcoming publication, this has been 
rectified as were have found additional evidence for this.  
  
 
 
9. Is one hypothesis from this study that HIV will use α4β7 if its there but that it is not 
required? 
This has been addressed in point 1 above and also added in the conclusion on page 110.  
 
10. Is there any relation between viral fitness and α4β7 dependence? 
This question is a very significant one, but no assays were done in this study to adequately 
assess this question. This is likely to be done in future studies. 
 
11. The examiner expresses concern about the effect of stimulation and culture conditions 
when investigating Treg and Th17 HIV infection. 
This concern has already been addressed in the internal examiner comments, however an 
additional statement of this pitfall has been included for clarity on page 109. 
  
12. In Figure 3.3.2- what are the other subsets? 
This was not investigated as we were only concerned with Th17 and Treg subsets. It is 
likely there will be varying proportions of Th1 and Th2 subsets but this would have had to 
be done with a different staining panel as the panel used for Th17 and Treg phenotyping 
contained the maximum number of colours for flow cytometry.  
  
13. For CD25, were the highest 2% gated for each individual? 
Yes, this was done in order to uphold the definition of what cells were CD25 high 
  
14. Do you think HIV drives expansion of the Treg phenotype? 
While this has been suggested by other studies, it is also possible that Treg are simply more 
resistant to depletion by HIV infection. I think it also depends what tissue is being 
considered as completely different patterns have been noted for blood as compared to 
lymph, GALT or genital tissue.  
 
15. How do your methods compare to Parrish, Nawaz and Etemad given the differences 
in your data? 
Parrish and colleagues did not take signalling of the integrin into consideration and did not 
titrate the inhibitory mAb Act-1, but rather worked with what was a saturating 
concentration used in binding assays. In addition, they used unmatched IMCs as compared 
to matched longitudinal IECs, a different virus expression system. Nawaz used a very 
limited pairing of viruses (3) to investigate the role of glycans and these were mutated to 
exclude glycans while this study uses 60 viruses occuring in natural HIV infection. In the 
pair of viruses that are common to both studies, the same dependences were observed 
(CAP 88 T/F and 12m viruses) with T/F having a higher binding to α4β7 as compared to 
the 12 month virus. This, despite the fact that the Nawaz study used monomeric gp120 
while our study used replicative virus. Contrary to observations by Nawaz and colleagues, 
the effect of α4β7 on replication has been deemed to remain unaffected by shorter 
glycosylated V1/V2 loops in matched early (1-6 months) and chronic (ranging between 24-
47 months) viruses from eight individuals. Although intriguing, these data from Etemad 
and colleagues generalise early viral time points, do not consider T/F viruses and defined 
chronic viruses at different time points across individuals and are only subtype A where as 
this study is subtype C only.  
 
16. Do Treg and Th17 levels and α4β7 expression change over the course of HIV infection 
in the donors where you looked at α4β7 dependence?  
This has not been assessed in this study, as only healthy donors were assessed for Th17 and 
Treg expresssion and then assessed following HIV infection in vitro. This would be a very 
interesting question and is planned for further study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
